{"PMC7314266": [["The Current Testing LandscapeCurrently there are 3 types of diagnostic tests available: molecular assays (polymerase chain reaction [PCR]), serology assays, and antigen tests.", [["diagnostic tests", "TEST", 60, 76], ["molecular assays", "TEST", 88, 104], ["polymerase chain reaction", "TEST", 106, 131], ["PCR", "TEST", 133, 136], ["serology assays", "TEST", 140, 155], ["antigen tests", "TEST", 161, 174]]], ["Each test has specific applications for personal health management and public health surveillance.", [["Each test", "TEST", 0, 9], ["personal health management", "TREATMENT", 40, 66], ["public health surveillance", "TEST", 71, 97]]], ["This discussion focuses on the first 2, because the antigen test has only recently received emergency use authorization from the Food and Drug Administration and is not yet widely available.3 Molecular and serology testing complement each other, and both are necessary to paint a complete picture of the current state of the pandemic.The Current Testing LandscapeThe molecular test identifies people currently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19.", [["acute respiratory syndrome coronavirus", "DISEASE", 431, 469], ["people", "ORGANISM", 393, 399], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 424, 471], ["SARS-CoV-2", "ORGANISM", 473, 483], ["people", "SPECIES", 393, 399], ["severe acute respiratory syndrome coronavirus", "SPECIES", 424, 469], ["SARS-CoV-2", "SPECIES", 473, 483], ["the antigen test", "TEST", 48, 64], ["Drug Administration", "TREATMENT", 138, 157], ["serology testing complement", "TEST", 206, 233], ["The molecular test", "TEST", 363, 381], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 424, 469], ["SARS", "TEST", 473, 477], ["CoV", "TEST", 478, 481], ["the virus", "PROBLEM", 486, 495], ["COVID", "TEST", 512, 517], ["severe", "OBSERVATION_MODIFIER", 424, 430], ["acute", "OBSERVATION_MODIFIER", 431, 436], ["respiratory syndrome", "OBSERVATION", 437, 457]]], ["Those who test positive, whether symptomatic or not, are presumed to be contagious and risk transmitting the virus; however, some patients who test positive later in the course of infection may have noninfectious viral remnants detected.4 These tests can be used to monitor active infection in the population and assess how infection dynamics change in response to policy modification (eg, opening schools) Table 1.", [["infection", "DISEASE", 180, 189], ["infection", "DISEASE", 281, 290], ["infection", "DISEASE", 324, 333], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["symptomatic", "PROBLEM", 33, 44], ["contagious", "PROBLEM", 72, 82], ["the virus", "PROBLEM", 105, 114], ["infection", "PROBLEM", 180, 189], ["noninfectious viral remnants", "PROBLEM", 199, 227], ["These tests", "TEST", 239, 250], ["active infection", "PROBLEM", 274, 290], ["infection dynamics change", "PROBLEM", 324, 349], ["presumed to be", "UNCERTAINTY", 57, 71], ["contagious", "OBSERVATION", 72, 82], ["infection", "OBSERVATION", 180, 189], ["noninfectious", "OBSERVATION_MODIFIER", 199, 212], ["viral remnants", "OBSERVATION", 213, 227], ["infection", "OBSERVATION", 281, 290], ["infection", "OBSERVATION", 324, 333]]], ["However, testing for public health surveillance must be conducted in a careful and targeted way.", [["testing", "TEST", 9, 16], ["public health surveillance", "TEST", 21, 47]]], ["Testing conducted for personal health or prevention cannot be used for public health surveillance.", [["Testing", "TEST", 0, 7], ["public health surveillance", "TEST", 71, 97]]], ["For example, in the initial phases of the pandemic, only the sickest patients were tested with the molecular test (due to limited availability).", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["the molecular test", "TEST", 95, 113]]], ["Using these test results to measure the number of positive cases drastically underestimates the extent of infection because many patients are asymptomatic.", [["infection", "DISEASE", 106, 115], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["these test", "TEST", 6, 16], ["positive cases", "PROBLEM", 50, 64], ["infection", "PROBLEM", 106, 115], ["asymptomatic", "PROBLEM", 142, 154], ["infection", "OBSERVATION", 106, 115]]], ["Furthermore, morbidity and mortality rates among tested individuals overestimate the true morbidity and mortality rates of COVID-19 because the denominator, rather than reflecting the total number of individuals infected, only incorporates those who were tested.The Current Testing LandscapeSerum-based serology tests identify people who were previously infected or who are recovering.", [["people", "ORGANISM", 327, 333], ["people", "SPECIES", 327, 333], ["morbidity", "PROBLEM", 13, 22], ["mortality rates", "TEST", 27, 42], ["the true morbidity", "PROBLEM", 81, 99], ["mortality rates", "TEST", 104, 119], ["COVID", "TEST", 123, 128], ["individuals infected", "PROBLEM", 200, 220], ["The Current Testing LandscapeSerum", "TEST", 262, 296], ["based serology tests", "TEST", 297, 317], ["infected", "OBSERVATION", 212, 220]]], ["These tests demonstrate an immune response by most patients as they recover from infection.", [["infection", "DISEASE", 81, 90], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["These tests", "TEST", 0, 11], ["infection", "PROBLEM", 81, 90], ["immune response", "OBSERVATION", 27, 42], ["infection", "OBSERVATION", 81, 90]]], ["While it is unknown how long antibodies to SARS-CoV-2 will be detectable, based on data from SARS-CoV and MERS-CoV it is likely to be at least a few years.5,6 Serology testing can identify how many people have been infected by SARS-CoV-2 and provide greater insight on exactly how harmful and deadly the virus actually is Table 2.", [["SARS", "DISEASE", 43, 47], ["SARS", "DISEASE", 93, 97], ["SARS", "DISEASE", 227, 231], ["SARS-CoV-2", "ORGANISM", 43, 53], ["SARS-CoV", "ORGANISM", 93, 101], ["MERS-CoV", "ORGANISM", 106, 114], ["people", "ORGANISM", 198, 204], ["SARS-CoV-2", "ORGANISM", 227, 237], ["long antibodies", "PROTEIN", 24, 39], ["people", "SPECIES", 198, 204], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 93, 101], ["SARS-CoV", "SPECIES", 227, 235], ["CoV", "TEST", 48, 51], ["SARS", "TEST", 93, 97], ["Serology testing", "TEST", 159, 175], ["CoV", "TEST", 232, 235], ["infected", "OBSERVATION", 215, 223]]], ["This will help refine estimates of the true morbidity and mortality rates for different populations, evaluate the prevalence of an immune response following infection, and identify populations or locations with greatest spread.", [["infection", "DISEASE", 157, 166], ["the true morbidity", "PROBLEM", 35, 53], ["mortality rates", "TEST", 58, 73], ["different populations", "PROBLEM", 78, 99], ["an immune response", "PROBLEM", 128, 146], ["infection", "PROBLEM", 157, 166], ["infection", "OBSERVATION", 157, 166], ["greatest", "OBSERVATION_MODIFIER", 211, 219], ["spread", "OBSERVATION_MODIFIER", 220, 226]]], ["If, for example, a large enough portion of people under 40 years of age are asymptomatic and the mortality rate is sufficiently low, this population could play a larger role in the initial stages of reopening the economy, provided they are not personally or living with individuals at increased risk.The Current Testing LandscapeAlthough not fully proven, experts expect that those with antibodies have immunity, at least in the near term.6,7 Thus, serology testing can also be used to monitor immunity in the population.", [["people", "ORGANISM", 43, 49], ["antibodies", "PROTEIN", 387, 397], ["people", "SPECIES", 43, 49], ["asymptomatic", "PROBLEM", 76, 88], ["the mortality rate", "TEST", 93, 111], ["The Current Testing LandscapeAlthough", "TEST", 300, 337], ["serology testing", "TEST", 449, 465], ["large", "OBSERVATION_MODIFIER", 19, 24], ["larger", "OBSERVATION_MODIFIER", 162, 168]]], ["At present, the primary application for serology testing is to monitor prevalence in communities, not to inform personal care or behavior of individual patients.5The Current Testing LandscapeTo date, several studies have been conducted for the purpose of disease surveillance in communities.", [["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["serology testing", "TEST", 40, 56], ["several studies", "TEST", 200, 215], ["disease surveillance", "TEST", 255, 275]]], ["Studies conducted in large metropolitan areas found seroprevalence levels of 4.6% in Los Angeles County,8 2.8% in Santa Clara County,9 and 21% in New York City.10 If accurate, these studies have large public policy implications.", [["Studies", "TEST", 0, 7], ["seroprevalence levels", "TEST", 52, 73], ["Santa Clara County", "TEST", 114, 132], ["these studies", "TEST", 176, 189], ["large", "OBSERVATION_MODIFIER", 21, 26], ["large", "OBSERVATION_MODIFIER", 195, 200]]], ["First, they suggest that the total number of infected individuals could be far higher and the death rate far lower than official records.", [["death", "DISEASE", 94, 99], ["infected individuals", "PROBLEM", 45, 65], ["the death rate", "TEST", 90, 104], ["infected", "OBSERVATION", 45, 53]]], ["Second, despite the devastating toll the virus already has had on society, these findings suggest that most people remain at risk.", [["people", "ORGANISM", 108, 114], ["people", "SPECIES", 108, 114], ["the devastating toll the virus", "PROBLEM", 16, 46], ["devastating", "OBSERVATION_MODIFIER", 20, 31], ["virus", "OBSERVATION", 41, 46]]], ["Experts expect that herd immunity, the level of immunity required in the community for disease spread to be unlikely, is not achieved until at least 55% to 60% are immune.11What Is the Current Seroprevalence and Acute Infection Prevalence? ::: Moving From Statistics to Testing PolicyThe number of tests required to monitor prevalence depends on several inputs.", [["herd", "ORGANISM_SUBDIVISION", 20, 24], ["disease spread", "PROBLEM", 87, 101], ["tests", "TEST", 298, 303], ["Acute", "OBSERVATION_MODIFIER", 212, 217], ["Infection", "OBSERVATION", 218, 227]]], ["When prevalence is lower, higher precision may be required.", [["lower", "OBSERVATION_MODIFIER", 19, 24]]], ["Prevalence of acute infections is much lower than seroprevalence because acute infection exists for only 2 weeks or less, whereas antibodies remain much longer.", [["acute infections", "DISEASE", 14, 30], ["infection", "DISEASE", 79, 88], ["antibodies", "PROTEIN", 130, 140], ["acute infections", "PROBLEM", 14, 30], ["acute infection", "PROBLEM", 73, 88], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["infections", "OBSERVATION", 20, 30], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["infection", "OBSERVATION", 79, 88]]], ["Thus, larger samples are generally needed for molecular than for serology testing to produce informative estimates.What Is the Current Seroprevalence and Acute Infection Prevalence? ::: Moving From Statistics to Testing PolicyAnother important consideration is test accuracy, typically described by measures of sensitivity and specificity.", [["samples", "ANATOMY", 13, 20], ["samples", "CANCER", 13, 20], ["larger samples", "TEST", 6, 20], ["serology testing", "TEST", 65, 81], ["test accuracy", "TEST", 261, 274], ["sensitivity", "TEST", 311, 322], ["specificity", "TEST", 327, 338], ["larger", "OBSERVATION_MODIFIER", 6, 12], ["Acute", "OBSERVATION_MODIFIER", 154, 159], ["Infection", "OBSERVATION", 160, 169]]], ["Low specificity or sensitivity can increase the number of tests required to attain adequate precision.What Is the Current Seroprevalence and Acute Infection Prevalence? ::: Moving From Statistics to Testing PolicyPerhaps counterintuitively, the number of tests needed to estimate prevalence does not depend sensitively on the total size of the population, when the population is large.", [["Low specificity or sensitivity", "PROBLEM", 0, 30], ["tests", "TEST", 58, 63], ["Acute", "OBSERVATION_MODIFIER", 141, 146], ["Infection", "OBSERVATION", 147, 156], ["size", "OBSERVATION_MODIFIER", 332, 336], ["large", "OBSERVATION", 379, 384]]], ["For instance, whether estimating prevalence in the entire US, the state of California, or Los Angeles County, the required sample size is virtually identical.", [["size", "OBSERVATION_MODIFIER", 130, 134]]], ["However, for smaller communities (eg, a small municipality or a large employer), population size does impact the sample size required.", [["population size", "PROBLEM", 81, 96], ["large", "OBSERVATION_MODIFIER", 64, 69], ["size", "OBSERVATION_MODIFIER", 92, 96], ["size", "OBSERVATION_MODIFIER", 120, 124]]], ["Figure 1 demonstrates how the required sample size changes as a function of population size when other parameters are fixed.", [["sample", "ANATOMY", 39, 45], ["size", "OBSERVATION_MODIFIER", 46, 50], ["population", "OBSERVATION_MODIFIER", 76, 86], ["size", "OBSERVATION_MODIFIER", 87, 91]]], ["As population size approaches 1 million, rather than continually increasing, required sample sizes actually plateau (in this example, the maximum required sample size for any population is 2,377).", [["size", "OBSERVATION_MODIFIER", 14, 18], ["increasing", "OBSERVATION_MODIFIER", 65, 75], ["sizes", "OBSERVATION_MODIFIER", 93, 98], ["plateau", "OBSERVATION_MODIFIER", 108, 115], ["size", "OBSERVATION_MODIFIER", 162, 166]]], ["This observation is a general result of statistical sampling, and applies equally to any random sample to determine prevalence, not specifically to COVID-19.13What Is the Current Seroprevalence and Acute Infection Prevalence? ::: Moving From Statistics to Testing Policy", [["statistical sampling", "TEST", 40, 60], ["Acute", "OBSERVATION_MODIFIER", 198, 203], ["Infection", "OBSERVATION", 204, 213]]]], "PMC7317263": [], "PMC7216571": [["While we agree with the authors that infectious risk is highest in ophthalmology clinic settings, we would like to discuss the precautions for virus transmission in amniotic membrane harvest and share our experience amidst the COVID-19 pandemic.To the Editor:Most elective surgeries have been suspended globally to mitigate the spread of COVID-19.", [["amniotic membrane", "ANATOMY", 165, 182], ["COVID-19", "CHEMICAL", 338, 346], ["amniotic membrane", "MULTI-TISSUE_STRUCTURE", 165, 182], ["the precautions", "TREATMENT", 123, 138], ["virus transmission", "TREATMENT", 143, 161], ["amniotic membrane harvest", "TREATMENT", 165, 190], ["the COVID", "TEST", 223, 232], ["Most elective surgeries", "TREATMENT", 259, 282], ["COVID", "TEST", 338, 343], ["amniotic membrane harvest", "OBSERVATION", 165, 190]]], ["However, the expiry date of our stock of amniotic membrane coincided with the local COVID-19 outbreak in February 2020.", [["amniotic membrane", "ANATOMY", 41, 58], ["amniotic membrane", "MULTI-TISSUE_STRUCTURE", 41, 58], ["amniotic membrane", "PROBLEM", 41, 58], ["amniotic membrane", "OBSERVATION", 41, 58]]], ["Furthermore, local distributors of dehydrated amniotic membrane also encountered a delay in shipment.", [["amniotic membrane", "ANATOMY", 46, 63], ["amniotic membrane", "MULTI-TISSUE_STRUCTURE", 46, 63], ["dehydrated amniotic membrane", "PROBLEM", 35, 63], ["dehydrated amniotic membrane", "OBSERVATION", 35, 63]]], ["Meanwhile, we had two cases of Stevens Johnson Syndrome with total conjunctival epithelial defects requiring urgent amniotic membrane transplant.", [["conjunctival epithelial", "ANATOMY", 67, 90], ["amniotic membrane", "ANATOMY", 116, 133], ["Stevens Johnson Syndrome", "DISEASE", 31, 55], ["conjunctival epithelial defects", "DISEASE", 67, 98], ["conjunctival epithelial", "TISSUE", 67, 90], ["amniotic membrane", "MULTI-TISSUE_STRUCTURE", 116, 133], ["Stevens Johnson Syndrome", "PROBLEM", 31, 55], ["total conjunctival epithelial defects", "PROBLEM", 61, 98], ["urgent amniotic membrane transplant", "TREATMENT", 109, 144], ["Stevens Johnson Syndrome", "OBSERVATION", 31, 55], ["conjunctival epithelial defects", "OBSERVATION", 67, 98], ["amniotic membrane transplant", "OBSERVATION", 116, 144]]], ["In view of this, we proceeded to amniotic membrane harvest according to the standard protocol [2] but adopted extra infection control measures.To the Editor:The selected donor was asymptomatic without fever and was screened by our protocol to confirm no prior travel, occupation, contact or clustering history [3].", [["amniotic membrane", "ANATOMY", 33, 50], ["infection", "DISEASE", 116, 125], ["fever", "DISEASE", 201, 206], ["amniotic membrane", "MULTI-TISSUE_STRUCTURE", 33, 50], ["amniotic membrane harvest", "TREATMENT", 33, 58], ["the standard protocol", "TREATMENT", 72, 93], ["extra infection control measures", "TREATMENT", 110, 142], ["asymptomatic", "PROBLEM", 180, 192], ["fever", "PROBLEM", 201, 206], ["infection", "OBSERVATION", 116, 125]]], ["After obtaining consent from the patient, a deep throat sputum sample was obtained 3 days before elective Caesarean section for real-time reverse transcriptase-polymerase chain reaction for SARS-CoV2 using the E gene assay, which came back negative.To the Editor:It is unknown whether amniotic membranes from infected donors carry COVID-19.", [["throat sputum sample", "ANATOMY", 49, 69], ["amniotic membranes", "ANATOMY", 285, 303], ["patient", "ORGANISM", 33, 40], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 190, 199], ["amniotic membranes", "MULTI-TISSUE_STRUCTURE", 285, 303], ["donors", "ORGANISM", 318, 324], ["reverse transcriptase", "PROTEIN", 138, 159], ["E gene", "DNA", 210, 216], ["COVID-19", "DNA", 331, 339], ["patient", "SPECIES", 33, 40], ["a deep throat sputum sample", "TEST", 42, 69], ["elective Caesarean section", "TREATMENT", 97, 123], ["polymerase chain reaction", "PROBLEM", 160, 185], ["SARS", "PROBLEM", 190, 194], ["the E gene assay", "TEST", 206, 222], ["amniotic membranes", "PROBLEM", 285, 303], ["COVID", "TEST", 331, 336], ["amniotic membranes", "OBSERVATION", 285, 303], ["infected", "OBSERVATION", 309, 317]]], ["Vertical transmission has been suggested to be probable but low risk and not definite [4].", [["low risk", "PROBLEM", 60, 68], ["suggested to be probable", "UNCERTAINTY", 31, 55]]], ["Currently, there is no data on the survival of SARS-CoV-2 on cryopreserved amniotic membranes.", [["amniotic membranes", "ANATOMY", 75, 93], ["SARS", "DISEASE", 47, 51], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["amniotic membranes", "MULTI-TISSUE_STRUCTURE", 75, 93], ["SARS-CoV", "SPECIES", 47, 55], ["SARS", "TEST", 47, 51], ["CoV", "TEST", 52, 55], ["cryopreserved amniotic membranes", "TREATMENT", 61, 93], ["no", "UNCERTAINTY", 20, 22], ["amniotic membranes", "OBSERVATION", 75, 93]]], ["However, the Global Alliance of Eye Bank Association recommends ocular tissue donors with confirmed or suspected COVID-19 to be excluded for harvesting [5].", [["ocular tissue", "ANATOMY", 64, 77], ["ocular tissue", "TISSUE", 64, 77], ["ocular tissue donors", "TREATMENT", 64, 84], ["COVID", "TEST", 113, 118], ["Eye", "ANATOMY", 32, 35]]], ["Before more evidence is available, we suggest taking a more prudent approach when conducting amniotic membrane harvest during COVID-19 outbreak.", [["amniotic membrane", "ANATOMY", 93, 110], ["amniotic membrane", "MULTI-TISSUE_STRUCTURE", 93, 110], ["a more prudent approach", "TREATMENT", 53, 76], ["conducting amniotic membrane harvest", "TREATMENT", 82, 118], ["COVID", "TEST", 126, 131], ["amniotic membrane harvest", "OBSERVATION", 93, 118]]]], "5d6e51d225a302057a601ae03ec8c5c3ecc9c6ae": [["Letter to the EditorWe are writing to highlight the potential for a post-viral syndrome to manifest following COVID-19 infection as previously reported following Severe Acute Respiratory Syndrome (SARS) infection, also a coronavirus.", [["post-viral syndrome", "DISEASE", 68, 87], ["infection", "DISEASE", 119, 128], ["Acute Respiratory Syndrome (SARS) infection", "DISEASE", 169, 212], ["coronavirus", "DISEASE", 221, 232], ["COVID-19", "ORGANISM", 110, 118], ["COVID-19", "SPECIES", 110, 118], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 162, 202], ["a post-viral syndrome", "PROBLEM", 66, 87], ["COVID-19 infection", "PROBLEM", 110, 128], ["Severe Acute Respiratory Syndrome", "PROBLEM", 162, 195], ["SARS) infection", "PROBLEM", 197, 212], ["a coronavirus", "PROBLEM", 219, 232], ["Severe", "OBSERVATION_MODIFIER", 162, 168], ["Acute", "OBSERVATION_MODIFIER", 169, 174], ["Respiratory Syndrome", "OBSERVATION", 175, 195]]], ["1 After the acute SARS episode some patients, many of whom were healthcare workers went on to develop a Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (CFS/ME) -like illness which nearly 20 months on prevented them returning to work.", [["SARS", "DISEASE", 18, 22], ["Chronic Fatigue Syndrome", "DISEASE", 104, 128], ["Myalgic Encephalomyelitis", "DISEASE", 131, 156], ["CFS/ME) -like illness", "DISEASE", 158, 179], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["the acute SARS episode", "PROBLEM", 8, 30], ["a Chronic Fatigue Syndrome", "PROBLEM", 102, 128], ["Myalgic Encephalomyelitis", "PROBLEM", 131, 156], ["CFS/ME)", "PROBLEM", 158, 165], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["SARS", "OBSERVATION", 18, 22], ["Chronic", "OBSERVATION_MODIFIER", 104, 111], ["Fatigue", "OBSERVATION", 112, 119], ["Myalgic Encephalomyelitis", "OBSERVATION", 131, 156]]], ["2 We propose that once an acute COVID-19 infection has been overcome, a subgroup of remitted patients are likely to experience long-term adverse effects resembling CFS/ME symptomatology such as persistent fatigue, diffuse myalgia, depressive symptoms, and non-restorative sleep.Letter to the EditorPost-mortem SARS research indicated the virus had crossed the blood brain barrier into the hypothalamus via the olfactory pathway.", [["blood brain", "ANATOMY", 360, 371], ["hypothalamus", "ANATOMY", 389, 401], ["olfactory", "ANATOMY", 410, 419], ["infection", "DISEASE", 41, 50], ["CFS", "DISEASE", 164, 167], ["fatigue", "DISEASE", 205, 212], ["myalgia", "DISEASE", 222, 229], ["depressive symptoms", "DISEASE", 231, 250], ["SARS", "DISEASE", 310, 314], ["patients", "ORGANISM", 93, 101], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 360, 379], ["hypothalamus", "ORGAN", 389, 401], ["olfactory", "ORGAN", 410, 419], ["patients", "SPECIES", 93, 101], ["an acute COVID-19 infection", "PROBLEM", 23, 50], ["long-term adverse effects", "PROBLEM", 127, 152], ["CFS/ME symptomatology", "PROBLEM", 164, 185], ["persistent fatigue", "PROBLEM", 194, 212], ["diffuse myalgia", "PROBLEM", 214, 229], ["depressive symptoms", "PROBLEM", 231, 250], ["non-restorative sleep", "PROBLEM", 256, 277], ["the virus", "PROBLEM", 334, 343], ["the blood brain barrier", "TREATMENT", 356, 379], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["infection", "OBSERVATION", 41, 50], ["persistent", "OBSERVATION_MODIFIER", 194, 204], ["fatigue", "OBSERVATION", 205, 212], ["diffuse", "OBSERVATION_MODIFIER", 214, 221], ["myalgia", "OBSERVATION", 222, 229], ["hypothalamus", "ANATOMY", 389, 401]]], ["2 The pathway of the virus seemed to follow that previously suggested in CFS/ME patients, involving disturbance of lymphatic drainage from the microglia in the brain.", [["lymphatic", "ANATOMY", 115, 124], ["microglia", "ANATOMY", 143, 152], ["brain", "ANATOMY", 160, 165], ["CFS", "DISEASE", 73, 76], ["patients", "ORGANISM", 80, 88], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 115, 124], ["microglia", "CELL", 143, 152], ["brain", "ORGAN", 160, 165], ["microglia", "CELL_TYPE", 143, 152], ["patients", "SPECIES", 80, 88], ["the virus", "PROBLEM", 17, 26], ["lymphatic drainage", "PROBLEM", 115, 133], ["the microglia in the brain", "PROBLEM", 139, 165], ["lymphatic drainage", "OBSERVATION", 115, 133], ["microglia", "OBSERVATION", 143, 152], ["brain", "ANATOMY", 160, 165]]], ["3 One of the main pathways of the lymphatic drainage of the brain is via the perivascular spaces along the olfactory nerves through the cribriform plate into the nasal mucosa.", [["lymphatic", "ANATOMY", 34, 43], ["brain", "ANATOMY", 60, 65], ["perivascular spaces", "ANATOMY", 77, 96], ["olfactory nerves", "ANATOMY", 107, 123], ["cribriform plate", "ANATOMY", 136, 152], ["nasal mucosa", "ANATOMY", 162, 174], ["lymphatic", "MULTI-TISSUE_STRUCTURE", 34, 43], ["brain", "ORGAN", 60, 65], ["perivascular spaces", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 96], ["olfactory nerves", "MULTI-TISSUE_STRUCTURE", 107, 123], ["cribriform plate", "TISSUE", 136, 152], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 162, 174], ["the lymphatic drainage", "TREATMENT", 30, 52], ["main", "OBSERVATION_MODIFIER", 13, 17], ["lymphatic drainage", "OBSERVATION", 34, 52], ["brain", "ANATOMY", 60, 65], ["perivascular", "ANATOMY_MODIFIER", 77, 89], ["olfactory nerves", "ANATOMY", 107, 123], ["cribriform", "ANATOMY_MODIFIER", 136, 146], ["plate", "ANATOMY_MODIFIER", 147, 152], ["nasal mucosa", "ANATOMY", 162, 174]]], ["4 If the pathogenesis of coronavirus affects a similar pathway, it could explain the anosmia observed in a proportion of COVID-19 patients.Letter to the EditorThis disturbance leads to a build-up of pro-inflammatory agents, especially postinfectious cytokines such as interferon gamma, and interleukin 7, 5 which have been hypothesized to affect the neurological control of the 'Glymphatic System' as observed in CFS/ME.", [["neurological", "ANATOMY", 350, 362], ["coronavirus", "DISEASE", 25, 36], ["anosmia", "DISEASE", 85, 92], ["CFS", "DISEASE", 413, 416], ["coronavirus", "ORGANISM", 25, 36], ["patients", "ORGANISM", 130, 138], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 268, 284], ["interleukin 7", "GENE_OR_GENE_PRODUCT", 290, 303], ["5", "ORGANISM", 305, 306], ["postinfectious cytokines", "PROTEIN", 235, 259], ["interferon gamma", "PROTEIN", 268, 284], ["interleukin 7", "PROTEIN", 290, 303], ["patients", "SPECIES", 130, 138], ["coronavirus", "PROBLEM", 25, 36], ["the anosmia", "PROBLEM", 81, 92], ["COVID", "TEST", 121, 126], ["the EditorThis disturbance", "PROBLEM", 149, 175], ["pro-inflammatory agents", "TREATMENT", 199, 222], ["postinfectious cytokines", "PROBLEM", 235, 259], ["interferon gamma", "TREATMENT", 268, 284], ["coronavirus", "OBSERVATION", 25, 36]]], ["3 The build up of cytokines in the Central Nervous System (CNS) may lead to post viral symptoms due to pro-inflammatory cytokines passing through the blood brain barrier in circumventricular organs such as the hypothalamus, leading to autonomic dysfunction manifesting acutely as a high fever and in the longer term to dysregulation of the sleep/wake cycle, cognitive dysfunction and profound unremitting anergia, all characteristic of CFS/ME.", [["CNS", "ANATOMY", 59, 62], ["blood brain barrier", "ANATOMY", 150, 169], ["circumventricular organs", "ANATOMY", 173, 197], ["hypothalamus", "ANATOMY", 210, 222], ["autonomic dysfunction", "DISEASE", 235, 256], ["fever", "DISEASE", 287, 292], ["cognitive dysfunction", "DISEASE", 358, 379], ["anergia", "DISEASE", 405, 412], ["CFS", "DISEASE", 436, 439], ["Nervous", "ANATOMICAL_SYSTEM", 43, 50], ["CNS", "ANATOMICAL_SYSTEM", 59, 62], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 150, 169], ["circumventricular organs", "ORGAN", 173, 197], ["hypothalamus", "ORGAN", 210, 222], ["cytokines", "PROTEIN", 18, 27], ["pro-inflammatory cytokines", "PROTEIN", 103, 129], ["post viral symptoms", "PROBLEM", 76, 95], ["pro-inflammatory cytokines", "PROBLEM", 103, 129], ["the hypothalamus", "PROBLEM", 206, 222], ["autonomic dysfunction", "PROBLEM", 235, 256], ["a high fever", "PROBLEM", 280, 292], ["the sleep/wake cycle", "PROBLEM", 336, 356], ["cognitive dysfunction", "PROBLEM", 358, 379], ["profound unremitting anergia", "PROBLEM", 384, 412], ["cytokines", "OBSERVATION", 18, 27], ["Central", "ANATOMY_MODIFIER", 35, 42], ["Nervous System", "ANATOMY", 43, 57], ["pro-inflammatory cytokines", "OBSERVATION", 103, 129], ["blood brain", "ANATOMY", 150, 161], ["circumventricular organs", "ANATOMY", 173, 197], ["hypothalamus", "ANATOMY", 210, 222], ["autonomic dysfunction", "OBSERVATION", 235, 256], ["high", "OBSERVATION_MODIFIER", 282, 286], ["fever", "OBSERVATION", 287, 292], ["profound", "OBSERVATION_MODIFIER", 384, 392], ["unremitting", "OBSERVATION_MODIFIER", 393, 404], ["anergia", "OBSERVATION", 405, 412]]], ["As It may be that early intervention and supportive treatments at the end of the acute phase of COVID-19 can help overcome acute phase symptoms and prevent them in becoming longer-term consequences.", [["COVID-19", "CHEMICAL", 96, 104], ["COVID-19", "CHEMICAL", 96, 104], ["early intervention", "TREATMENT", 18, 36], ["supportive treatments", "TREATMENT", 41, 62], ["COVID", "TREATMENT", 96, 101], ["acute phase symptoms", "PROBLEM", 123, 143], ["may be", "UNCERTAINTY", 6, 12], ["early", "OBSERVATION_MODIFIER", 18, 23]]], ["Without this, in a contracted future economy (at least in the short to intermediate term), managing these likely Post COVID-19 syndrome cases, in addition to existing CFS/ME cases will place additional burden on our already hard pressed healthcare system.Letter to the EditorIn the light of this and similar cases and in the context of the available evidence for SARS, we suggest that priority should be given to examine the prevalence of fatigue related symptoms following COVID-19 infection and to explore pragmatic relatively low cost techniques to treat post-viral fatigue, to alleviate symptoms and improve the quality of life for those affected by the longer term sequelae of COVID-19.Letter to the EditorLet's start the preparations now for what may come in due course.Conflict of Interest Statement:RP developed the Perrin Technique which is described here.", [["CFS", "DISEASE", 167, 170], ["SARS", "DISEASE", 363, 367], ["fatigue", "DISEASE", 439, 446], ["infection", "DISEASE", 483, 492], ["fatigue", "DISEASE", 569, 576], ["COVID-19", "CHEMICAL", 682, 690], ["Post COVID-19 syndrome cases", "PROBLEM", 113, 141], ["existing CFS/ME cases", "PROBLEM", 158, 179], ["SARS", "PROBLEM", 363, 367], ["fatigue related symptoms", "PROBLEM", 439, 463], ["COVID-19 infection", "PROBLEM", 474, 492], ["pragmatic relatively low cost techniques", "TREATMENT", 508, 548], ["post-viral fatigue", "PROBLEM", 558, 576], ["symptoms", "PROBLEM", 591, 599], ["COVID", "TEST", 682, 687], ["the Perrin Technique", "TREATMENT", 820, 840]]], ["No other author has any competing interests.Conflict of Interest Statement:Ethical Approval:Conflict of Interest Statement:No ethical approval was required for this piece of work.", [["ethical approval", "TREATMENT", 126, 142]]]], "PMC7156878": [["BackgroundSince December 2019, a series of unexplained pneumonia cases spread in Wuhan, China.", [["pneumonia", "DISEASE", 55, 64], ["unexplained pneumonia cases", "PROBLEM", 43, 70], ["pneumonia", "OBSERVATION", 55, 64]]], ["The clinical manifestations of pneumonia were similar to those of viral pneumonia.", [["pneumonia", "DISEASE", 31, 40], ["pneumonia", "DISEASE", 72, 81], ["pneumonia", "PROBLEM", 31, 40], ["viral pneumonia", "PROBLEM", 66, 81], ["pneumonia", "OBSERVATION", 31, 40], ["viral", "OBSERVATION_MODIFIER", 66, 71], ["pneumonia", "OBSERVATION", 72, 81]]], ["The source of the infection was a novel coronavirus, which was known as 2019 novel coronavirus (2019-nCoV), and the disease was then named coronavirus disease 2019 (COVID-19) [1\u20133].", [["infection", "DISEASE", 18, 27], ["coronavirus disease", "DISEASE", 139, 158], ["coronavirus", "ORGANISM", 40, 51], ["coronavirus", "ORGANISM", 83, 94], ["coronavirus", "SPECIES", 83, 94], ["the infection", "PROBLEM", 14, 27], ["a novel coronavirus", "PROBLEM", 32, 51], ["novel coronavirus", "PROBLEM", 77, 94], ["the disease", "PROBLEM", 112, 123], ["coronavirus disease", "PROBLEM", 139, 158], ["COVID", "TEST", 165, 170], ["infection", "OBSERVATION", 18, 27], ["disease", "OBSERVATION", 116, 123], ["coronavirus disease", "OBSERVATION", 139, 158]]], ["At present, COVID-19 has spread throughout the world with an increasing number of confirmed and suspected cases.", [["COVID-19", "CHEMICAL", 12, 20]]], ["Thoracic high-resolution computed tomography (HRCT), a highly feasible imaging method, plays an important role in the screening and treatment evaluation of COVID-19.", [["the screening", "TEST", 114, 127], ["treatment evaluation", "TEST", 132, 152], ["COVID", "TEST", 156, 161]]], ["We retrospectively reviewed 6 cases diagnosed with COVID-19 in our hospital to better understand the imaging features of early-stage pneumonia and provide radiologists with key diagnostic points.Material and MethodsFrom 20 January 2020 to 2 February 2020, 6 patients diagnosed with COVID-19 in our hospital were recruited, including 1 male and 5 females (average age 40\u00b110 years) (Table 1).", [["pneumonia", "DISEASE", 133, 142], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 258, 266], ["COVID", "TEST", 51, 56], ["early-stage pneumonia", "PROBLEM", 121, 142], ["stage", "OBSERVATION_MODIFIER", 127, 132], ["pneumonia", "OBSERVATION", 133, 142]]], ["All patients underwent HRCT within 2 days after the onset of symptoms.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["HRCT", "TEST", 23, 27], ["symptoms", "PROBLEM", 61, 69]]], ["All 6 patients had visited Wuhan or had contact with a confirmed COVID-19 patient.", [["patients", "ORGANISM", 6, 14], ["patient", "ORGANISM", 74, 81], ["patients", "SPECIES", 6, 14], ["patient", "SPECIES", 74, 81]]], ["The clinical manifestations of these patients included fever, cough, sore throat, and fatigue.", [["fever", "DISEASE", 55, 60], ["cough", "DISEASE", 62, 67], ["sore throat", "DISEASE", 69, 80], ["fatigue", "DISEASE", 86, 93], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["fever", "PROBLEM", 55, 60], ["cough", "PROBLEM", 62, 67], ["sore throat", "PROBLEM", 69, 80], ["fatigue", "PROBLEM", 86, 93], ["sore throat", "ANATOMY", 69, 80], ["fatigue", "OBSERVATION", 86, 93]]], ["All patients were positive for 2019 novel coronavirus nucleic acid via laboratory testing of respiratory secretions obtained by bronchoalveolar lavage, endotracheal aspirate, nasopharyngeal swab, or oropharyngeal swab.", [["respiratory secretions", "ANATOMY", 93, 115], ["bronchoalveolar lavage", "ANATOMY", 128, 150], ["endotracheal", "ANATOMY", 152, 164], ["nasopharyngeal swab", "ANATOMY", 175, 194], ["oropharyngeal swab", "ANATOMY", 199, 217], ["nucleic acid", "CHEMICAL", 54, 66], ["patients", "ORGANISM", 4, 12], ["coronavirus", "ORGANISM", 42, 53], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 128, 150], ["endotracheal aspirate", "MULTI-TISSUE_STRUCTURE", 152, 173], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 175, 194], ["oropharyngeal", "ORGANISM_SUBDIVISION", 199, 212], ["swab", "ORGANISM_SUBSTANCE", 213, 217], ["patients", "SPECIES", 4, 12], ["novel coronavirus nucleic acid", "TEST", 36, 66], ["laboratory testing", "TEST", 71, 89], ["respiratory secretions", "PROBLEM", 93, 115], ["bronchoalveolar lavage", "TEST", 128, 150], ["endotracheal aspirate", "TEST", 152, 173], ["nasopharyngeal swab", "TEST", 175, 194], ["oropharyngeal swab", "TEST", 199, 217], ["respiratory", "ANATOMY", 93, 104], ["secretions", "OBSERVATION", 105, 115], ["bronchoalveolar lavage", "OBSERVATION", 128, 150], ["endotracheal", "ANATOMY", 152, 164], ["nasopharyngeal", "ANATOMY", 175, 189], ["oropharyngeal", "ANATOMY", 199, 212]]], ["HRCT images were acquired using a GE scanner (GE Medical Systems Optima CT540) with slice thickness of 1.25 mm.", [["HRCT images", "TEST", 0, 11], ["a GE scanner", "TEST", 32, 44], ["slice thickness", "TEST", 84, 99]]], ["The images were transmitted to the workstation and viewed in the PACS system.Material and MethodsCT images were evaluated by 2 experienced radiologists.", [["The images", "TEST", 0, 10], ["MethodsCT images", "TEST", 90, 106]]], ["Imaging features were evaluated in the following patterns:ResultsCT imaging features of COVID-19 in our 6 patients (Figure 1) are summarized below:DiscussionCOVID-19 cases are clinically categorized into 4 types \u2013 mild, normal, severe, and critical \u2013 according to the \u201cDiagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Fifth Edition)\u201d.", [["Pneumonia", "DISEASE", 320, 329], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["Imaging features", "TEST", 0, 16], ["COVID", "TEST", 88, 93], ["Treatment", "TREATMENT", 283, 292], ["Novel Coronavirus Pneumonia", "PROBLEM", 302, 329], ["mild", "OBSERVATION_MODIFIER", 214, 218], ["normal", "OBSERVATION", 220, 226], ["severe", "OBSERVATION_MODIFIER", 228, 234]]], ["Based on their imaging feathers, COVID-19 can also be categorized into early stage, progressive stage, peak stage and absorption stage [4].", [["COVID-19", "DNA", 33, 41], ["their imaging feathers", "TEST", 9, 31], ["COVID", "TEST", 33, 38], ["progressive stage, peak stage and absorption stage", "PROBLEM", 84, 134], ["progressive", "OBSERVATION_MODIFIER", 84, 95], ["peak stage", "OBSERVATION_MODIFIER", 103, 113]]], ["Studies show that early-stage COVID-19 usually manifests as localized inflammatory infiltration, with subpleural ground-glass opacity (GGO) in both lungs.", [["lungs", "ANATOMY", 148, 153], ["GGO", "DISEASE", 135, 138], ["COVID-19", "CELL", 30, 38], ["lungs", "ORGAN", 148, 153], ["Studies", "TEST", 0, 7], ["early-stage COVID", "PROBLEM", 18, 35], ["localized inflammatory infiltration", "PROBLEM", 60, 95], ["subpleural ground-glass opacity (GGO) in both lungs", "PROBLEM", 102, 153], ["early", "OBSERVATION_MODIFIER", 18, 23], ["-stage", "OBSERVATION_MODIFIER", 23, 29], ["localized", "OBSERVATION_MODIFIER", 60, 69], ["inflammatory", "OBSERVATION_MODIFIER", 70, 82], ["infiltration", "OBSERVATION", 83, 95], ["subpleural", "ANATOMY_MODIFIER", 102, 112], ["glass opacity", "OBSERVATION", 120, 133], ["GGO", "OBSERVATION", 135, 138], ["both", "ANATOMY_MODIFIER", 143, 147], ["lungs", "ANATOMY", 148, 153]]], ["Lesions are usually associated with thickened micro-vessels and thick-walled bronchi.", [["micro-vessels", "ANATOMY", 46, 59], ["bronchi", "ANATOMY", 77, 84], ["micro-vessels", "CANCER", 46, 59], ["bronchi", "MULTI-TISSUE_STRUCTURE", 77, 84], ["Lesions", "PROBLEM", 0, 7], ["thickened micro-vessels and thick-walled bronchi", "PROBLEM", 36, 84], ["usually associated with", "UNCERTAINTY", 12, 35], ["thickened", "OBSERVATION_MODIFIER", 36, 45], ["micro-vessels", "OBSERVATION", 46, 59], ["thick", "OBSERVATION_MODIFIER", 64, 69], ["walled", "ANATOMY_MODIFIER", 70, 76], ["bronchi", "ANATOMY", 77, 84]]], ["If an air bronchogram accompanied with or without thickened interlobular septum can be seen within the lesion, a halo sign may also appear around the lesion.", [["interlobular septum", "ANATOMY", 60, 79], ["lesion", "ANATOMY", 103, 109], ["lesion", "ANATOMY", 150, 156], ["interlobular septum", "MULTI-TISSUE_STRUCTURE", 60, 79], ["lesion", "PATHOLOGICAL_FORMATION", 150, 156], ["an air bronchogram", "PROBLEM", 3, 21], ["thickened interlobular septum", "PROBLEM", 50, 79], ["the lesion", "PROBLEM", 99, 109], ["a halo sign", "TEST", 111, 122], ["the lesion", "PROBLEM", 146, 156], ["air bronchogram", "OBSERVATION", 6, 21], ["interlobular septum", "ANATOMY", 60, 79], ["can be seen", "UNCERTAINTY", 80, 91], ["lesion", "OBSERVATION", 103, 109], ["halo", "OBSERVATION", 113, 117], ["may also appear", "UNCERTAINTY", 123, 138], ["lesion", "OBSERVATION", 150, 156]]], ["In rare cases, initial CT images are normal, while follow-up scans are positive [5].DiscussionThe imaging features we observed in the present study are similar to other studies, with minor differences.", [["initial CT images", "TEST", 15, 32], ["follow-up scans", "TEST", 51, 66], ["The imaging features", "TEST", 94, 114], ["other studies", "TEST", 163, 176], ["normal", "OBSERVATION", 37, 43]]], ["Two patients with a single lesion only showed small-nodule or small-patchy GGO.", [["lesion", "ANATOMY", 27, 33], ["small-nodule", "ANATOMY", 46, 58], ["GGO", "DISEASE", 75, 78], ["patients", "ORGANISM", 4, 12], ["small-nodule", "CANCER", 46, 58], ["patients", "SPECIES", 4, 12], ["a single lesion", "PROBLEM", 18, 33], ["small-nodule", "PROBLEM", 46, 58], ["small-patchy GGO", "PROBLEM", 62, 78], ["lesion", "OBSERVATION", 27, 33], ["small", "OBSERVATION_MODIFIER", 46, 51], ["nodule", "OBSERVATION", 52, 58], ["small", "OBSERVATION_MODIFIER", 62, 67], ["patchy", "OBSERVATION_MODIFIER", 68, 74], ["GGO", "OBSERVATION", 75, 78]]], ["One patient who presented with bronchiolitis showed tree-in-bud (TIB) sign (Figure 1A, 1B), which is a rare imaging sign in viral infections, and this is the first report of this in a COVID-19 patient.", [["bud", "ANATOMY", 60, 63], ["bronchiolitis", "DISEASE", 31, 44], ["viral infections", "DISEASE", 124, 140], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 193, 200], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 193, 200], ["bronchiolitis", "PROBLEM", 31, 44], ["tree", "TEST", 52, 56], ["viral infections", "PROBLEM", 124, 140], ["bronchiolitis", "OBSERVATION", 31, 44], ["tree", "OBSERVATION_MODIFIER", 52, 56], ["bud", "ANATOMY", 60, 63], ["TIB", "ANATOMY", 65, 68], ["viral infections", "OBSERVATION", 124, 140]]], ["The pathological basis of TIB is that mucus or pus blocking alveolar duct, respiratory bronchioles, and terminal bronchioles causes bronchiectasis, thickening of the bronchiole wall, and peribronchial inflammation [6].", [["mucus", "ANATOMY", 38, 43], ["pus", "ANATOMY", 47, 50], ["alveolar duct", "ANATOMY", 60, 73], ["respiratory bronchioles", "ANATOMY", 75, 98], ["terminal bronchioles", "ANATOMY", 104, 124], ["bronchiole wall", "ANATOMY", 166, 181], ["peribronchial", "ANATOMY", 187, 200], ["TIB", "DISEASE", 26, 29], ["bronchiectasis", "DISEASE", 132, 146], ["inflammation", "DISEASE", 201, 213], ["TIB", "CANCER", 26, 29], ["mucus", "ORGANISM_SUBSTANCE", 38, 43], ["pus", "ORGANISM_SUBSTANCE", 47, 50], ["alveolar duct", "MULTI-TISSUE_STRUCTURE", 60, 73], ["respiratory bronchioles", "MULTI-TISSUE_STRUCTURE", 75, 98], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 113, 124], ["bronchiole wall", "TISSUE", 166, 181], ["pus blocking alveolar duct", "PROBLEM", 47, 73], ["respiratory bronchioles, and terminal bronchioles", "PROBLEM", 75, 124], ["bronchiectasis", "PROBLEM", 132, 146], ["thickening of the bronchiole wall", "PROBLEM", 148, 181], ["peribronchial inflammation", "PROBLEM", 187, 213], ["TIB", "ANATOMY", 26, 29], ["mucus", "OBSERVATION", 38, 43], ["pus", "OBSERVATION", 47, 50], ["alveolar", "ANATOMY_MODIFIER", 60, 68], ["duct", "ANATOMY", 69, 73], ["respiratory bronchioles", "ANATOMY", 75, 98], ["terminal", "ANATOMY_MODIFIER", 104, 112], ["bronchioles", "ANATOMY", 113, 124], ["bronchiectasis", "OBSERVATION", 132, 146], ["thickening", "OBSERVATION", 148, 158], ["bronchiole", "ANATOMY", 166, 176], ["wall", "ANATOMY_MODIFIER", 177, 181], ["peribronchial", "ANATOMY", 187, 200], ["inflammation", "OBSERVATION", 201, 213]]], ["Tree-in-bud sign can be seen in viral infection patients with immune dysfunction [7].ConclusionsWe found that some of the imaging features of COVID-19 are atypical, especially at the early stage, and this can lead to missed diagnoses.", [["bud", "ANATOMY", 8, 11], ["viral infection", "DISEASE", 32, 47], ["immune dysfunction", "DISEASE", 62, 80], ["patients", "ORGANISM", 48, 56], ["COVID-19", "GENE_OR_GENE_PRODUCT", 142, 150], ["patients", "SPECIES", 48, 56], ["Tree", "TEST", 0, 4], ["viral infection", "PROBLEM", 32, 47], ["immune dysfunction", "PROBLEM", 62, 80], ["the imaging features", "TEST", 118, 138], ["COVID", "TEST", 142, 147], ["can be seen", "UNCERTAINTY", 17, 28], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infection", "OBSERVATION", 38, 47], ["early stage", "OBSERVATION_MODIFIER", 183, 194]]], ["Thus, clinicians should use multiple diagnostic methods such as epidemiological history, clinical characteristics, laboratory tests, and etiological characteristics to make the final diagnosis.", [["laboratory tests", "TEST", 115, 131]]], ["Among these, HRCT is of great importance due to its feasibility, which allows it to be widely used in screening and treatment response evaluation.", [["screening", "TEST", 102, 111], ["treatment response evaluation", "TEST", 116, 145]]]], "793ac115ec70cf284086319b14f22b5f8299f41f": [["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020 . . https://doi.org/10.1101 /2020 Abstract 25 Some countries have been more successful than others at dealing with the COVID-19 26 pandemic.", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101 /2020", "CHEMICAL", 275, 304], ["The copyright holder", "TREATMENT", 198, 218], ["the COVID", "TEST", 386, 395], ["med", "ANATOMY", 102, 105]]], ["When we explore the different policy approaches adopted as well as the underlying 27 socio-economic factors, we note an interesting set of correlations: countries led by women 28 leaders have fared significantly better than those led by men on a wide range of dimensions 29 concerning the global health crisis.", [["women", "ORGANISM", 170, 175], ["men", "ORGANISM", 237, 240], ["women", "SPECIES", 170, 175], ["men", "SPECIES", 237, 240], ["the global health crisis", "PROBLEM", 285, 309], ["global", "OBSERVATION_MODIFIER", 289, 295], ["health crisis", "OBSERVATION", 296, 309]]], ["In this paper, we analyze available data for 35 countries, 30 focusing on the following variables: number of deaths per capita due to COVID-19, number of 31 days with reported deaths, peaks in daily deaths, deaths occurred on the first day of lockdown, 32 and excess mortality.", [["deaths", "DISEASE", 109, 115], ["deaths", "DISEASE", 176, 182], ["deaths", "DISEASE", 199, 205], ["deaths", "DISEASE", 207, 213]]], ["Results show that countries governed by female leaders experienced 33 much fewer COVID-19 deaths per capita and were more effective and rapid at flattening the 34 epidemic's curve, with lower peaks in daily deaths.", [["deaths", "DISEASE", 90, 96], ["deaths", "DISEASE", 207, 213]]], ["We argue that there are both contingent 35 and structural reasons that may explain these stark differences.", [["may explain", "UNCERTAINTY", 71, 82]]], ["First of all, most women-led 36 governments were more prompt at introducing restrictive measures in the initial phase of the 37 epidemic, prioritizing public health over economic concerns, and more successful at eliciting 38 collaboration from the population.", [["women", "ORGANISM", 19, 24], ["women", "SPECIES", 19, 24], ["restrictive measures", "TREATMENT", 76, 96]]], ["Secondly, most countries led by women are also those with 39 a stronger focus on social equality, human needs and generosity.", [["women", "ORGANISM", 32, 37], ["human", "ORGANISM", 98, 103], ["women", "SPECIES", 32, 37], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020 . . https://doi.org/10.1101 /2020Introduction: policy approaches and the global pandemic 50The coronavirus pandemic is impacting daily lives, communities, economies, and 51 exacerbating already existing inequalities.", [["CC", "CHEMICAL", 0, 2], ["coronavirus pandemic", "DISEASE", 366, 386], ["coronavirus", "ORGANISM", 366, 377], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["Since 1980, the global number of human infectious disease outbreaks has risen, as 54 well as the proportion of vector-borne diseases (Smith et al., 2014) .", [["infectious disease", "DISEASE", 39, 57], ["vector-borne diseases", "DISEASE", 111, 132], ["human", "ORGANISM", 33, 38], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["human infectious disease outbreaks", "PROBLEM", 33, 67], ["global", "OBSERVATION_MODIFIER", 16, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["infectious", "OBSERVATION_MODIFIER", 39, 49], ["disease", "OBSERVATION", 50, 57]]], ["The risk of pandemic 55 outbreaks increases with the loss of natural habitat and biodiversity (IPBES, 2019; Min.", [["pandemic", "DISEASE", 12, 20], ["pandemic", "PROBLEM", 12, 20]]], ["Climate change is already affecting vector-borne disease transmission, 57 geographic spread and re-emergence, and its impacts are likely to worsen (Rockl\u00f6v and 58 Dubrow, 2020; IPCC, 2018) .", [["Climate change", "PROBLEM", 0, 14]]], ["The outcomes of pandemics depend on how risk-prepared 59 societies and economies are, including levels of population health (Wood and J\u00f3hannsson 60 2020), health systems, and financial markets.", [["pandemics", "PROBLEM", 16, 25]]], ["67Introduction: policy approaches and the global pandemic 50The short-term impacts of COVID-19 can be limited by \"flattening the curve\" (i.e. 68 reducing the spread) of number of cases over time.", [["COVID-19", "CHEMICAL", 86, 94], ["COVID-19", "CHEMICAL", 86, 94], ["COVID", "TEST", 86, 91]]], ["A higher peak in number of cases implies 69 a higher risk of overloading health care systems.", [["A higher peak", "PROBLEM", 0, 13], ["overloading health care systems", "PROBLEM", 61, 92], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["peak", "OBSERVATION_MODIFIER", 9, 13], ["overloading", "OBSERVATION", 61, 72]]], ["This in turn causes ineffective treatment for 70 individuals suffering from COVID-19 (and other conditions), leading to a higher number of 71 deaths, greater restrictive measures for longer periods, and eventually generating higher 72 impacts in terms of job losses and economic recession (and their health consequences).", [["COVID", "DISEASE", 76, 81], ["deaths", "DISEASE", 142, 148], ["ineffective treatment", "TREATMENT", 20, 41], ["COVID", "TEST", 76, 81], ["economic recession", "PROBLEM", 270, 288], ["ineffective", "OBSERVATION_MODIFIER", 20, 31], ["greater restrictive", "OBSERVATION_MODIFIER", 150, 169]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Introduction: policy approaches and the global pandemic 50The copyright holder for this preprint this version posted July 15, 2020 . . https://doi.org/10.1101 /2020 4 To flatten the curve, most countries adopted lockdown measures, recommending that 74 people stay home, work from home whenever possible, and respect physical distancing .", [["CC", "CHEMICAL", 0, 2], ["people", "ORGANISM", 451, 457], ["people", "SPECIES", 451, 457], ["med", "ANATOMY", 102, 105]]], ["The 75 containment measures, together with fiscal and monetary measures, as well as employment and 76 social measures, differed across countries in terms of the timeliness of the implementation, 77 level of stringency, and extent of interventions (e.g. amount and type of financial aid or income 78 support).", [["fiscal and monetary measures", "TREATMENT", 43, 71], ["interventions", "TREATMENT", 233, 246]]], ["In general, countries that implemented emergency measures early on were more 79 successful at limiting contagion and required stricter lockdowns only for a shorter period of 80 time.", [["stricter lockdowns", "TREATMENT", 126, 144]]], ["81Introduction: policy approaches and the global pandemic 50Responsiveness to COVID-19 implies early testing, tracing and treating (Sheridan, 82 2020; Normile, 2020) , which also depend on resource capacity.", [["50Responsiveness", "DISEASE", 58, 74], ["COVID-19", "CHEMICAL", 78, 86], ["COVID", "TEST", 78, 83], ["early testing", "TEST", 95, 108], ["tracing", "TEST", 110, 117]]], ["In this 85 regard, some commentators have noted how women leaders were less hesitant than men leaders 86 (Fioramonti et al., 2020; Henley and Roy, 2020; Wittenberg-Cox, 2020) .", [["women", "ORGANISM", 52, 57], ["men", "ORGANISM", 90, 93], ["women", "SPECIES", 52, 57], ["men", "SPECIES", 90, 93]]], ["87Introduction: policy approaches and the global pandemic 50Against this backdrop, we explore differences in COVID-19 outcomes in terms of 88 number of deaths, number of days with reported deaths, peak in daily deaths, deaths at first day 89 of lockdown, and excess mortality in countries governed by women as opposed to countries 90 led by men.", [["deaths", "DISEASE", 152, 158], ["deaths", "DISEASE", 189, 195], ["deaths", "DISEASE", 211, 217], ["deaths", "DISEASE", 219, 225], ["women", "ORGANISM", 301, 306], ["men", "ORGANISM", 341, 344], ["women", "SPECIES", 301, 306], ["men", "SPECIES", 341, 344]]], ["91 92Country selection and measures of COVID-19 impacts 94Public data on confirmed cases and deaths from COVID-19 is available from the European 95Country selection and measures of COVID-19 impacts 94Centre for Disease Prevention and Control (ECDC) (https://www.ecdc.europa.eu/ last accessed 96 31 July 2020).", [["deaths", "DISEASE", 93, 99], ["COVID", "TEST", 39, 44], ["COVID", "TEST", 105, 110], ["COVID", "TEST", 181, 186], ["Disease Prevention", "TREATMENT", 211, 229]]], ["Cases and deaths are reported on a daily basis from December 31, 2019.", [["deaths", "DISEASE", 10, 16]]], ["The 97 total number of cases and deaths from COVID-19 in the ECDC dataset are in accordance with 98 .", [["deaths", "DISEASE", 33, 39], ["COVID", "TEST", 45, 50]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020. . https://doi.org/10.1101/2020.07.13.20152397 doi: medRxiv preprint 5 the World Health Organization (WHO) COVID-19 Dashboard (https://covid19.who.int/).", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["99(which was not certified by peer review)From the ECDC dataset, we selected countries with 1) continuous data from December 31, 100 2019 to June 11, 2020, 2) Gross National Income per capita higher than $3,956 (upper-middle 101 income to high income countries), 3) high to very high Human Development Index (HDI) 102 (which includes life expectancy), and 4) a democratic regime (according to the 2019 103 Democracy Index).", [["Human", "ORGANISM", 284, 289], ["Human", "SPECIES", 284, 289], ["a democratic regime", "TREATMENT", 359, 378]]], ["Finally, we excluded countries (Thailand and Sri Lanka) without a distinct 104 peak in daily deaths over the study period.", [["deaths", "DISEASE", 93, 99]]], ["These selection criteria ensure good quality of data 105 and robust cross-country comparisons with regards to the impacts of COVID-19, thus 106 excluding that poverty, lack of liberties or state capacity may determine the differences in 107 outcomes.", [["These selection criteria", "TEST", 0, 24], ["COVID", "TEST", 125, 130], ["lack of liberties or state capacity", "PROBLEM", 168, 203], ["good", "OBSERVATION_MODIFIER", 32, 36]]], ["Furthermore, concerns have been raised by good governance advocates that 108 authoritarian governments may not have been transparent with COVID-19 data, and there is 109 no mechanism for the WHO to verify these numbers (Winter, 2020; The Economist 18 110 February 2020), hence our decision to only select established democracies.", [["COVID", "TEST", 138, 143]]], ["We made one 111 exception to this particular selection criterion for China, for its relevant role as the first country 112 with a COVID-19 outbreak.", [["a COVID", "TEST", 128, 135]]], ["For each of the 35 countries selected we calculated 1) the count of 113 confirmed deaths from COVID-19 and the mortality rate (deaths/total population), 2) the 114 number of days with at least one reported death, 3) and the highest daily number of deaths over 115 population.", [["deaths", "DISEASE", 82, 88], ["deaths", "DISEASE", 127, 133], ["death", "DISEASE", 206, 211], ["deaths", "DISEASE", 248, 254], ["the count", "TEST", 55, 64], ["COVID", "TEST", 94, 99], ["the mortality rate", "TEST", 107, 125]]], ["Further, we calculated the slope of the curve of deaths, as the ratio of the peak in 116 daily deaths and the number of days from first confirmed death to the day of the peak ( Fig. 1) .", [["deaths", "DISEASE", 49, 55], ["deaths", "DISEASE", 95, 101], ["death", "DISEASE", 146, 151]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020. . https://doi.org/10.1101/2020.07.13.20152397 doi: medRxiv preprint As an indicator of the effectiveness and promptness of the policy responses since the 125 outset of the epidemic, we considered the number of deaths in the population at first day of 126 national lockdown.", [["CC", "CHEMICAL", 0, 2], ["deaths", "DISEASE", 482, 488], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv", "TREATMENT", 323, 330], ["med", "ANATOMY", 102, 105]]], ["In order to control for levels of 128 mortality, we analyzed excess mortality from the Financial Times database on \"excess 129 mortality during the COVID-19 pandemic\" compiled from multiple official sources (the full 130 dataset is available at https://github.com/Financial-Times/coronavirus-excess-mortality-data).", [["the COVID", "TEST", 144, 153]]], ["131(which was not certified by peer review)From this database, we extracted weekly data of excess mortality and excess of deaths per 132 capita for 18 countries between December 31, 2019 and June 11, 2020.", [["deaths", "DISEASE", 122, 128], ["excess mortality", "PROBLEM", 91, 107]]], ["133(which was not certified by peer review)We grouped countries by the gender of the head of state and government, also 134 considering leaders elected and appointed by a governing committee or parliament where heads 135 of state or government are not directly elected by citizens, excluding women chosen by a 136 hereditary monarch.", [["hereditary monarch", "DISEASE", 314, 332], ["head", "ORGANISM_SUBDIVISION", 85, 89], ["women", "ORGANISM", 292, 297], ["women", "SPECIES", 292, 297], ["head", "ANATOMY", 85, 89]]], ["Of the 35 countries considered, 10 have a woman-led government 137 .", [["woman", "SPECIES", 42, 47]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020.Measures of social performance and inequality 143Some of the countries currently led by women are also those with the highest global 144 standards in terms of social progress.", [["CC", "CHEMICAL", 0, 2], ["women", "ORGANISM", 359, 364], ["women", "SPECIES", 359, 364], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["This is why we have used the Social Progress Index (SPI) 145 2019 total score, as well as the score of its three main components, namely Basic Human Needs, 146Measures of social performance and inequality 143Foundations of Wellbeing, and Opportunity.", [["Human", "ORGANISM", 143, 148], ["Human", "SPECIES", 143, 148], ["total score", "TEST", 66, 77]]], ["Each of these components include four sub-147 dimensions with three to five indicators each (please refer to https://www.socialprogress.org/ 148 for data and the full list of indicators).", [["components", "OBSERVATION_MODIFIER", 14, 24]]], ["In order to explore possible relations between female 149 leadership, impacts of COVID-19, and economic inequality, we have used the Gini coefficient, .", [["COVID", "TEST", 81, 86]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020. . https://doi.org/10.1101/2020.07.13.20152397 doi: medRxiv preprint 8 163Countries with women leaders are better at reducing negative impacts of COVID-16519 166Countries with women leaders are better at reducing negative impacts of COVID-165Countries with women in position of leadership have suffered six times as few deaths from 167 COVID-19 than countries with governments led by men.", [["CC", "CHEMICAL", 0, 2], ["COVID-16519", "CHEMICAL", 417, 428], ["deaths", "DISEASE", 591, 597], ["COVID-16519", "CHEMICAL", 417, 428], ["women", "ORGANISM", 360, 365], ["women", "ORGANISM", 447, 452], ["women", "ORGANISM", 528, 533], ["men", "ORGANISM", 655, 658], ["women", "SPECIES", 360, 365], ["women", "SPECIES", 447, 452], ["women", "SPECIES", 528, 533], ["men", "SPECIES", 655, 658], ["The copyright holder", "TREATMENT", 198, 218], ["medRxiv preprint", "TREATMENT", 323, 339], ["COVID", "TEST", 417, 422], ["COVID", "TREATMENT", 504, 509], ["med", "ANATOMY", 102, 105], ["six times", "OBSERVATION_MODIFIER", 574, 583]]], ["When we normalize the data per 168 population, we find that countries led by women had 1.6-times fewer deaths per capita than 169 their male-dominated counterparts ( Fig. 2A) .", [["deaths", "DISEASE", 103, 109], ["women", "ORGANISM", 77, 82], ["women", "SPECIES", 77, 82]]], ["Female-led countries reported 1,983 (\u00b1 2,724; 170 95% CI) deaths, while men-led countries 13,276 (\u00b1 9,848; 95% CI), by considering average 171 values.", [["deaths", "DISEASE", 58, 64]]], ["The peak in daily deaths was seven times as low in women-led countries (1.5-times 172 lower per capita), where the average highest number of daily COVID-19 deaths was 91 (\u00b1 122; 173 95% CI) across countries, and 643 (\u00b1 435; 95% CI) for men-led countries (Fig. 2B) .", [["deaths", "DISEASE", 18, 24], ["deaths", "DISEASE", 156, 162], ["women", "ORGANISM", 51, 56], ["women", "SPECIES", 51, 56], ["COVID", "TEST", 147, 152], ["CI", "TEST", 186, 188], ["CI", "TEST", 228, 230], ["peak", "OBSERVATION_MODIFIER", 4, 8]]], ["The 174 number of days with confirmed COVID-19 deaths was, on average, 50 (\u00b1 23; 95% CI) days in 175 women-led countries and 79 (\u00b1 7; 95% CI) in male-led countries (Fig. 2C) .", [["COVID", "DISEASE", 38, 43], ["deaths", "DISEASE", 47, 53], ["women", "ORGANISM", 101, 106], ["women", "SPECIES", 101, 106], ["COVID", "TEST", 38, 43], ["CI", "TEST", 138, 140]]], ["Female-led 176 governments managed to flatten the curve more effectively and faster than male-led 177 governments: the slope of the curve of daily deaths from COVID-19 is 4-times less steep in 178 female-led countries (Fig 2D) .", [["deaths", "DISEASE", 147, 153], ["COVID", "TEST", 159, 164]]], ["179Countries with women leaders are better at reducing negative impacts of COVID-165As further evidence of different timeliness in implementing emergency response, the 180 average deaths over population at first day of national lockdown was 1.6-times higher in male-181 led (7.38E-07 \u00b16.88E-07; 95% CI) than in female-led countries (1.17E-06 \u00b11.11E-06; 95% 182 CI).", [["deaths", "DISEASE", 180, 186], ["women", "ORGANISM", 18, 23], ["women", "SPECIES", 18, 23], ["COVID", "TEST", 75, 80], ["CI", "TEST", 299, 301], ["CI", "TEST", 361, 363]]], ["Average excess mortality per capita was 4.8 (\u00b113; 95% CI) in female-led countries, and 183 21 (\u00b124; 95% CI) in men-led countries.", [["capita", "TEST", 29, 35], ["CI", "TEST", 54, 56]]], ["This latter result is of particular relevance as excess 184 mortality is acknowledged as the fairest way to compare COVID-19 deaths internationally 185 (Krelle et al., 2020) .", [["deaths", "DISEASE", 125, 131], ["COVID", "TEST", 116, 121]]], ["Furthermore, we found significant positive correlations between deaths 186 .", [["deaths", "DISEASE", 64, 70], ["significant positive correlations between deaths", "PROBLEM", 22, 70], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["positive", "OBSERVATION", 34, 42]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020. we considered (Fig. 4) Wellbeing was 88 (\u00b1 2.01; 95% CI) in female-led countries, and 83.6 (\u00b1 2.82; 95% CI) in men-204 led countries.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["CI", "TEST", 325, 327], ["CI", "TEST", 376, 378], ["med", "ANATOMY", 102, 105]]], ["Opportunity was 80.16 (\u00b1 3.39; 95% CI) in female-led countries, and 70.89 (\u00b1 205 4.44; 95% CI) in men-led countries.", [["CI", "TEST", 35, 37]]], ["The Gini coefficient was 29.2 (\u00b1 1.9; 95% CI) in female-206 led countries, and 35.7 (\u00b1 2.5; 95% CI) in men-led countries.", [["The Gini coefficient", "TEST", 0, 20], ["\u00b1", "TEST", 31, 32], ["CI", "TEST", 42, 44], ["CI", "TEST", 96, 98]]], ["The GII was 0.07 (\u00b1 0.02; 95% 207 CI) in female-led countries, and 0.15 (\u00b1 0.04; 95% CI) in men-led countries.", [["The GII", "TEST", 0, 7], ["CI", "TEST", 34, 36], ["GII", "ANATOMY", 4, 7]]], ["The average global 208 rank in happiness score was 21 in female-led countries, and 32 in men-led countries, and the 209 rank in generosity was 44 in female-led countries and 59 in men-led countries.", [["happiness score", "TEST", 31, 46], ["average", "OBSERVATION_MODIFIER", 4, 11], ["global", "OBSERVATION_MODIFIER", 12, 18]]], ["We found that countries with higher female participation and 215 lower gender inequality, besides having higher SPI scores (R = -0.8; p = 2.61E-10), are also 216 happier (R = -0.5; p = 0.004) and more generous (R = -0.5; p = 4.81E-04) (Fig. S2) .", [["higher SPI scores", "PROBLEM", 105, 122], ["p", "TEST", 134, 135], ["p", "TEST", 181, 182], ["p", "TEST", 221, 222], ["S2", "ANATOMY", 241, 243]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020. . https://doi.org/10.1101/2020.07.13.20152397 doi: medRxiv preprintIndex (C) in countries with male leaders and countries with female leaders.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["233 234Opportunity includes \"Equality of political power by gender\", 237 https://www.socialprogress.org/) we further explored if more gender equal countries perform 238 better on Basic Human Needs (the one SPI dimension not directly including gender equality 239 indicators).", [["Human", "ORGANISM", 185, 190], ["Human", "SPECIES", 185, 190]]], ["We found that higher scores in the Basic Human Needs dimension of the SPI 240 negatively correlate to the GII (R = -0.8; p = 9.93E-13) (Fig. S3) .", [["Human", "ORGANISM", 41, 46], ["SPI 240", "DNA", 70, 77], ["Human", "SPECIES", 41, 46], ["the SPI", "TEST", 66, 73], ["the GII", "TEST", 102, 109], ["p", "TEST", 121, 122], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["scores", "OBSERVATION_MODIFIER", 21, 27], ["S3", "ANATOMY", 141, 143]]], ["233 234To explore if female leadership relates with less negative impacts from COVID-19 even 242 among equal countries with good social performance, we repeated the analysis by considering 243 a sub-set of countries with below-average values of Gini coefficient and GII, and above-244 average values of SPI.", [["COVID", "TEST", 79, 84], ["the analysis", "TEST", 161, 173], ["Gini coefficient", "TEST", 245, 261], ["GII", "TEST", 266, 269]]], ["In 245 particular, among the 18 countries with below-average Gini coefficient, female-led countries 246 have 26 less days with deaths, 1.12-times fewer deaths over population, and 33.5-times lower 247 excess mortality per capita.", [["deaths", "DISEASE", 127, 133], ["deaths", "DISEASE", 152, 158]]], ["Among the 25 countries with below-average GII, female-led 248 countries have 17 less days with deaths, 1.6-times fewer deaths over population, and 6.5-times 249 lower excess mortality per capita.", [["deaths", "DISEASE", 95, 101], ["deaths", "DISEASE", 119, 125]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["From a policy perspective, the COVID-19 crisis has been characterised by three 255 overarching elements: (1) it has threatened the priority goals of the decision-making unit, 256 namely economic growth; (2) it has compressed the time necessary to develop an appropriate 257 decision; and 3) its eruption has taken the members of the decision-making unit by surprise 258 (Hermann, 1979; de Swielande, 2020) .", [["the COVID", "TEST", 27, 36]]], ["259(which was not certified by peer review)As COVID-19 deaths began to add up, national leaders were faced with an urgent decision: 260 prioritize economic growth and market openness or shift toward people's wellbeing.", [["deaths", "DISEASE", 55, 61], ["people", "ORGANISM", 199, 205], ["people", "SPECIES", 199, 205]]], ["Leaders 261 who opted for the former demonstrated a short-term vision and lack of understanding of the 262 fact that social wellbeing (and a healthy environment) is the basis for a healthy economy.", [["a short-term vision", "PROBLEM", 50, 69]]], ["Our 263 results show that this is the case for most men leaders, while women leaders did not hesitate to 264 adopt precautionary measures, even when they posed immediate economic costs.", [["men", "ORGANISM", 52, 55], ["women", "ORGANISM", 71, 76], ["men", "SPECIES", 52, 55], ["women", "SPECIES", 71, 76], ["precautionary measures", "TREATMENT", 115, 137]]], ["265(which was not certified by peer review)George Lakoff (2010) has argued that conservative and liberal/progressive political views 266 stem ultimately from conceptions of the family and the metaphor of government as parent.", [["liberal/progressive political views", "TREATMENT", 97, 132]]], ["269(which was not certified by peer review)The alternative is the \"nurturing mother\" model corresponding to liberal/progressive politics.", [["liberal/progressive politics", "TREATMENT", 108, 136], ["progressive", "OBSERVATION_MODIFIER", 116, 127], ["politics", "OBSERVATION", 128, 136]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["1101 /2020 All modern societies are a mixture of both of these models and they are better adapted 275 to different circumstances.", [["modern", "OBSERVATION_MODIFIER", 15, 21], ["societies", "OBSERVATION", 22, 31]]], ["The fact that countries, such as the United States, supposedly 279 best prepared to fight a pandemic, ended up failing to contain it and suffered more deaths than 280 other nations is evidence of leaders' failure to take appropriate decisions at the right time. .", [["deaths", "DISEASE", 151, 157], ["' failure", "PROBLEM", 203, 212], ["right", "ANATOMY_MODIFIER", 250, 255]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020 . . https://doi.org/10.1101 /2020 15 shaking hands and \"high-fiving\" COVID-19 patients, in a blunt disrespect of any social 300 distancing precautions.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 349, 357], ["patients", "SPECIES", 349, 357], ["The copyright holder", "TREATMENT", 198, 218], ["shaking hands", "PROBLEM", 308, 321], ["med", "ANATOMY", 102, 105]]], ["301(which was not certified by peer review)On the opposite side of the spectrum, a number of women leaders heeded scientific 302 active and took immediate action to manage the crisis.", [["women", "ORGANISM", 93, 98], ["women", "SPECIES", 93, 98], ["the crisis", "PROBLEM", 172, 182]]], ["Taiwan's Prime Minister Tsai Ing-wen, 303 building on the country's previous experience with SARS, introduced targeted measures and 304 medical checks early on, while the epidemic was still in its initial phase in the Chinese city of 305(which was not certified by peer review)Wuhan (Wang et al., 2020) .", [["SARS", "DISEASE", 93, 97], ["SARS", "PROBLEM", 93, 97], ["medical checks", "TEST", 136, 150]]], ["This massively reduced the risk of an outbreak and therefore made the earliest and toughest self-isolation measures of any country.", [["an outbreak", "PROBLEM", 35, 46], ["self-isolation measures", "TREATMENT", 92, 115], ["reduced", "OBSERVATION_MODIFIER", 15, 22], ["outbreak", "OBSERVATION", 38, 46]]], ["One week later New Zealand was in complete lockdown.", [["New Zealand", "TREATMENT", 15, 26], ["New", "OBSERVATION_MODIFIER", 15, 18], ["Zealand", "OBSERVATION", 19, 26]]], ["320(which was not certified by peer review)In Scandinavia, the only country that prioritised economic objectives and, as a 321 consequence, did not impose any serious restrictions was Sweden (led by a male prime 322 minister), while all other countries of the region (led my women) took immediate measures.", [["women", "ORGANISM", 275, 280], ["women", "SPECIES", 275, 280], ["immediate measures", "TREATMENT", 287, 305]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020 . . https://doi.org/10.1101 /2020 While Norway implemented strict lockdown for almost two months, and Denmark closed 324 upper primary schools (above age 12) from 13 March to 17 May, Sweden opted for a 'herd 325 immunity' approach, placing economic priorities ahead of health concerns, keeping primary 326 schools (under age 16) open and only isolating, as much as possible, people over 70 (OCED, 327 2020) .", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101 /2020", "CHEMICAL", 275, 304], ["people", "ORGANISM", 646, 652], ["people", "SPECIES", 646, 652], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["This resulted in the highest COVID-19 mortality rate across Nordic countries by the 328 end of May 2020, with 40.5 deaths per 100,000 population, compared to 9.7 for Denmark and 329 4.4 for Norway.", [["deaths", "DISEASE", 115, 121], ["the highest COVID", "TEST", 17, 34]]], ["This trend seems to confirm that progressive 333 female leadership is more engaged on issues of health and wellbeing, social equality, 334 sustainability, and innovation, making societies more resilient.", [["progressive", "OBSERVATION_MODIFIER", 33, 44]]], ["Some of these governments 335 have also launched an international alliance to promote, share and further implement wellbeing 336 policies taking the focus off economic growth and putting it on issues that lead to social and 337 ecological wellbeing (https://wellbeingeconomy.org/wego).", [["economic growth", "TREATMENT", 159, 174]]], ["338(which was not certified by peer review)In business, there is a tendency for preferential selection of female leaders in times of crisis 339 known as the 'glass cliff' effect (Ryan et al., 2011) .", [["crisis", "PROBLEM", 133, 139]]], ["However, women still represent only 29% 340 of senior leadership in companies (Catalyst 2019).", [["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14]]], ["Recognizing the effectiveness of women 341 political leaders in reacting to this coronavirus crisis is one step towards understanding the 342 underlying conditions for effective leadership to emerge.", [["coronavirus", "DISEASE", 81, 92], ["women", "ORGANISM", 33, 38], ["coronavirus", "ORGANISM", 81, 92], ["women", "SPECIES", 33, 38], ["this coronavirus crisis", "PROBLEM", 76, 99]]], ["343(which was not certified by peer review)Implementing policies with short-term economic returns and long-term negative health and 344 social impacts is more common in hierarchical, autocratic societies.", [["more common", "OBSERVATION_MODIFIER", 154, 165]]], ["There is evidence for 346 women to be more likely to take up positions of political leadership in societies that value 347 equity, solidarity, nurturing, and collaboration, which are usually associated with healthier 348 .", [["women", "ORGANISM", 26, 31], ["women", "SPECIES", 26, 31]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 15, 2020. and being members of parliaments and local governments (Schneir, 1994) .", [["CC", "CHEMICAL", 0, 2], ["The copyright holder", "TREATMENT", 198, 218], ["med", "ANATOMY", 102, 105]]], ["351(which was not certified by peer review)Women's status suffers where there is a stronger dominance hierarchy and the \"strict 352 father\" approach to politics and governance.", [["Women", "ORGANISM", 43, 48], ["Women", "SPECIES", 43, 48]]], ["In more nurturing, sociable (and egalitarian) 353 societies, where position and authority count for less, women's status tends to be better 354 (Wilkinson and Pickett, 2009 ).", [["women", "ORGANISM", 106, 111], ["women", "SPECIES", 106, 111], ["authority count", "TEST", 80, 95]]], ["Women's status is thus a marker for the more egalitarian and 355 sociable societies in which health is less affected by the costs of competition for dominance.", [["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5]]], ["356(which was not certified by peer review)Our results support these points, showing how hierarchical, unequal societies paid higher 357 costs in terms of a broad range of impacts from COVID-19.", [["COVID", "TEST", 185, 190], ["unequal", "OBSERVATION_MODIFIER", 103, 110]]], ["Furthermore, even among equal societies, female 360 leaders were more successful than male leaders at dealing with the COVID-19 pandemic.", [["the COVID", "TEST", 115, 124], ["pandemic", "PROBLEM", 128, 136]]], ["363We are facing increasing risk of pandemics due to climate change and increasing 364 destruction of ecosystems and biodiversity (IPCC, 2018; IPBES, 2019) .", [["pandemics", "DISEASE", 36, 45], ["pandemics", "PROBLEM", 36, 45], ["climate change", "PROBLEM", 53, 67], ["increasing 364 destruction of ecosystems", "PROBLEM", 72, 112], ["pandemics", "OBSERVATION", 36, 45], ["increasing", "OBSERVATION_MODIFIER", 72, 82], ["364", "OBSERVATION_MODIFIER", 83, 86], ["destruction", "OBSERVATION_MODIFIER", 87, 98], ["ecosystems", "OBSERVATION_MODIFIER", 102, 112], ["biodiversity", "OBSERVATION_MODIFIER", 117, 129]]], ["The COVID-19 crisis is showing us how political decisions directly 368 affect health and social wellbeing.", [["The COVID", "TEST", 0, 9]]], ["Women are elected and lead in societies where social and 369 environmental wellbeing is at the core of national policymaking, and this affects a broad range 370 of impacts from Our results show that female-led countries have consistently less deaths from COVID-19 372 per capita, a shorter number of days with confirmed deaths, a lower peak in daily deaths per 373 .", [["deaths", "DISEASE", 243, 249], ["COVID", "DISEASE", 255, 260], ["deaths", "DISEASE", 320, 326], ["deaths", "DISEASE", 350, 356], ["Women", "ORGANISM", 0, 5], ["Women", "SPECIES", 0, 5], ["COVID", "TEST", 255, 260]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Conclusion.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["363The copyright holder for this preprint this version posted July 15, 2020. . https://doi.org/10.1101/2020.07.13.20152397 doi: medRxiv preprint capita, and a lower excess mortality.", [["The copyright holder", "TREATMENT", 3, 23], ["a lower excess mortality", "PROBLEM", 157, 181]]], ["Our results also show that 375 women are more likely to take up positions of leadership in societies that value equity, 376 nurturing, solidarity, and collaboration, which are usually associated with healthier 377 communities, more resilient to external shocks.", [["women", "ORGANISM", 31, 36], ["women", "SPECIES", 31, 36], ["external shocks", "TREATMENT", 245, 260]]], ["378 Current data about economic growth forecasts also point out that countries that have taken 379 more determined containment measures will also be rewarded in economic terms: they will 380 suffer much less severe recessions than countries that have hesitated, thus spreading the 381 contagion further afield.", [["economic growth forecasts", "PROBLEM", 23, 48]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Conclusion.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["363The copyright holder for this preprint this version posted July 15, 2020. . https://doi.org/10.", [["The copyright holder", "TREATMENT", 3, 23]]]], "bf044a9a57f52791d126ec12717efcce356053aa": [["IntroductionUp to 1 st of May 2020, more than 3,000,000 cases with COVID-19 were diagnosed and 200,000 death cases were recorded.", [["death", "DISEASE", 103, 108], ["COVID", "TEST", 67, 72]]], ["The coronavirus disease 2019 (COVID- 19) first was reported in December 2019, in Wuhan, China.", [["coronavirus disease", "DISEASE", 4, 23], ["The coronavirus disease", "PROBLEM", 0, 23], ["COVID", "TEST", 30, 35], ["coronavirus disease", "OBSERVATION", 4, 23]]], ["Like other pneumonia, including the Middle East respiratory syndrome (MERS) and the severe acute respiratory syndrome (SARS), COVID-19 could also cause acute respiratory distress syndrome (ARDS) [2] .IntroductionCOVID-19 has been stated to be originated from wild bats and belonged to genera \u03b2coronavirus.", [["respiratory", "ANATOMY", 158, 169], ["pneumonia", "DISEASE", 11, 20], ["Middle East respiratory syndrome", "DISEASE", 36, 68], ["MERS", "DISEASE", 70, 74], ["acute respiratory syndrome", "DISEASE", 91, 117], ["SARS", "DISEASE", 119, 123], ["COVID-19", "CHEMICAL", 126, 134], ["acute respiratory distress syndrome", "DISEASE", 152, 187], ["ARDS", "DISEASE", 189, 193], ["Middle East respiratory syndrome (MERS)", "SPECIES", 36, 75], ["other pneumonia", "PROBLEM", 5, 20], ["the Middle East respiratory syndrome", "PROBLEM", 32, 68], ["the severe acute respiratory syndrome", "PROBLEM", 80, 117], ["COVID", "TEST", 126, 131], ["acute respiratory distress syndrome", "PROBLEM", 152, 187], ["ARDS)", "PROBLEM", 189, 194], ["IntroductionCOVID", "TREATMENT", 200, 217], ["pneumonia", "OBSERVATION", 11, 20], ["Middle", "ANATOMY_MODIFIER", 36, 42], ["respiratory syndrome", "OBSERVATION", 48, 68], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["respiratory syndrome", "OBSERVATION", 97, 117], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["respiratory distress", "OBSERVATION", 158, 178]]], ["Although COVID-19 and SARS-associated Coronavirus (SARS-CoV) belong to the same \u03b2-coronavirus, similarity at genome level is only 70%, and the new group has been reported to display genetic differences from SARS-CoV [3] .IntroductionAlmost all of the earlier cases had a history of contact to the Wuhan city, and some cases present a family clustering character.", [["SARS", "DISEASE", 22, 26], ["SARS", "DISEASE", 207, 211], ["COVID-19", "GENE_OR_GENE_PRODUCT", 9, 17], ["SARS-associated Coronavirus", "ORGANISM", 22, 49], ["SARS-CoV", "ORGANISM", 51, 59], ["\u03b2-coronavirus", "CANCER", 80, 93], ["SARS-CoV", "ORGANISM", 207, 215], ["COVID-19", "DNA", 9, 17], ["\u03b2-coronavirus", "DNA", 80, 93], ["COVID-19", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 51, 59], ["SARS-CoV", "SPECIES", 207, 215], ["COVID", "TEST", 9, 14], ["SARS", "PROBLEM", 22, 26], ["Coronavirus", "PROBLEM", 38, 49]]], ["The exact source of COVID-19 is still unknown; nevertheless, it is reported that the infection may have been induced by vipers or bats [4] .", [["infection", "DISEASE", 85, 94], ["COVID-19", "CHEMICAL", 20, 28], ["COVID-19", "GENE_OR_GENE_PRODUCT", 20, 28], ["COVID-19", "DNA", 20, 28], ["COVID", "TEST", 20, 25], ["the infection", "PROBLEM", 81, 94], ["infection", "OBSERVATION", 85, 94]]], ["This novel virus exhibits high person-to-person transmissibility and typically infects animals, including mammals and birds.", [["birds", "ORGANISM", 118, 123], ["person", "SPECIES", 31, 37], ["person", "SPECIES", 41, 47], ["This novel virus", "PROBLEM", 0, 16], ["virus", "OBSERVATION", 11, 16], ["high", "OBSERVATION_MODIFIER", 26, 30]]], ["In patients, coronavirus usually leads to respiratory infections, like those detected in the common cold.", [["respiratory", "ANATOMY", 42, 53], ["coronavirus", "DISEASE", 13, 24], ["respiratory infections", "DISEASE", 42, 64], ["patients", "ORGANISM", 3, 11], ["coronavirus", "ORGANISM", 13, 24], ["patients", "SPECIES", 3, 11], ["coronavirus", "PROBLEM", 13, 24], ["respiratory infections", "PROBLEM", 42, 64], ["coronavirus", "OBSERVATION", 13, 24], ["respiratory", "ANATOMY", 42, 53], ["infections", "OBSERVATION", 54, 64], ["common cold", "ANATOMY", 93, 104]]], ["But, some new human coronavirus infections have caused lethal endemics including MERS and SARS endemics [1] .", [["coronavirus infections", "DISEASE", 20, 42], ["SARS", "DISEASE", 90, 94], ["human", "ORGANISM", 14, 19], ["coronavirus", "ORGANISM", 20, 31], ["human", "SPECIES", 14, 19], ["human coronavirus", "SPECIES", 14, 31], ["some new human coronavirus infections", "PROBLEM", 5, 42], ["lethal endemics", "PROBLEM", 55, 70], ["MERS", "PROBLEM", 81, 85], ["SARS endemics", "PROBLEM", 90, 103], ["new", "OBSERVATION_MODIFIER", 10, 13], ["human coronavirus", "OBSERVATION", 14, 31]]], ["WHO, in the first report, projected about a 4% fatality rate for COVID-19.", [["COVID", "TEST", 65, 70]]], ["However, among hospitalized cases, the fatality rate is about 4-15% [1, 5] .IntroductionMost of the COVID-19 subjects are adults.", [["subjects", "ORGANISM", 109, 117], ["the fatality rate", "TEST", 35, 52], ["the COVID", "TREATMENT", 96, 105]]], ["About 5% of patients experienced critically ill conditions and 14% were experienced severe disease.", [["critically ill", "DISEASE", 33, 47], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["critically ill conditions", "PROBLEM", 33, 58], ["severe disease", "PROBLEM", 84, 98], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["disease", "OBSERVATION", 91, 98]]], ["Initial reports documented that disease severity was accompanied with age over the 60 years and a history of co-morbid condition.", [["disease severity", "PROBLEM", 32, 48], ["co-morbid condition", "PROBLEM", 109, 128], ["disease", "OBSERVATION", 32, 39]]], ["Rapid detection of COVID-19 is vital to guarantee timely treatment, and from a public health perspective, quick isolation of the patient is essential to discontinue the cascade of contamination [6] .IntroductionStructure morbidities such as underlying cardiovascular disease, hypertension, and diabetes were reported in nearly half of the patients [3] .", [["cardiovascular", "ANATOMY", 252, 266], ["cardiovascular disease", "DISEASE", 252, 274], ["hypertension", "DISEASE", 276, 288], ["diabetes", "DISEASE", 294, 302], ["patient", "ORGANISM", 129, 136], ["patients", "ORGANISM", 339, 347], ["patient", "SPECIES", 129, 136], ["patients", "SPECIES", 339, 347], ["COVID", "TEST", 19, 24], ["the cascade of contamination", "TREATMENT", 165, 193], ["IntroductionStructure morbidities", "PROBLEM", 199, 232], ["underlying cardiovascular disease", "PROBLEM", 241, 274], ["hypertension", "PROBLEM", 276, 288], ["diabetes", "PROBLEM", 294, 302], ["cardiovascular", "ANATOMY", 252, 266], ["disease", "OBSERVATION", 267, 274], ["hypertension", "OBSERVATION", 276, 288], ["diabetes", "OBSERVATION", 294, 302]]], ["The symptoms of acute respiratory infection appeared within the early stage of disease.", [["respiratory", "ANATOMY", 22, 33], ["acute respiratory infection", "DISEASE", 16, 43], ["The symptoms", "PROBLEM", 0, 12], ["acute respiratory infection", "PROBLEM", 16, 43], ["disease", "PROBLEM", 79, 86], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["respiratory", "ANATOMY", 22, 33], ["infection", "OBSERVATION", 34, 43], ["early stage", "OBSERVATION_MODIFIER", 64, 75], ["disease", "OBSERVATION", 79, 86]]], ["In next stages septic shock, metabolic acidosis, coagulation dysfunction, and ARDS [8] can appear in severe cases [15] .IntroductionThe incubation period for the COVID-19, on average, is 5.2 days, but it is different among patients.", [["septic shock", "DISEASE", 15, 27], ["metabolic acidosis", "DISEASE", 29, 47], ["coagulation dysfunction", "DISEASE", 49, 72], ["ARDS", "DISEASE", 78, 82], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["septic shock", "PROBLEM", 15, 27], ["metabolic acidosis", "PROBLEM", 29, 47], ["coagulation dysfunction", "PROBLEM", 49, 72], ["ARDS", "PROBLEM", 78, 82], ["the COVID", "TEST", 158, 167], ["septic shock", "OBSERVATION", 15, 27], ["metabolic acidosis", "OBSERVATION", 29, 47], ["coagulation dysfunction", "OBSERVATION", 49, 72], ["ARDS", "OBSERVATION", 78, 82], ["5.2 days", "OBSERVATION_MODIFIER", 187, 195]]], ["Studies support a 14-day medical treatment following period for subjects exposed to the pathogen [13] .Pneumonia is a significant problemIn SARS subjects, lung injury diagnosed in the first week from the symptom onset [16] .Pneumonia is a significant problemThen, the lesions develop into peripheral/subpleural distribution, bilateral involvement, posterior part /lower lobe predilection mixed with ground-glass opacity (GGO) in the fourth week.", [["lung", "ANATOMY", 155, 159], ["lesions", "ANATOMY", 268, 275], ["subpleural", "ANATOMY", 300, 310], ["posterior part", "ANATOMY", 348, 362], ["lower lobe", "ANATOMY", 364, 374], ["Pneumonia", "DISEASE", 103, 112], ["SARS", "DISEASE", 140, 144], ["lung injury", "DISEASE", 155, 166], ["Pneumonia", "DISEASE", 224, 233], ["GGO", "DISEASE", 421, 424], ["lung", "ORGAN", 155, 159], ["lesions", "PATHOLOGICAL_FORMATION", 268, 275], ["subpleural", "TISSUE", 300, 310], ["a 14-day medical treatment", "TREATMENT", 16, 42], ["Pneumonia", "PROBLEM", 103, 112], ["a significant problemIn SARS subjects", "PROBLEM", 116, 153], ["lung injury", "PROBLEM", 155, 166], ["Pneumonia", "PROBLEM", 224, 233], ["a significant problem", "PROBLEM", 237, 258], ["the lesions", "PROBLEM", 264, 275], ["peripheral/subpleural distribution", "PROBLEM", 289, 323], ["bilateral involvement", "PROBLEM", 325, 346], ["posterior part /lower lobe predilection", "PROBLEM", 348, 387], ["ground-glass opacity", "PROBLEM", 399, 419], ["significant", "OBSERVATION_MODIFIER", 118, 129], ["problemIn", "OBSERVATION_MODIFIER", 130, 139], ["SARS", "OBSERVATION", 140, 144], ["lung", "ANATOMY", 155, 159], ["injury", "OBSERVATION", 160, 166], ["significant", "OBSERVATION_MODIFIER", 239, 250], ["problem", "OBSERVATION", 251, 258], ["lesions", "OBSERVATION", 268, 275], ["peripheral", "ANATOMY_MODIFIER", 289, 299], ["subpleural", "ANATOMY_MODIFIER", 300, 310], ["bilateral", "ANATOMY_MODIFIER", 325, 334], ["posterior", "ANATOMY_MODIFIER", 348, 357], ["lower lobe", "ANATOMY", 364, 374], ["ground-glass opacity", "OBSERVATION", 399, 419], ["GGO", "OBSERVATION_MODIFIER", 421, 424]]], ["Likewise, Pan et al. [2] in a cohort study showed 85.7% pneumonia progression including consolidation and GGO at early CT scans in COVID-19.", [["pneumonia", "DISEASE", 56, 65], ["GGO", "DISEASE", 106, 109], ["a cohort study", "TEST", 28, 42], ["pneumonia progression", "PROBLEM", 56, 77], ["consolidation", "PROBLEM", 88, 101], ["GGO", "PROBLEM", 106, 109], ["early CT scans", "TEST", 113, 127], ["COVID", "TEST", 131, 136], ["pneumonia", "OBSERVATION", 56, 65], ["consolidation", "OBSERVATION", 88, 101], ["GGO", "OBSERVATION", 106, 109]]], ["Of note, there is asymptomatic pneumonia among some COVID-19 patients.", [["pneumonia", "DISEASE", 31, 40], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["asymptomatic pneumonia", "PROBLEM", 18, 40], ["asymptomatic", "OBSERVATION_MODIFIER", 18, 30], ["pneumonia", "OBSERVATION", 31, 40]]], ["Therefore, care must be taken for the diagnosis of such atypical subjects as these might sources of public transmission [16] .Pneumonia is a significant problemOther types of pneumonia induced by streptococcus, chlamydia and mycoplasma, and other coronavirus infections should be differentiated from COVID-19 pneumonia.", [["Pneumonia", "DISEASE", 126, 135], ["pneumonia", "DISEASE", 175, 184], ["streptococcus, chlamydia and mycoplasma", "DISEASE", 196, 235], ["coronavirus infections", "DISEASE", 247, 269], ["pneumonia", "DISEASE", 309, 318], ["coronavirus", "ORGANISM", 247, 258], ["COVID-19", "ORGANISM", 300, 308], ["such atypical subjects", "PROBLEM", 51, 73], ["Pneumonia", "PROBLEM", 126, 135], ["pneumonia", "PROBLEM", 175, 184], ["streptococcus", "PROBLEM", 196, 209], ["chlamydia", "PROBLEM", 211, 220], ["mycoplasma", "PROBLEM", 225, 235], ["other coronavirus infections", "PROBLEM", 241, 269], ["COVID", "TEST", 300, 305], ["pneumonia", "PROBLEM", 309, 318], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["pneumonia", "OBSERVATION", 175, 184], ["streptococcus", "OBSERVATION_MODIFIER", 196, 209], ["coronavirus", "OBSERVATION_MODIFIER", 247, 258], ["infections", "OBSERVATION", 259, 269], ["pneumonia", "OBSERVATION", 309, 318]]], ["It is very vital to early separate suspected subjects with fever from the others to reduce cross-infection.Pneumonia is a significant problemRespiratory symptoms in COVID-19, including breathlessness, lung failure, and constitutional symptoms such as fever, muscle ache, confusion, and headache accompanied by diffuse heterogeneous consolidation with GGO [13] .Detection of COVID-19 infectionThe history of exposure or being in close contact with suspected or confirmed patients is critical evidence for the diagnosis.", [["lung", "ANATOMY", 201, 205], ["muscle", "ANATOMY", 258, 264], ["fever", "DISEASE", 59, 64], ["Pneumonia", "DISEASE", 107, 116], ["breathlessness", "DISEASE", 185, 199], ["lung failure", "DISEASE", 201, 213], ["fever", "DISEASE", 251, 256], ["muscle ache", "DISEASE", 258, 269], ["confusion", "DISEASE", 271, 280], ["headache", "DISEASE", 286, 294], ["GGO", "DISEASE", 351, 354], ["infection", "DISEASE", 383, 392], ["lung", "ORGAN", 201, 205], ["muscle", "ORGAN", 258, 264], ["COVID-19", "ORGANISM", 374, 382], ["patients", "ORGANISM", 470, 478], ["patients", "SPECIES", 470, 478], ["COVID-19", "SPECIES", 374, 382], ["fever", "PROBLEM", 59, 64], ["cross-infection", "PROBLEM", 91, 106], ["Pneumonia", "PROBLEM", 107, 116], ["a significant problemRespiratory symptoms", "PROBLEM", 120, 161], ["COVID", "TEST", 165, 170], ["breathlessness", "PROBLEM", 185, 199], ["lung failure", "PROBLEM", 201, 213], ["constitutional symptoms", "PROBLEM", 219, 242], ["fever", "PROBLEM", 251, 256], ["muscle ache", "PROBLEM", 258, 269], ["confusion", "PROBLEM", 271, 280], ["headache", "PROBLEM", 286, 294], ["diffuse heterogeneous consolidation", "PROBLEM", 310, 345], ["GGO", "PROBLEM", 351, 354], ["COVID-19 infection", "PROBLEM", 374, 392], ["significant", "OBSERVATION_MODIFIER", 122, 133], ["problemRespiratory", "OBSERVATION_MODIFIER", 134, 152], ["symptoms", "OBSERVATION", 153, 161], ["lung", "ANATOMY", 201, 205], ["failure", "OBSERVATION", 206, 213], ["muscle", "ANATOMY", 258, 264], ["diffuse", "OBSERVATION_MODIFIER", 310, 317], ["heterogeneous", "OBSERVATION_MODIFIER", 318, 331], ["consolidation", "OBSERVATION", 332, 345], ["GGO", "OBSERVATION", 351, 354], ["infection", "OBSERVATION", 383, 392]]], ["Nevertheless, for patients with an unknown history, clinical features and imaging appearances can show suspected COVID-19.", [["patients", "ORGANISM", 18, 26], ["COVID-19", "DNA", 113, 121], ["patients", "SPECIES", 18, 26], ["imaging appearances", "TEST", 74, 93], ["COVID", "TEST", 113, 118]]], ["After that, the real-time reverse-transcription-polymerase-chain-reaction (RT-PCR) test should be done in these cases, as a reference standard [13] .Detection of COVID-19 infectionAccording to the National Health Commission (NHC) of China, the diagnostic criteria are; 1: exposure history to cases with respiratory symptoms from Wuhan or infected cities within two weeks before the onset of disease, 2: clinical findings (fever, normal or decreased WBC count or reduced lymphocyte count and/or imaging features of pneumonia), and 3: Real-time PCR showing positive results for COVID-19.", [["respiratory", "ANATOMY", 303, 314], ["WBC", "ANATOMY", 449, 452], ["lymphocyte", "ANATOMY", 470, 480], ["respiratory symptoms from Wuhan or infected", "DISEASE", 303, 346], ["fever", "DISEASE", 422, 427], ["pneumonia", "DISEASE", 514, 523], ["lymphocyte", "CELL", 470, 480], ["RT-PCR) test", "TEST", 75, 87], ["COVID", "TEST", 162, 167], ["respiratory symptoms", "PROBLEM", 303, 323], ["disease", "PROBLEM", 391, 398], ["clinical findings", "PROBLEM", 403, 420], ["fever", "PROBLEM", 422, 427], ["decreased WBC count", "PROBLEM", 439, 458], ["reduced lymphocyte count", "PROBLEM", 462, 486], ["imaging features", "TEST", 494, 510], ["pneumonia", "PROBLEM", 514, 523], ["Real-time PCR", "TEST", 533, 546], ["COVID", "TEST", 576, 581], ["disease", "OBSERVATION", 391, 398], ["pneumonia", "OBSERVATION", 514, 523]]], ["The confirmed COVID-19 pneumonia should hospitalize and isolated for therapy [2] .", [["pneumonia", "DISEASE", 23, 32], ["COVID-19", "SPECIES", 14, 22], ["COVID", "TEST", 14, 19], ["pneumonia", "PROBLEM", 23, 32], ["therapy", "TREATMENT", 69, 76], ["pneumonia", "OBSERVATION", 23, 32]]], ["Based on WHO recommendations for SARS and MERS, the NHC of China proposed criteria for diagnosis and treatment of COVID-19 pneumonia [13] .", [["SARS", "DISEASE", 33, 37], ["COVID", "DISEASE", 114, 119], ["pneumonia", "DISEASE", 123, 132], ["SARS", "PROBLEM", 33, 37], ["treatment", "TREATMENT", 101, 110], ["COVID", "TEST", 114, 119], ["pneumonia", "PROBLEM", 123, 132], ["pneumonia", "OBSERVATION", 123, 132]]], ["A person with two clinical conditions and one contact history is regarded as a suspected patient.", [["patient", "ORGANISM", 89, 96], ["person", "SPECIES", 2, 8], ["patient", "SPECIES", 89, 96]]], ["The discharge criteria were; 1: afebrile for more than 3 days, 2: significant improvement of respiratory symptoms, and 3: improvement in the imaging abnormalities on the chest.", [["respiratory", "ANATOMY", 93, 104], ["chest", "ANATOMY", 170, 175], ["respiratory symptoms", "DISEASE", 93, 113], ["chest", "ORGANISM_SUBDIVISION", 170, 175], ["afebrile", "PROBLEM", 32, 40], ["respiratory symptoms", "PROBLEM", 93, 113], ["the imaging abnormalities on the chest", "PROBLEM", 137, 175], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["improvement", "OBSERVATION_MODIFIER", 78, 89], ["respiratory symptoms", "OBSERVATION", 93, 113], ["chest", "ANATOMY", 170, 175]]], ["The definitive etiology diagnosis of infection is needed, which can be more approved by PCR assay using blood or lung specimen or by viral gene sequencing.", [["blood", "ANATOMY", 104, 109], ["lung specimen", "ANATOMY", 113, 126], ["infection", "DISEASE", 37, 46], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["lung specimen", "MULTI-TISSUE_STRUCTURE", 113, 126], ["infection", "PROBLEM", 37, 46], ["PCR assay", "TEST", 88, 97], ["blood or lung specimen", "TEST", 104, 126], ["infection", "OBSERVATION", 37, 46], ["lung", "ANATOMY", 113, 117]]], ["Based on the clinical findings, approved subjects are divided into different classes, including critical, severe, moderate, and mild [13] .Laboratory testsAbout nearly half of the patients infected with COVID-19 had a reduced WBC count and lymphopenia (reduced lymphocytes), or thrombocytopenia (low blood platelet count) with increased activated thromboplastin time.", [["WBC", "ANATOMY", 226, 229], ["lymphocytes", "ANATOMY", 261, 272], ["blood platelet", "ANATOMY", 300, 314], ["lymphopenia", "DISEASE", 240, 251], ["thrombocytopenia", "DISEASE", 278, 294], ["patients", "ORGANISM", 180, 188], ["WBC", "CELL", 226, 229], ["lymphocytes", "CELL", 261, 272], ["blood", "ORGANISM_SUBSTANCE", 300, 305], ["platelet", "CELL", 306, 314], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 347, 361], ["lymphocytes", "CELL_TYPE", 261, 272], ["patients", "SPECIES", 180, 188], ["critical, severe, moderate, and mild [13]", "PROBLEM", 96, 137], ["Laboratory tests", "TEST", 139, 155], ["COVID", "TEST", 203, 208], ["a reduced WBC count", "PROBLEM", 216, 235], ["lymphopenia", "PROBLEM", 240, 251], ["reduced lymphocytes)", "PROBLEM", 253, 273], ["thrombocytopenia", "PROBLEM", 278, 294], ["low blood platelet count", "PROBLEM", 296, 320], ["increased activated thromboplastin time", "TREATMENT", 327, 366], ["critical", "OBSERVATION_MODIFIER", 96, 104], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["moderate", "OBSERVATION_MODIFIER", 114, 122], ["mild", "OBSERVATION_MODIFIER", 128, 132], ["infected", "OBSERVATION", 189, 197], ["reduced", "OBSERVATION_MODIFIER", 218, 225], ["WBC count", "OBSERVATION", 226, 235], ["lymphopenia", "OBSERVATION", 240, 251], ["reduced lymphocytes", "OBSERVATION", 253, 272], ["thrombocytopenia", "OBSERVATION", 278, 294], ["activated thromboplastin", "OBSERVATION", 337, 361]]], ["C-reactive protein (CRP) levels were increased in most patients, but procalcitonin (PCT) concentrations were normal [8] .", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["CRP", "GENE_OR_GENE_PRODUCT", 20, 23], ["patients", "ORGANISM", 55, 63], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 69, 82], ["PCT", "SIMPLE_CHEMICAL", 84, 87], ["C-reactive protein", "PROTEIN", 0, 18], ["CRP", "PROTEIN", 20, 23], ["procalcitonin", "PROTEIN", 69, 82], ["PCT", "PROTEIN", 84, 87], ["patients", "SPECIES", 55, 63], ["C-reactive protein", "TEST", 0, 18], ["CRP) levels", "TEST", 20, 31], ["procalcitonin (PCT) concentrations", "TEST", 69, 103], ["reactive protein", "OBSERVATION", 2, 18]]], ["Elevated serum ferritin levels reported in some patients [14] .", [["serum", "ANATOMY", 9, 14], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["ferritin", "GENE_OR_GENE_PRODUCT", 15, 23], ["patients", "ORGANISM", 48, 56], ["serum ferritin", "PROTEIN", 9, 23], ["patients", "SPECIES", 48, 56], ["Elevated serum ferritin levels", "PROBLEM", 0, 30]]], ["All these alterations further explained that COVID-19 may exert a potential effect on lymphocytes, especially T cells.", [["lymphocytes", "ANATOMY", 86, 97], ["T cells", "ANATOMY", 110, 117], ["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "GENE_OR_GENE_PRODUCT", 45, 53], ["lymphocytes", "CELL", 86, 97], ["T cells", "CELL", 110, 117], ["lymphocytes", "CELL_TYPE", 86, 97], ["T cells", "CELL_TYPE", 110, 117], ["COVID", "TEST", 45, 50], ["lymphocytes", "PROBLEM", 86, 97]]], ["COVID-19 outbreaks and invades via lung mucosa stimulates inflammation cascades, and motivates cytokine storm, resulting in alteration in immune response such as peripheral blood leukocytes and lymphocytes.", [["lung mucosa", "ANATOMY", 35, 46], ["peripheral blood leukocytes", "ANATOMY", 162, 189], ["lymphocytes", "ANATOMY", 194, 205], ["inflammation", "DISEASE", 58, 70], ["lung mucosa", "MULTI-TISSUE_STRUCTURE", 35, 46], ["peripheral blood leukocytes", "CELL", 162, 189], ["lymphocytes", "CELL", 194, 205], ["cytokine", "PROTEIN", 95, 103], ["peripheral blood leukocytes", "CELL_TYPE", 162, 189], ["lymphocytes", "CELL_TYPE", 194, 205], ["COVID", "TEST", 0, 5], ["inflammation cascades", "PROBLEM", 58, 79], ["alteration in immune response", "PROBLEM", 124, 153], ["peripheral blood leukocytes", "TEST", 162, 189], ["lymphocytes", "TEST", 194, 205], ["lung mucosa", "ANATOMY", 35, 46], ["inflammation", "OBSERVATION", 58, 70], ["immune response", "OBSERVATION", 138, 153], ["peripheral", "ANATOMY_MODIFIER", 162, 172], ["blood leukocytes", "ANATOMY", 173, 189], ["lymphocytes", "ANATOMY", 194, 205]]], ["Hence, intravenous immunoglobulin was applied in most subjects with reduced WBC and lymphocyte count [8] .", [["intravenous", "ANATOMY", 7, 18], ["WBC", "ANATOMY", 76, 79], ["lymphocyte", "ANATOMY", 84, 94], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 7, 18], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 19, 33], ["WBC", "CELL", 76, 79], ["lymphocyte", "CELL", 84, 94], ["intravenous immunoglobulin", "PROTEIN", 7, 33], ["WBC", "CELL_TYPE", 76, 79], ["intravenous immunoglobulin", "TREATMENT", 7, 33], ["reduced WBC", "PROBLEM", 68, 79], ["lymphocyte count", "TEST", 84, 100], ["lymphocyte count", "OBSERVATION", 84, 100]]], ["Augmented serum pro-inflammatory cytokine levels have also been documented, associating with the severity of the disease.", [["serum", "ANATOMY", 10, 15], ["serum", "ORGANISM_SUBSTANCE", 10, 15], ["cytokine", "PROTEIN", 33, 41], ["Augmented serum pro-inflammatory cytokine levels", "TEST", 0, 48], ["the disease", "PROBLEM", 109, 120], ["disease", "OBSERVATION", 113, 120]]], ["Nevertheless elevated interleukin-10 levels, which is known as an anti-inflammatory cytokine, indicates a diverse pattern from that of SARS-CoV infection [14] .", [["SARS-CoV infection", "DISEASE", 135, 153], ["interleukin-10", "GENE_OR_GENE_PRODUCT", 22, 36], ["SARS-CoV", "ORGANISM", 135, 143], ["interleukin-10", "PROTEIN", 22, 36], ["anti-inflammatory cytokine", "PROTEIN", 66, 92], ["SARS-CoV", "SPECIES", 135, 143], ["elevated interleukin", "PROBLEM", 13, 33], ["an anti-inflammatory cytokine", "TEST", 63, 92], ["SARS", "PROBLEM", 135, 139], ["CoV infection", "PROBLEM", 140, 153], ["anti-inflammatory cytokine", "OBSERVATION", 66, 92]]], ["Some patients showed increased liver enzymes, and glucose levels and few patients exhibited abnormal muscle enzymes.", [["liver", "ANATOMY", 31, 36], ["muscle", "ANATOMY", 101, 107], ["glucose", "CHEMICAL", 50, 57], ["abnormal muscle enzymes", "DISEASE", 92, 115], ["glucose", "CHEMICAL", 50, 57], ["patients", "ORGANISM", 5, 13], ["liver", "ORGAN", 31, 36], ["glucose", "SIMPLE_CHEMICAL", 50, 57], ["patients", "ORGANISM", 73, 81], ["muscle", "ORGAN", 101, 107], ["liver enzymes", "PROTEIN", 31, 44], ["abnormal muscle enzymes", "PROTEIN", 92, 115], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 73, 81], ["increased liver enzymes", "PROBLEM", 21, 44], ["glucose levels", "TEST", 50, 64], ["abnormal muscle enzymes", "PROBLEM", 92, 115], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["liver", "ANATOMY", 31, 36], ["muscle", "ANATOMY", 101, 107]]], ["Liver test abnormality of COVID-19 may not be induced by liver cell damage but by bile duct cell dysfunction and other reasons [8] .", [["Liver", "ANATOMY", 0, 5], ["liver cell", "ANATOMY", 57, 67], ["bile duct cell", "ANATOMY", 82, 96], ["COVID-19", "CHEMICAL", 26, 34], ["liver cell damage", "DISEASE", 57, 74], ["bile duct cell dysfunction", "DISEASE", 82, 108], ["COVID-19", "CHEMICAL", 26, 34], ["Liver", "ORGAN", 0, 5], ["COVID-19", "GENE_OR_GENE_PRODUCT", 26, 34], ["liver cell", "CELL", 57, 67], ["bile duct cell", "CELL", 82, 96], ["Liver test abnormality", "TEST", 0, 22], ["COVID", "TEST", 26, 31], ["liver cell damage", "PROBLEM", 57, 74], ["bile duct cell dysfunction", "PROBLEM", 82, 108], ["liver", "ANATOMY", 57, 62], ["cell damage", "OBSERVATION", 63, 74], ["bile duct", "ANATOMY", 82, 91], ["cell dysfunction", "OBSERVATION", 92, 108]]], ["In summary, blood routine test, CRP, PCT, coagulation function, arterial blood gas, and tissue function tests (e.g. transaminases, bilirubin, myocardial enzyme, creatinine, urea nitrogen, urine volume, etc.) as tabulated in Table 3 should be monitored in patients [17] .", [["blood", "ANATOMY", 12, 17], ["arterial blood", "ANATOMY", 64, 78], ["tissue", "ANATOMY", 88, 94], ["myocardial", "ANATOMY", 142, 152], ["urine", "ANATOMY", 188, 193], ["bilirubin", "CHEMICAL", 131, 140], ["creatinine", "CHEMICAL", 161, 171], ["urea nitrogen", "CHEMICAL", 173, 186], ["bilirubin", "CHEMICAL", 131, 140], ["creatinine", "CHEMICAL", 161, 171], ["urea", "CHEMICAL", 173, 177], ["nitrogen", "CHEMICAL", 178, 186], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["CRP", "GENE_OR_GENE_PRODUCT", 32, 35], ["arterial", "MULTI-TISSUE_STRUCTURE", 64, 72], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["tissue", "TISSUE", 88, 94], ["transaminases", "SIMPLE_CHEMICAL", 116, 129], ["bilirubin", "SIMPLE_CHEMICAL", 131, 140], ["myocardial", "MULTI-TISSUE_STRUCTURE", 142, 152], ["creatinine", "SIMPLE_CHEMICAL", 161, 171], ["urea", "SIMPLE_CHEMICAL", 173, 177], ["urine", "ORGANISM_SUBSTANCE", 188, 193], ["patients", "ORGANISM", 255, 263], ["CRP", "PROTEIN", 32, 35], ["patients", "SPECIES", 255, 263], ["blood routine test", "TEST", 12, 30], ["CRP", "TEST", 32, 35], ["PCT", "TEST", 37, 40], ["coagulation function", "TEST", 42, 62], ["arterial blood gas", "TEST", 64, 82], ["tissue function tests", "TEST", 88, 109], ["transaminases", "TEST", 116, 129], ["bilirubin", "TEST", 131, 140], ["myocardial enzyme", "TEST", 142, 159], ["creatinine", "TEST", 161, 171], ["urea nitrogen", "TEST", 173, 186], ["urine volume", "TEST", 188, 200]]], ["Furthermore, subjects having upper respiratory tract symptoms and fever with leukopenia or lymphopenia should be suspected, particularly for cases with close contact or exposure history [18] .ImagingRadiological evaluations, particularly thin slice chest computed tomography (CT) scan, has a critical role in diagnosis, management, and follow-up of COVID-19 infection [18] .ImagingRadiologists play the main role in the outbreak of COVID-19.", [["upper respiratory tract", "ANATOMY", 29, 52], ["upper respiratory tract symptoms", "DISEASE", 29, 61], ["fever", "DISEASE", 66, 71], ["leukopenia", "DISEASE", 77, 87], ["lymphopenia", "DISEASE", 91, 102], ["infection", "DISEASE", 358, 367], ["upper respiratory", "ORGANISM_SUBDIVISION", 29, 46], ["tract", "ORGANISM_SUBDIVISION", 47, 52], ["COVID-19", "ORGANISM", 349, 357], ["upper respiratory tract symptoms", "PROBLEM", 29, 61], ["fever", "PROBLEM", 66, 71], ["leukopenia", "PROBLEM", 77, 87], ["lymphopenia", "PROBLEM", 91, 102], ["ImagingRadiological evaluations", "TEST", 192, 223], ["thin slice chest computed tomography", "TEST", 238, 274], ["CT) scan", "TEST", 276, 284], ["management", "TREATMENT", 320, 330], ["COVID", "TEST", 349, 354], ["infection", "PROBLEM", 358, 367], ["COVID", "TEST", 432, 437], ["upper", "ANATOMY_MODIFIER", 29, 34], ["respiratory tract", "ANATOMY", 35, 52], ["lymphopenia", "OBSERVATION", 91, 102], ["chest", "ANATOMY", 249, 254], ["main", "OBSERVATION_MODIFIER", 403, 407]]], ["Early diagnosis of the imaging abnormality could offer suspect pneumonia in cases at risk.", [["pneumonia", "DISEASE", 63, 72], ["the imaging abnormality", "PROBLEM", 19, 42], ["pneumonia", "PROBLEM", 63, 72], ["pneumonia", "OBSERVATION", 63, 72]]], ["Although the final detection of COVID-19 is based on RT-PCR, findings of imaging are vital for pneumonia detection [16] .ImagingCT scans are proposed in cases with suspicious lung abnormalities.", [["lung", "ANATOMY", 175, 179], ["pneumonia", "DISEASE", 95, 104], ["lung abnormalities", "DISEASE", 175, 193], ["lung", "ORGAN", 175, 179], ["COVID-19", "DNA", 32, 40], ["COVID", "TEST", 32, 37], ["RT-PCR", "TEST", 53, 59], ["imaging", "TEST", 73, 80], ["pneumonia detection", "PROBLEM", 95, 114], ["ImagingCT scans", "TEST", 121, 136], ["suspicious lung abnormalities", "PROBLEM", 164, 193], ["pneumonia", "OBSERVATION", 95, 104], ["suspicious", "OBSERVATION_MODIFIER", 164, 174], ["lung", "ANATOMY", 175, 179], ["abnormalities", "OBSERVATION", 180, 193]]], ["Appropriate recognition of COVID-19 pneumonia could provide quick management and follow-ups.", [["pneumonia", "DISEASE", 36, 45], ["COVID", "TEST", 27, 32], ["pneumonia", "PROBLEM", 36, 45], ["quick management", "TREATMENT", 60, 76], ["pneumonia", "OBSERVATION", 36, 45]]], ["Lung imaging shows the severity of COVID-19 disease therefore physicians should be informed about radiological reports.", [["Lung", "ANATOMY", 0, 4], ["Lung", "ORGAN", 0, 4], ["Lung imaging", "TEST", 0, 12], ["COVID-19 disease", "PROBLEM", 35, 51]]], ["Clinical findings from COVID-19-infected cases with a high abnormality on the CT scan who were admitted to the ICU [16] exhibited that patients on admission frequently showed subsegmental consolidation and bilateral multiple lobular, whereas CT reports from non-ICU patients showed subsegmental consolidation and bilateral ground-glass opacity (GGO) [15] .", [["lobular", "ANATOMY", 225, 232], ["GGO", "DISEASE", 345, 348], ["patients", "ORGANISM", 135, 143], ["lobular", "CANCER", 225, 232], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 266, 274], ["Clinical findings", "TEST", 0, 17], ["COVID", "TEST", 23, 28], ["infected cases", "PROBLEM", 32, 46], ["a high abnormality", "PROBLEM", 52, 70], ["the CT scan", "TEST", 74, 85], ["subsegmental consolidation", "PROBLEM", 175, 201], ["bilateral multiple lobular", "PROBLEM", 206, 232], ["subsegmental consolidation", "PROBLEM", 282, 308], ["bilateral ground-glass opacity", "PROBLEM", 313, 343], ["subsegmental", "ANATOMY_MODIFIER", 175, 187], ["consolidation", "OBSERVATION", 188, 201], ["bilateral", "ANATOMY_MODIFIER", 206, 215], ["multiple", "OBSERVATION_MODIFIER", 216, 224], ["lobular", "OBSERVATION", 225, 232], ["subsegmental", "ANATOMY_MODIFIER", 282, 294], ["consolidation", "OBSERVATION", 295, 308], ["bilateral", "ANATOMY_MODIFIER", 313, 322], ["ground", "OBSERVATION_MODIFIER", 323, 329], ["glass opacity", "OBSERVATION", 330, 343]]], ["In severe infection, imaging can confirm heterogeneous consolidation with GGOs in bilateral lungs and bronchiectasis, indicating as \"white lung\" when most lobes of the lung are affected [19] .", [["lungs", "ANATOMY", 92, 97], ["lung", "ANATOMY", 139, 143], ["lobes", "ANATOMY", 155, 160], ["lung", "ANATOMY", 168, 172], ["infection", "DISEASE", 10, 19], ["GGOs", "DISEASE", 74, 78], ["bronchiectasis", "DISEASE", 102, 116], ["lungs", "ORGAN", 92, 97], ["lung", "ORGAN", 139, 143], ["lobes", "ORGAN", 155, 160], ["lung", "ORGAN", 168, 172], ["severe infection", "PROBLEM", 3, 19], ["imaging", "TEST", 21, 28], ["heterogeneous consolidation", "PROBLEM", 41, 68], ["GGOs in bilateral lungs", "PROBLEM", 74, 97], ["bronchiectasis", "PROBLEM", 102, 116], ["white lung\"", "PROBLEM", 133, 144], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["infection", "OBSERVATION", 10, 19], ["heterogeneous", "OBSERVATION_MODIFIER", 41, 54], ["consolidation", "OBSERVATION", 55, 68], ["bilateral", "ANATOMY_MODIFIER", 82, 91], ["lungs", "ANATOMY", 92, 97], ["bronchiectasis", "OBSERVATION", 102, 116], ["lung", "ANATOMY", 139, 143], ["lobes", "ANATOMY_MODIFIER", 155, 160], ["lung", "ANATOMY", 168, 172]]], ["Furthermore, COVID-19 cases might show intralobular septal thickening and bilateral pleura along with little pleural effusion [13] .", [["intralobular septal", "ANATOMY", 39, 58], ["pleura", "ANATOMY", 84, 90], ["pleural", "ANATOMY", 109, 116], ["pleural effusion", "DISEASE", 109, 125], ["intralobular septal", "PATHOLOGICAL_FORMATION", 39, 58], ["pleura", "ORGAN", 84, 90], ["COVID", "PROTEIN", 13, 18], ["COVID", "TEST", 13, 18], ["intralobular septal thickening", "PROBLEM", 39, 69], ["bilateral pleura", "PROBLEM", 74, 90], ["little pleural effusion", "PROBLEM", 102, 125], ["intralobular", "ANATOMY_MODIFIER", 39, 51], ["septal", "ANATOMY_MODIFIER", 52, 58], ["thickening", "OBSERVATION", 59, 69], ["bilateral", "ANATOMY_MODIFIER", 74, 83], ["pleura", "ANATOMY", 84, 90], ["little", "OBSERVATION_MODIFIER", 102, 108], ["pleural", "ANATOMY", 109, 116], ["effusion", "OBSERVATION", 117, 125]]], ["CT scan enables recognition of the initial phase of respiratory infection and provides opportunity for a quick public health care response [20] .", [["respiratory", "ANATOMY", 52, 63], ["respiratory infection", "DISEASE", 52, 73], ["CT scan", "TEST", 0, 7], ["respiratory infection", "PROBLEM", 52, 73], ["respiratory", "ANATOMY", 52, 63], ["infection", "OBSERVATION", 64, 73]]], ["Slice chest CT has been shown as the main evidence for approved findings.", [["Slice chest CT", "TEST", 0, 14], ["chest", "ANATOMY", 6, 11]]], ["Since chest radiography is not sensitive for the diagnosis of GGO and might show normal results in the initial stage of disease [20] , it is not considered as the first-line imaging method for COVID-19.", [["chest", "ANATOMY", 6, 11], ["GGO", "DISEASE", 62, 65], ["chest", "ORGAN", 6, 11], ["GGO", "CANCER", 62, 65], ["chest radiography", "TEST", 6, 23], ["GGO", "PROBLEM", 62, 65], ["disease", "PROBLEM", 120, 127], ["COVID", "TEST", 193, 198], ["chest", "ANATOMY", 6, 11], ["GGO", "OBSERVATION", 62, 65], ["not considered", "UNCERTAINTY", 141, 155]]], ["Nevertheless, bilateral multifocal consolidation can be observed in severe cases, partially fused into high consolidation with minor pleural effusions and even showing with \"white lung\" [13] .", [["pleural effusions", "ANATOMY", 133, 150], ["lung", "ANATOMY", 180, 184], ["pleural effusions", "DISEASE", 133, 150], ["pleural effusions", "CANCER", 133, 150], ["lung", "ORGAN", 180, 184], ["bilateral multifocal consolidation", "PROBLEM", 14, 48], ["high consolidation", "PROBLEM", 103, 121], ["minor pleural effusions", "PROBLEM", 127, 150], ["\"white lung\"", "PROBLEM", 173, 185], ["bilateral", "ANATOMY_MODIFIER", 14, 23], ["multifocal", "OBSERVATION_MODIFIER", 24, 34], ["consolidation", "OBSERVATION", 35, 48], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["high", "OBSERVATION_MODIFIER", 103, 107], ["consolidation", "OBSERVATION", 108, 121], ["minor", "OBSERVATION_MODIFIER", 127, 132], ["pleural", "ANATOMY", 133, 140], ["effusions", "OBSERVATION", 141, 150], ["lung", "ANATOMY", 180, 184]]], ["In this respect, the thin slice chest CT test is more useful for the early diagnosis of COVID-19 pneumonia [18, 20] .", [["COVID", "DISEASE", 88, 93], ["pneumonia", "DISEASE", 97, 106], ["the thin slice chest CT test", "TEST", 17, 45], ["COVID", "TEST", 88, 93], ["pneumonia", "PROBLEM", 97, 106], ["chest", "ANATOMY", 32, 37], ["pneumonia", "OBSERVATION", 97, 106]]], ["Highresolution computed tomography (HRCT) will be easier to detect GGOs in the early stage [4] .ImagingA study with large sample size (3665 confirmed disease) has reported that 95.5% of cases were detected as pneumonia.", [["pneumonia", "DISEASE", 209, 218], ["Highresolution computed tomography", "TEST", 0, 34], ["HRCT", "TEST", 36, 40], ["GGOs", "PROBLEM", 67, 71], ["ImagingA study", "TEST", 96, 110], ["large sample size", "PROBLEM", 116, 133], ["disease", "PROBLEM", 150, 157], ["pneumonia", "PROBLEM", 209, 218], ["large", "OBSERVATION_MODIFIER", 116, 121], ["size", "OBSERVATION_MODIFIER", 129, 133], ["pneumonia", "OBSERVATION", 209, 218]]], ["The Pan et al. [2] conducted an experiment with 21 approved COVID-19 who underwent repeated CT at about 4-day intervals and observed negative results in four cases on initial stage (0-4 days after onset of the early symptom), but repeated CT displayed abnormalities in the lung in all of these four patients.ImagingThe usual imaging features of COVID-19 pneumonia include interstitial inflammation, extensive consolidation with multifocal bilateral GGOs, bilateral involvement, noticeable peripheral or subpleural distribution, posterior part or lower lobe predilection, and multiple lesions [13] .", [["lung", "ANATOMY", 273, 277], ["interstitial", "ANATOMY", 372, 384], ["GGOs", "ANATOMY", 449, 453], ["subpleural", "ANATOMY", 503, 513], ["posterior part", "ANATOMY", 528, 542], ["lower lobe", "ANATOMY", 546, 556], ["lesions", "ANATOMY", 584, 591], ["pneumonia", "DISEASE", 354, 363], ["interstitial inflammation", "DISEASE", 372, 397], ["GGOs", "DISEASE", 449, 453], ["lung", "ORGAN", 273, 277], ["patients", "ORGANISM", 299, 307], ["peripheral", "TISSUE", 489, 499], ["patients", "SPECIES", 299, 307], ["repeated CT", "TEST", 83, 94], ["the early symptom", "PROBLEM", 206, 223], ["repeated CT", "TEST", 230, 241], ["abnormalities in the lung", "PROBLEM", 252, 277], ["Imaging", "TEST", 308, 315], ["COVID", "TEST", 345, 350], ["pneumonia", "PROBLEM", 354, 363], ["interstitial inflammation", "PROBLEM", 372, 397], ["extensive consolidation", "PROBLEM", 399, 422], ["multifocal bilateral GGOs", "PROBLEM", 428, 453], ["bilateral involvement", "PROBLEM", 455, 476], ["noticeable peripheral or subpleural distribution", "PROBLEM", 478, 526], ["posterior part or lower lobe predilection", "PROBLEM", 528, 569], ["multiple lesions", "PROBLEM", 575, 591], ["abnormalities", "OBSERVATION", 252, 265], ["lung", "ANATOMY", 273, 277], ["pneumonia", "OBSERVATION", 354, 363], ["interstitial", "ANATOMY_MODIFIER", 372, 384], ["inflammation", "OBSERVATION", 385, 397], ["extensive", "OBSERVATION_MODIFIER", 399, 408], ["consolidation", "OBSERVATION", 409, 422], ["multifocal", "OBSERVATION_MODIFIER", 428, 438], ["bilateral", "ANATOMY_MODIFIER", 439, 448], ["GGOs", "OBSERVATION", 449, 453], ["bilateral", "ANATOMY_MODIFIER", 455, 464], ["involvement", "OBSERVATION", 465, 476], ["noticeable", "OBSERVATION_MODIFIER", 478, 488], ["peripheral", "ANATOMY_MODIFIER", 489, 499], ["subpleural", "ANATOMY_MODIFIER", 503, 513], ["posterior", "ANATOMY_MODIFIER", 528, 537], ["lower lobe", "ANATOMY", 546, 556], ["multiple", "OBSERVATION_MODIFIER", 575, 583], ["lesions", "OBSERVATION", 584, 591]]], ["Nevertheless, certain cases with COVID-19 pneumonia regularly revealed no respiratory distress or hypoxemia during the course of hospitalization [2] .", [["respiratory", "ANATOMY", 74, 85], ["pneumonia", "DISEASE", 42, 51], ["respiratory distress", "DISEASE", 74, 94], ["hypoxemia", "DISEASE", 98, 107], ["COVID", "TEST", 33, 38], ["pneumonia", "PROBLEM", 42, 51], ["respiratory distress", "PROBLEM", 74, 94], ["hypoxemia", "PROBLEM", 98, 107], ["pneumonia", "OBSERVATION", 42, 51], ["no", "UNCERTAINTY", 71, 73], ["respiratory distress", "OBSERVATION", 74, 94], ["hypoxemia", "OBSERVATION", 98, 107]]], ["Furthermore, since the CT scan results of COVID-19 overlap with other viral pneumonia, therefore RT-PCR assay is strongly recommended for rapid detection and treatment [4] .ImagingAccording to the Pan et al. report, the cases who recovered from this virus pneumonia, experienced four stages based on their CT results: (1) early stage (0-4 days) that shows small GGO distributed subpleurally in the lower part, (2) progressive stage (5-8 days) with infection quickly extended to a bilateral multi-lobe with diffused GGO, consolidation, and crazy-paving pattern, (3) peak stage (10-13 days) that shows slowly expanding of the involved part to the peak involvement, including diffused GGO, crazy-paving pattern, residual parenchymal bands, and consolidation, and finally (4) absorption stage which occurs two weeks after the onset of first symptoms and shows that the disease is managed and the consolidation is slowly absorbed ( Fig. 3 and Table 4 ).", [["subpleurally", "ANATOMY", 378, 390], ["lower part", "ANATOMY", 398, 408], ["multi-lobe", "ANATOMY", 490, 500], ["parenchymal", "ANATOMY", 718, 729], ["viral pneumonia", "DISEASE", 70, 85], ["pneumonia", "DISEASE", 256, 265], ["infection", "DISEASE", 448, 457], ["GGO", "DISEASE", 515, 518], ["GGO", "DISEASE", 682, 685], ["COVID-19", "DNA", 42, 50], ["the CT scan", "TEST", 19, 30], ["COVID", "TEST", 42, 47], ["other viral pneumonia", "PROBLEM", 64, 85], ["RT-PCR assay", "TEST", 97, 109], ["rapid detection", "TEST", 138, 153], ["this virus pneumonia", "PROBLEM", 245, 265], ["their CT", "TEST", 300, 308], ["small GGO", "PROBLEM", 356, 365], ["progressive stage", "PROBLEM", 414, 431], ["infection", "PROBLEM", 448, 457], ["a bilateral multi-lobe", "PROBLEM", 478, 500], ["diffused GGO", "PROBLEM", 506, 518], ["consolidation", "PROBLEM", 520, 533], ["crazy-paving pattern", "PROBLEM", 539, 559], ["peak stage", "TEST", 565, 575], ["the peak involvement", "PROBLEM", 641, 661], ["diffused GGO", "PROBLEM", 673, 685], ["crazy-paving pattern", "PROBLEM", 687, 707], ["residual parenchymal bands", "PROBLEM", 709, 735], ["consolidation", "PROBLEM", 741, 754], ["first symptoms", "PROBLEM", 831, 845], ["the disease", "PROBLEM", 861, 872], ["the consolidation", "PROBLEM", 888, 905], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["pneumonia", "OBSERVATION", 76, 85], ["pneumonia", "OBSERVATION", 256, 265], ["small", "OBSERVATION_MODIFIER", 356, 361], ["GGO", "OBSERVATION", 362, 365], ["distributed", "OBSERVATION_MODIFIER", 366, 377], ["subpleurally", "OBSERVATION_MODIFIER", 378, 390], ["lower part", "ANATOMY_MODIFIER", 398, 408], ["progressive", "OBSERVATION_MODIFIER", 414, 425], ["stage", "OBSERVATION_MODIFIER", 426, 431], ["infection", "OBSERVATION", 448, 457], ["bilateral", "ANATOMY_MODIFIER", 480, 489], ["multi-lobe", "ANATOMY", 490, 500], ["diffused", "OBSERVATION_MODIFIER", 506, 514], ["GGO", "OBSERVATION", 515, 518], ["consolidation", "OBSERVATION", 520, 533], ["crazy", "OBSERVATION_MODIFIER", 539, 544], ["slowly", "OBSERVATION_MODIFIER", 600, 606], ["peak involvement", "OBSERVATION", 645, 661], ["diffused", "OBSERVATION_MODIFIER", 673, 681], ["GGO", "OBSERVATION", 682, 685], ["crazy", "OBSERVATION_MODIFIER", 687, 692], ["residual", "OBSERVATION_MODIFIER", 709, 717], ["parenchymal bands", "OBSERVATION", 718, 735], ["consolidation", "OBSERVATION", 741, 754], ["disease", "OBSERVATION", 865, 872], ["consolidation", "OBSERVATION", 892, 905], ["slowly", "OBSERVATION_MODIFIER", 909, 915], ["absorbed", "OBSERVATION_MODIFIER", 916, 924]]], ["No crazy-paving signs exist anymore.ImagingNevertheless, in this step, widespread GGO can be observed as an indication of the consolidation absorption.", [["crazy", "PROBLEM", 3, 8], ["Imaging", "TEST", 36, 43], ["widespread GGO", "PROBLEM", 71, 85], ["the consolidation absorption", "PROBLEM", 122, 150], ["crazy", "OBSERVATION", 3, 8], ["widespread", "OBSERVATION_MODIFIER", 71, 81], ["GGO", "OBSERVATION", 82, 85], ["consolidation", "OBSERVATION", 126, 139]]], ["According to the CT scores, the absorption step extended beyond 26 days after the onset of first symptom [2] .RT-PCR testThe most common detection assay is RT-PCR based on the RNA isolated from respiratory specimens such as oropharyngeal swabs, sputum, nasopharyngeal aspirate, bronchoalveolar lavage, or deep tracheal aspirate [3] .RT-PCR testAt the moment, the RT-PCR method is used in clinics to confirm the COVID-19 infection.RT-PCR testWhile this assay remains the reference standard to the detection of COVID-19, the high falsenegative RT-PCR results [21] and inapplicability of RT-PCR in the initial phase of the disease limited the rapid diagnosis of infected subjects [13] .", [["respiratory specimens", "ANATOMY", 194, 215], ["oropharyngeal swabs", "ANATOMY", 224, 243], ["sputum", "ANATOMY", 245, 251], ["nasopharyngeal aspirate", "ANATOMY", 253, 276], ["bronchoalveolar lavage", "ANATOMY", 278, 300], ["tracheal", "ANATOMY", 310, 318], ["infection", "DISEASE", 420, 429], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 224, 243], ["sputum", "ORGANISM_SUBSTANCE", 245, 251], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 253, 276], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 278, 300], ["COVID-19", "CELL", 509, 517], ["COVID-19", "DNA", 509, 517], ["COVID-19", "SPECIES", 411, 419], ["COVID-19", "SPECIES", 509, 517], ["the CT scores", "TEST", 13, 26], ["first symptom", "PROBLEM", 91, 104], [".RT-PCR test", "TEST", 109, 121], ["The most common detection assay", "TEST", 121, 152], ["RT-PCR", "TEST", 156, 162], ["the RNA", "TEST", 172, 179], ["respiratory specimens", "TEST", 194, 215], ["oropharyngeal swabs", "TEST", 224, 243], ["sputum", "TEST", 245, 251], ["nasopharyngeal aspirate", "TEST", 253, 276], ["bronchoalveolar lavage", "TEST", 278, 300], ["deep tracheal aspirate", "TEST", 305, 327], [".RT-PCR test", "TEST", 332, 344], ["the RT-PCR method", "TREATMENT", 359, 376], ["the COVID-19 infection", "PROBLEM", 407, 429], ["RT-PCR test", "TEST", 430, 441], ["this assay", "TEST", 447, 457], ["COVID", "TEST", 509, 514], ["RT-PCR", "TEST", 585, 591], ["the disease", "PROBLEM", 616, 627], ["infected subjects", "PROBLEM", 659, 676], ["oropharyngeal", "ANATOMY", 224, 237], ["nasopharyngeal", "ANATOMY", 253, 267], ["bronchoalveolar lavage", "OBSERVATION", 278, 300], ["deep", "ANATOMY_MODIFIER", 305, 309], ["tracheal", "ANATOMY", 310, 318], ["aspirate", "OBSERVATION", 319, 327], ["infection", "OBSERVATION", 420, 429], ["disease", "OBSERVATION", 620, 627], ["infected", "OBSERVATION", 659, 667]]], ["It has been reported that the sensitivity of chest CT was superior to that of RT-PCR (98% vs. 71%, respectively).", [["chest", "ANATOMY", 45, 50], ["chest", "ORGAN", 45, 50], ["chest CT", "TEST", 45, 53], ["RT", "TEST", 78, 80], ["PCR", "TEST", 81, 84], ["chest", "ANATOMY", 45, 50]]], ["The causes for the low effectiveness of viral nucleic acid measurement might include; low viral load, inappropriate sample, variation in the diagnosis rate from different kits, and undeveloped technology for detection of the nucleic acid [22] .", [["sample", "ANATOMY", 116, 122], ["nucleic acid", "CHEMICAL", 46, 58], ["nucleic acid", "CHEMICAL", 225, 237], ["viral nucleic acid measurement", "TEST", 40, 70], ["low viral load", "PROBLEM", 86, 100], ["inappropriate sample", "PROBLEM", 102, 122], ["the nucleic acid", "TEST", 221, 237]]], ["Lower respiratory tract sample (bronchoalveolar lavage fluid, deep tracheal aspirates), and induced sputum has the highest genome fraction and viral load compared to upper respiratory tract samples, which are optimal for improving detection accuracy [3] .", [["Lower respiratory tract sample", "ANATOMY", 0, 30], ["bronchoalveolar lavage fluid", "ANATOMY", 32, 60], ["tracheal aspirates", "ANATOMY", 67, 85], ["sputum", "ANATOMY", 100, 106], ["upper respiratory tract samples", "ANATOMY", 166, 197], ["bronchoalveolar lavage fluid", "MULTI-TISSUE_STRUCTURE", 32, 60], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 67, 85], ["Lower respiratory tract sample", "PROBLEM", 0, 30], ["bronchoalveolar lavage fluid", "TEST", 32, 60], ["deep tracheal aspirates", "TEST", 62, 85], ["induced sputum", "PROBLEM", 92, 106], ["viral load", "PROBLEM", 143, 153], ["upper respiratory tract samples", "TEST", 166, 197], ["respiratory tract", "ANATOMY", 6, 23], ["bronchoalveolar lavage", "OBSERVATION", 32, 54], ["deep", "ANATOMY_MODIFIER", 62, 66], ["tracheal", "ANATOMY", 67, 75], ["viral load", "OBSERVATION", 143, 153], ["upper", "ANATOMY_MODIFIER", 166, 171], ["respiratory tract", "ANATOMY", 172, 189]]], ["Nevertheless, with sample collection and transportation, as well as kit quality, the total positive rate of RT-PCR for throat swab specimens was about 60% at initial presentation in different studies (Table 5 ) [23, 24] .RT-PCR testThe positive rate of chest CT imaging and RT-PCR assay in Ai et al. [23] cohort study was 88%, and 59% for the detection of suspected subjects with COVID-19, respectively.", [["sample", "ANATOMY", 19, 25], ["throat swab specimens", "ANATOMY", 119, 140], ["sample collection", "TEST", 19, 36], ["PCR", "TEST", 111, 114], ["throat swab specimens", "TEST", 119, 140], ["PCR test", "TEST", 224, 232], ["chest CT imaging", "TEST", 253, 269], ["RT-PCR assay", "TEST", 274, 286], ["cohort study", "TEST", 305, 317], ["the detection", "TEST", 339, 352], ["COVID", "TEST", 380, 385], ["chest", "ANATOMY", 253, 258]]], ["They showed that chest CT imaging had higher sensitivity for the diagnosis of the COVID-19RT-PCR testinfection as compared with initial RT-PCR from swab samples.", [["chest", "ANATOMY", 17, 22], ["swab samples", "ANATOMY", 148, 160], ["19RT", "DNA", 88, 92], ["chest CT imaging", "TEST", 17, 33], ["the COVID", "TEST", 78, 87], ["PCR testinfection", "PROBLEM", 93, 110], ["initial RT-PCR", "TEST", 128, 142], ["swab samples", "TEST", 148, 160], ["chest", "ANATOMY", 17, 22]]], ["They also reported that 42% of infected subjects exhibited improvement of follow-up chest CT scans before the RT-PCR finding turning negative [23] .RT-PCR testXie et al. [25] , by evaluating of the 167 infected cases, showed that 3% (5/167) of patients had negative RT-PCR while they had positive chest CT.", [["subjects", "ORGANISM", 40, 48], ["patients", "ORGANISM", 244, 252], ["patients", "SPECIES", 244, 252], ["infected subjects", "PROBLEM", 31, 48], ["follow-up chest CT scans", "TEST", 74, 98], ["the RT-PCR", "TEST", 106, 116], ["positive chest CT", "TEST", 288, 305], ["chest", "ANATOMY", 84, 89], ["chest", "ANATOMY", 297, 302]]], ["PCR procedure for COVID-19 may be falsely negative because of laboratory error, inappropriate sample, or inadequate viral load in the sample.", [["sample", "ANATOMY", 94, 100], ["PCR procedure", "TEST", 0, 13], ["COVID", "TEST", 18, 23], ["laboratory error", "PROBLEM", 62, 78], ["inappropriate sample", "PROBLEM", 80, 100], ["inadequate viral load in the sample", "PROBLEM", 105, 140], ["viral load", "OBSERVATION", 116, 126]]], ["The chest CT gives fast results, easy to do, and enables quick diagnoses of initial COVID-19 pneumonia [13] .Mechanism of actionThe COVID-19 spreads and invades via the lung, stimulates inflammation, and induces cytokine storm, leading to alteration in immune cells such as WBC and lymphocytes.Mechanism of actionAccordingly, administration of intravenous immunoglobulins is being used as therapeutic strategy for most subjects with decreased levels of WBC and lymphocyte [8] .Mechanism of actionCOVID-19 patients are susceptible to liver failure, since COVID-19 directly binds to angiotensin-converting enzyme-2 (ACE2) positive bile duct cells [26] .", [["chest", "ANATOMY", 4, 9], ["lung", "ANATOMY", 169, 173], ["immune cells", "ANATOMY", 253, 265], ["WBC", "ANATOMY", 274, 277], ["lymphocytes", "ANATOMY", 282, 293], ["intravenous", "ANATOMY", 344, 355], ["WBC", "ANATOMY", 453, 456], ["lymphocyte", "ANATOMY", 461, 471], ["liver", "ANATOMY", 533, 538], ["bile duct cells", "ANATOMY", 629, 644], ["pneumonia", "DISEASE", 93, 102], ["COVID-19", "CHEMICAL", 132, 140], ["inflammation", "DISEASE", 186, 198], ["liver failure", "DISEASE", 533, 546], ["COVID-19", "CHEMICAL", 554, 562], ["angiotensin", "CHEMICAL", 581, 592], ["COVID-19", "CHEMICAL", 554, 562], ["lung", "ORGAN", 169, 173], ["immune cells", "CELL", 253, 265], ["WBC", "CELL", 274, 277], ["lymphocytes", "CELL", 282, 293], ["WBC", "CELL", 453, 456], ["lymphocyte", "CELL", 461, 471], ["patients", "ORGANISM", 505, 513], ["liver", "ORGAN", 533, 538], ["COVID-19", "GENE_OR_GENE_PRODUCT", 554, 562], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 581, 612], ["ACE2", "GENE_OR_GENE_PRODUCT", 614, 618], ["COVID-19", "DNA", 132, 140], ["cytokine", "PROTEIN", 212, 220], ["immune cells", "CELL_TYPE", 253, 265], ["WBC", "CELL_TYPE", 274, 277], ["lymphocytes", "CELL_TYPE", 282, 293], ["WBC", "CELL_TYPE", 453, 456], ["angiotensin-converting enzyme-2 (ACE2) positive bile duct cells", "CELL_LINE", 581, 644], ["patients", "SPECIES", 505, 513], ["The chest CT", "TEST", 0, 12], ["initial COVID", "TEST", 76, 89], ["pneumonia", "PROBLEM", 93, 102], ["The COVID", "TREATMENT", 128, 137], ["stimulates inflammation", "PROBLEM", 175, 198], ["cytokine storm", "PROBLEM", 212, 226], ["alteration in immune cells", "PROBLEM", 239, 265], ["WBC", "TEST", 274, 277], ["lymphocytes", "TEST", 282, 293], ["intravenous immunoglobulins", "TREATMENT", 344, 371], ["therapeutic strategy", "TREATMENT", 389, 409], ["WBC", "TEST", 453, 456], ["lymphocyte", "TEST", 461, 471], ["actionCOVID", "TEST", 490, 501], ["liver failure", "PROBLEM", 533, 546], ["COVID", "TEST", 554, 559], ["angiotensin", "TEST", 581, 592], ["ACE2", "TEST", 614, 618], ["positive bile duct cells", "PROBLEM", 620, 644], ["chest", "ANATOMY", 4, 9], ["pneumonia", "OBSERVATION", 93, 102], ["lung", "ANATOMY", 169, 173], ["inflammation", "OBSERVATION", 186, 198], ["cytokine storm", "OBSERVATION", 212, 226], ["immune cells", "OBSERVATION", 253, 265], ["lymphocytes", "ANATOMY", 282, 293], ["liver", "ANATOMY", 533, 538], ["failure", "OBSERVATION", 539, 546], ["bile duct", "ANATOMY", 629, 638]]], ["It has been shown that ACE2 is protective against several lung diseases, including ARDS, asthma, acute lung injury (ALI), chronic obstructive pulmonary disease (COPD), and pulmonary hypertension [27] .Mechanism of actionACE2 has also been demonstrated to be the receptor for both the SARS-CoV and the human respiratory coronavirus NL63.", [["lung", "ANATOMY", 58, 62], ["lung", "ANATOMY", 103, 107], ["pulmonary", "ANATOMY", 142, 151], ["pulmonary", "ANATOMY", 172, 181], ["lung diseases", "DISEASE", 58, 71], ["ARDS", "DISEASE", 83, 87], ["asthma", "DISEASE", 89, 95], ["acute lung injury", "DISEASE", 97, 114], ["ALI", "DISEASE", 116, 119], ["chronic obstructive pulmonary disease", "DISEASE", 122, 159], ["COPD", "DISEASE", 161, 165], ["pulmonary hypertension", "DISEASE", 172, 194], ["actionACE2", "CHEMICAL", 214, 224], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["lung", "ORGAN", 58, 62], ["lung", "ORGAN", 103, 107], ["pulmonary", "ORGAN", 142, 151], ["pulmonary", "ORGAN", 172, 181], ["actionACE2", "GENE_OR_GENE_PRODUCT", 214, 224], ["SARS-CoV", "ORGANISM", 284, 292], ["human", "ORGANISM", 301, 306], ["respiratory coronavirus", "ORGANISM", 307, 330], ["NL63", "ORGANISM", 331, 335], ["ACE2", "PROTEIN", 23, 27], ["actionACE2", "PROTEIN", 214, 224], ["human respiratory coronavirus NL63", "PROTEIN", 301, 335], ["human", "SPECIES", 301, 306], ["coronavirus", "SPECIES", 319, 330], ["SARS-CoV", "SPECIES", 284, 292], ["human respiratory coronavirus", "SPECIES", 301, 330], ["several lung diseases", "PROBLEM", 50, 71], ["ARDS", "PROBLEM", 83, 87], ["asthma", "PROBLEM", 89, 95], ["acute lung injury", "PROBLEM", 97, 114], ["chronic obstructive pulmonary disease", "PROBLEM", 122, 159], ["COPD)", "PROBLEM", 161, 166], ["pulmonary hypertension", "PROBLEM", 172, 194], ["Mechanism of actionACE2", "PROBLEM", 201, 224], ["the SARS", "TEST", 280, 288], ["the human respiratory coronavirus", "TEST", 297, 330], ["protective against", "UNCERTAINTY", 31, 49], ["lung", "ANATOMY", 58, 62], ["diseases", "OBSERVATION", 63, 71], ["ARDS", "OBSERVATION", 83, 87], ["asthma", "OBSERVATION", 89, 95], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["lung", "ANATOMY", 103, 107], ["injury", "OBSERVATION", 108, 114], ["ALI", "ANATOMY", 116, 119], ["chronic", "OBSERVATION_MODIFIER", 122, 129], ["obstructive", "OBSERVATION_MODIFIER", 130, 141], ["pulmonary", "ANATOMY", 142, 151], ["disease", "OBSERVATION", 152, 159], ["COPD", "OBSERVATION", 161, 165], ["pulmonary", "ANATOMY", 172, 181], ["hypertension", "OBSERVATION", 182, 194], ["respiratory coronavirus", "OBSERVATION", 307, 330]]], ["The previous experiment established the positive correlation of ACE2 expression and the infection of SARS-CoV in vitro [28] .", [["infection", "DISEASE", 88, 97], ["SARS", "DISEASE", 101, 105], ["ACE2", "GENE_OR_GENE_PRODUCT", 64, 68], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 101, 109], ["ACE2", "PROTEIN", 64, 68], ["SARS-CoV", "SPECIES", 101, 109], ["ACE2 expression", "PROBLEM", 64, 79], ["the infection of SARS", "PROBLEM", 84, 105], ["infection", "OBSERVATION", 88, 97]]], ["SARS-CoV significantly decreased ACE2 protein expression after infecting the host [28] .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["ACE2", "PROTEIN", 33, 37], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV significantly decreased ACE2 protein expression", "PROBLEM", 5, 56]]], ["Consequently, the ACE2 expression in different organs might be vital for the vulnerability, signs, and outcome of COVID-19.", [["organs", "ANATOMY", 47, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["organs", "ORGAN", 47, 53], ["ACE2", "PROTEIN", 18, 22], ["the ACE2 expression in different organs", "PROBLEM", 14, 53], ["COVID", "TEST", 114, 119]]], ["An analysis of single-cell RNA-sequencing (RNA-seq) showed that Asian males might have higher ACE2 expression levels [28] .Mechanism of actionACE2 is one of the components of the renin angiotensin system (RAS) that regulates blood pressure, systemic vascular resistance, and electrolyte balance.", [["blood", "ANATOMY", 225, 230], ["vascular", "ANATOMY", 250, 258], ["angiotensin", "CHEMICAL", 185, 196], ["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["actionACE2", "GENE_OR_GENE_PRODUCT", 136, 146], ["renin angiotensin system", "GENE_OR_GENE_PRODUCT", 179, 203], ["RAS", "GENE_OR_GENE_PRODUCT", 205, 208], ["blood", "ORGANISM_SUBSTANCE", 225, 230], ["vascular", "MULTI-TISSUE_STRUCTURE", 250, 258], ["ACE2", "PROTEIN", 94, 98], ["actionACE2", "PROTEIN", 136, 146], ["renin", "PROTEIN", 179, 184], ["An analysis", "TEST", 0, 11], ["single-cell RNA", "TEST", 15, 30], ["RNA", "TEST", 43, 46], ["higher ACE2 expression levels", "PROBLEM", 87, 116], ["the renin angiotensin system", "TREATMENT", 175, 203], ["blood pressure", "TEST", 225, 239], ["systemic vascular resistance", "TEST", 241, 269], ["pressure", "OBSERVATION_MODIFIER", 231, 239], ["vascular resistance", "OBSERVATION", 250, 269], ["electrolyte balance", "OBSERVATION", 275, 294]]], ["In the respiratory system, local lung RAS activation can influence the pathogenesis of lung damage through numerous mechanisms, including elevation of vascular permeability and changes in alveolar epithelial cells.", [["respiratory system", "ANATOMY", 7, 25], ["lung", "ANATOMY", 33, 37], ["lung", "ANATOMY", 87, 91], ["vascular", "ANATOMY", 151, 159], ["alveolar epithelial cells", "ANATOMY", 188, 213], ["lung damage", "DISEASE", 87, 98], ["lung", "ORGAN", 33, 37], ["RAS", "GENE_OR_GENE_PRODUCT", 38, 41], ["lung", "ORGAN", 87, 91], ["vascular", "MULTI-TISSUE_STRUCTURE", 151, 159], ["alveolar epithelial cells", "CELL", 188, 213], ["RAS", "PROTEIN", 38, 41], ["alveolar epithelial cells", "CELL_TYPE", 188, 213], ["local lung RAS activation", "PROBLEM", 27, 52], ["lung damage", "PROBLEM", 87, 98], ["elevation of vascular permeability", "PROBLEM", 138, 172], ["changes in alveolar epithelial cells", "PROBLEM", 177, 213], ["respiratory system", "ANATOMY", 7, 25], ["lung", "ANATOMY", 33, 37], ["RAS", "OBSERVATION", 38, 41], ["lung", "ANATOMY", 87, 91], ["damage", "OBSERVATION", 92, 98], ["elevation", "OBSERVATION_MODIFIER", 138, 147], ["vascular", "ANATOMY", 151, 159], ["permeability", "OBSERVATION", 160, 172], ["alveolar epithelial cells", "OBSERVATION", 188, 213]]], ["In this cascade, renin increases angiotensinogen to produce angiotensin I (Ang I, a decapeptide hormone) [29] .", [["angiotensin I", "CHEMICAL", 60, 73], ["Ang", "CHEMICAL", 75, 78], ["renin", "GENE_OR_GENE_PRODUCT", 17, 22], ["angiotensinogen", "GENE_OR_GENE_PRODUCT", 33, 48], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 60, 73], ["Ang I", "GENE_OR_GENE_PRODUCT", 75, 80], ["renin", "PROTEIN", 17, 22], ["angiotensinogen", "PROTEIN", 33, 48], ["angiotensin I", "PROTEIN", 60, 73], ["Ang I", "PROTEIN", 75, 80], ["renin increases angiotensinogen", "TREATMENT", 17, 48], ["angiotensin I (Ang I, a decapeptide hormone", "TREATMENT", 60, 103]]], ["The ACE hydrolyzes Ang I to angiotensin II.", [["Ang I", "CHEMICAL", 19, 24], ["angiotensin II", "CHEMICAL", 28, 42], ["ACE", "GENE_OR_GENE_PRODUCT", 4, 7], ["Ang I", "GENE_OR_GENE_PRODUCT", 19, 24], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 28, 42], ["ACE", "PROTEIN", 4, 7], ["Ang I", "PROTEIN", 19, 24], ["angiotensin II", "PROTEIN", 28, 42], ["The ACE hydrolyzes Ang I to angiotensin II", "TREATMENT", 0, 42]]], ["The angiotensins II binds to its receptors and induces vasoactive effects.", [["angiotensins II", "CHEMICAL", 4, 19], ["angiotensins II", "GENE_OR_GENE_PRODUCT", 4, 19], ["angiotensins II", "PROTEIN", 4, 19], ["The angiotensins II binds", "TREATMENT", 0, 25], ["vasoactive effects", "TREATMENT", 55, 73], ["vasoactive effects", "OBSERVATION", 55, 73]]], ["ACE2 catalyzes Ang I to generate angiotensin-(1-9) and Ang II to Ang-(1-7), and antagonize several effects of Ang II.", [["Ang", "CHEMICAL", 15, 18], ["angiotensin-(1-9", "CHEMICAL", 33, 49], ["Ang II", "CHEMICAL", 55, 61], ["Ang-(1-7", "CHEMICAL", 65, 73], ["Ang II", "CHEMICAL", 110, 116], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang I", "GENE_OR_GENE_PRODUCT", 15, 20], ["angiotensin-(1-9", "GENE_OR_GENE_PRODUCT", 33, 49], ["Ang II", "GENE_OR_GENE_PRODUCT", 55, 61], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 65, 73], ["Ang II", "GENE_OR_GENE_PRODUCT", 110, 116], ["ACE2", "PROTEIN", 0, 4], ["Ang I", "PROTEIN", 15, 20], ["Ang II", "PROTEIN", 110, 116], ["ACE2 catalyzes", "TREATMENT", 0, 14], ["angiotensin", "TEST", 33, 44], ["Ang II to Ang", "TREATMENT", 55, 68], ["Ang II", "TREATMENT", 110, 116]]], ["ACE2, by reducing local Ang II levels, acts as a counter-regulatory enzyme [29, 30] .", [["Ang II", "CHEMICAL", 24, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang II", "GENE_OR_GENE_PRODUCT", 24, 30], ["ACE2", "PROTEIN", 0, 4], ["Ang II", "PROTEIN", 24, 30], ["regulatory enzyme", "PROTEIN", 57, 74], ["ACE2", "TREATMENT", 0, 4]]], ["ACE2 deficiency and consequent high Ang II concentration, lead to increased vascular permeability, neutrophil accumulation, pulmonary oedema, disruption of gas exchange, and exacerbation in lung function.", [["vascular", "ANATOMY", 76, 84], ["neutrophil", "ANATOMY", 99, 109], ["pulmonary", "ANATOMY", 124, 133], ["lung", "ANATOMY", 190, 194], ["Ang II", "CHEMICAL", 36, 42], ["pulmonary oedema", "DISEASE", 124, 140], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ang II", "GENE_OR_GENE_PRODUCT", 36, 42], ["vascular", "MULTI-TISSUE_STRUCTURE", 76, 84], ["neutrophil", "CELL", 99, 109], ["pulmonary", "ORGAN", 124, 133], ["lung", "ORGAN", 190, 194], ["ACE2", "PROTEIN", 0, 4], ["Ang II", "PROTEIN", 36, 42], ["ACE2 deficiency", "PROBLEM", 0, 15], ["consequent high Ang II concentration", "PROBLEM", 20, 56], ["increased vascular permeability", "PROBLEM", 66, 97], ["neutrophil accumulation", "PROBLEM", 99, 122], ["pulmonary oedema", "PROBLEM", 124, 140], ["disruption of gas exchange", "PROBLEM", 142, 168], ["exacerbation in lung function", "PROBLEM", 174, 203], ["deficiency", "OBSERVATION", 5, 15], ["high Ang II", "OBSERVATION_MODIFIER", 31, 42], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["vascular", "ANATOMY", 76, 84], ["permeability", "OBSERVATION", 85, 97], ["neutrophil accumulation", "OBSERVATION", 99, 122], ["pulmonary", "ANATOMY", 124, 133], ["oedema", "OBSERVATION", 134, 140], ["gas exchange", "OBSERVATION", 156, 168], ["exacerbation", "OBSERVATION_MODIFIER", 174, 186], ["lung", "ANATOMY", 190, 194]]], ["On the other hand, active recombinant ACE2 protein alleviates ALI symptoms in ACE2 knockout animals [31] .", [["ALI", "DISEASE", 62, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 38, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["recombinant ACE2 protein", "PROTEIN", 26, 50], ["ACE2", "PROTEIN", 78, 82], ["active recombinant ACE2 protein", "TREATMENT", 19, 50], ["ALI symptoms", "PROBLEM", 62, 74]]], ["In the lungs, RAS activity is basically high, and the activity of the ACE2 is also highly increased to control the balance of Ang II/Ang-(1-7)Mechanism of actionconcentration [29, 30] .", [["lungs", "ANATOMY", 7, 12], ["Ang II", "CHEMICAL", 126, 132], ["Ang", "CHEMICAL", 133, 136], ["lungs", "ORGAN", 7, 12], ["RAS", "GENE_OR_GENE_PRODUCT", 14, 17], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["Ang II", "GENE_OR_GENE_PRODUCT", 126, 132], ["Ang", "GENE_OR_GENE_PRODUCT", 133, 136], ["1-7", "GENE_OR_GENE_PRODUCT", 138, 141], ["RAS", "PROTEIN", 14, 17], ["ACE2", "PROTEIN", 70, 74], ["Ang II", "PROTEIN", 126, 132], ["the ACE2", "TEST", 66, 74], ["Ang II/Ang", "TREATMENT", 126, 136], ["lungs", "ANATOMY", 7, 12], ["activity", "OBSERVATION_MODIFIER", 18, 26], ["basically", "OBSERVATION_MODIFIER", 30, 39], ["high", "OBSERVATION_MODIFIER", 40, 44]]], ["It has been shown that ACE2 participates in the severe ALI and failure that is induced by SARS, influenza A H5N1 virus, acid aspiration, sepsis, and lethal avian.Mechanism of actionCurrently, ACE2 is proposed as a potential therapeutic target for the treatment of ALI in humans [32] .Mechanism of actionIn animal models of ARDS, ACE2 knockout animals showed more severe symptoms, whereas the upregulation of the ACE2 has protective effects.", [["ALI", "DISEASE", 55, 58], ["SARS", "DISEASE", 90, 94], ["sepsis", "DISEASE", 137, 143], ["ALI", "DISEASE", 264, 267], ["ARDS", "DISEASE", 323, 327], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["influenza A H5N1 virus", "ORGANISM", 96, 118], ["ACE2", "GENE_OR_GENE_PRODUCT", 192, 196], ["humans", "ORGANISM", 271, 277], ["ACE2", "GENE_OR_GENE_PRODUCT", 329, 333], ["ACE2", "GENE_OR_GENE_PRODUCT", 412, 416], ["ACE2", "PROTEIN", 23, 27], ["ACE2", "PROTEIN", 192, 196], ["ACE2", "PROTEIN", 329, 333], ["ACE2", "PROTEIN", 412, 416], ["A H5N1 virus", "SPECIES", 106, 118], ["humans", "SPECIES", 271, 277], ["A H5N1 virus", "SPECIES", 106, 118], ["humans", "SPECIES", 271, 277], ["the severe ALI", "PROBLEM", 44, 58], ["failure", "PROBLEM", 63, 70], ["SARS", "PROBLEM", 90, 94], ["influenza", "PROBLEM", 96, 105], ["A H5N1 virus", "PROBLEM", 106, 118], ["acid aspiration", "PROBLEM", 120, 135], ["sepsis", "PROBLEM", 137, 143], ["lethal avian", "PROBLEM", 149, 161], ["ALI", "PROBLEM", 264, 267], ["ARDS", "PROBLEM", 323, 327], ["ACE2 knockout animals", "PROBLEM", 329, 350], ["more severe symptoms", "PROBLEM", 358, 378], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["ALI", "OBSERVATION", 55, 58], ["failure", "OBSERVATION", 63, 70], ["sepsis", "OBSERVATION", 137, 143], ["ARDS", "OBSERVATION", 323, 327], ["severe", "OBSERVATION_MODIFIER", 363, 369]]], ["In animals infected by SARS-CoV, both the viral spike protein and replication protein alone can decrease ACE2 but not ACE expression.", [["SARS", "DISEASE", 23, 27], ["animals", "ORGANISM", 3, 10], ["SARS-CoV", "ORGANISM", 23, 31], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["ACE", "GENE_OR_GENE_PRODUCT", 118, 121], ["viral spike protein", "PROTEIN", 42, 61], ["replication protein", "PROTEIN", 66, 85], ["ACE2", "PROTEIN", 105, 109], ["ACE", "PROTEIN", 118, 121], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["CoV", "PROBLEM", 28, 31], ["the viral spike protein", "PROBLEM", 38, 61], ["replication protein", "TREATMENT", 66, 85], ["ACE2", "TEST", 105, 109], ["infected", "OBSERVATION", 11, 19]]], ["Furthermore, SARS-CoV also motivates quick ACE2 downregulation from the cell surface.", [["cell surface", "ANATOMY", 72, 84], ["SARS", "DISEASE", 13, 17], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["cell surface", "CELLULAR_COMPONENT", 72, 84], ["ACE2", "PROTEIN", 43, 47], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["cell surface", "OBSERVATION", 72, 84]]], ["These findings suggest that the SARS-CoV interrupts physiological balance between ACE/ACE2 and Ang II/Ang-(1-7) [29] .", [["SARS", "DISEASE", 32, 36], ["Ang II", "CHEMICAL", 95, 101], ["Ang", "CHEMICAL", 102, 105], ["SARS-CoV", "ORGANISM", 32, 40], ["ACE", "GENE_OR_GENE_PRODUCT", 82, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["Ang II", "GENE_OR_GENE_PRODUCT", 95, 101], ["Ang-(1-7", "GENE_OR_GENE_PRODUCT", 102, 110], ["ACE", "PROTEIN", 82, 85], ["ACE2", "PROTEIN", 86, 90], ["Ang II", "PROTEIN", 95, 101], ["SARS-CoV", "SPECIES", 32, 40], ["the SARS", "PROBLEM", 28, 36], ["ACE/ACE2", "TREATMENT", 82, 90], ["Ang II/Ang", "TREATMENT", 95, 105]]], ["Consequently, high Ang II concentration in the lung tissue aggravates acid-induced acute lung injury and causes severe lung failure.Mechanism of actionLikewise, the spike protein of COVID-19 interacts with ACE2, and probably the pathogenic mechanism might share between SARS-CoV and COVID-19 [29] .Surgery in COVID-19 patientsHealthcare workers are on the front lines of battling COVID-19 that put them at high risk of COVID-19 infection.", [["lung tissue", "ANATOMY", 47, 58], ["lung", "ANATOMY", 89, 93], ["lung", "ANATOMY", 119, 123], ["Ang II", "CHEMICAL", 19, 25], ["lung injury", "DISEASE", 89, 100], ["lung failure", "DISEASE", 119, 131], ["infection", "DISEASE", 428, 437], ["Ang II", "GENE_OR_GENE_PRODUCT", 19, 25], ["lung tissue", "TISSUE", 47, 58], ["lung", "ORGAN", 89, 93], ["lung", "ORGAN", 119, 123], ["COVID-19", "GENE_OR_GENE_PRODUCT", 182, 190], ["ACE2", "GENE_OR_GENE_PRODUCT", 206, 210], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 270, 278], ["patients", "ORGANISM", 318, 326], ["Ang II", "PROTEIN", 19, 25], ["spike protein", "PROTEIN", 165, 178], ["COVID-19", "PROTEIN", 182, 190], ["ACE2", "PROTEIN", 206, 210], ["patients", "SPECIES", 318, 326], ["SARS-CoV", "SPECIES", 270, 278], ["high Ang II concentration", "PROBLEM", 14, 39], ["the lung tissue", "PROBLEM", 43, 58], ["acid-induced acute lung injury", "PROBLEM", 70, 100], ["severe lung failure", "PROBLEM", 112, 131], ["the spike protein", "TEST", 161, 178], ["COVID", "TEST", 182, 187], ["ACE2", "TREATMENT", 206, 210], ["the pathogenic mechanism", "PROBLEM", 225, 249], ["SARS", "TEST", 270, 274], ["CoV", "TEST", 275, 278], ["COVID", "TEST", 283, 288], ["Surgery", "TREATMENT", 298, 305], ["battling COVID", "TREATMENT", 371, 385], ["COVID-19 infection", "PROBLEM", 419, 437], ["lung", "ANATOMY", 47, 51], ["tissue", "ANATOMY_MODIFIER", 52, 58], ["acid-induced", "OBSERVATION_MODIFIER", 70, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["lung", "ANATOMY", 89, 93], ["injury", "OBSERVATION", 94, 100], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["lung", "ANATOMY", 119, 123], ["failure", "OBSERVATION", 124, 131], ["infection", "OBSERVATION", 428, 437]]], ["Since Covid-19 quickly spread through respiratory droplets, head and neck surgeons who have close contact with the upper aerodigestive tract are principally at high risk.", [["respiratory droplets", "ANATOMY", 38, 58], ["head", "ANATOMY", 60, 64], ["neck", "ANATOMY", 69, 73], ["upper aerodigestive tract", "ANATOMY", 115, 140], ["head", "ORGANISM_SUBDIVISION", 60, 64], ["upper aerodigestive", "ORGANISM_SUBDIVISION", 115, 134], ["tract", "ORGANISM_SUBDIVISION", 135, 140], ["Covid", "TEST", 6, 11], ["head and neck surgeons", "TREATMENT", 60, 82], ["respiratory droplets", "OBSERVATION", 38, 58], ["head", "ANATOMY", 60, 64], ["neck", "ANATOMY", 69, 73], ["upper", "ANATOMY_MODIFIER", 115, 120], ["aerodigestive tract", "ANATOMY", 121, 140]]], ["Given the high number of surgeries done worldwide, it is essential for the surgeons and surgical team to be adequately protected from coronavirus transmission.", [["coronavirus", "DISEASE", 134, 145], ["coronavirus", "ORGANISM", 134, 145], ["surgeries", "TREATMENT", 25, 34], ["surgical team", "TREATMENT", 88, 101], ["surgeries", "OBSERVATION", 25, 34], ["coronavirus", "OBSERVATION", 134, 145]]], ["In the COVID-19 patients who need surgery, risks versus benefits of the procedure for the patient should be cautiously evaluated.", [["patients", "ORGANISM", 16, 24], ["patient", "ORGANISM", 90, 97], ["patients", "SPECIES", 16, 24], ["patient", "SPECIES", 90, 97], ["surgery", "TREATMENT", 34, 41], ["the procedure", "TREATMENT", 68, 81]]], ["The surgeon may temporary postpone an emergency or urgent surgery on cases that show coronavirus symptoms (e.g., cough, sore throat, fever).", [["coronavirus symptoms", "DISEASE", 85, 105], ["cough", "DISEASE", 113, 118], ["sore throat", "DISEASE", 120, 131], ["fever", "DISEASE", 133, 138], ["coronavirus", "ORGANISM", 85, 96], ["urgent surgery", "TREATMENT", 51, 65], ["coronavirus symptoms", "PROBLEM", 85, 105], ["cough", "PROBLEM", 113, 118], ["sore throat", "PROBLEM", 120, 131], ["fever", "PROBLEM", 133, 138]]], ["For all suspected cases that are undergoing operation, chest CT and blood tests need to be checked before admission.", [["chest", "ANATOMY", 55, 60], ["blood", "ANATOMY", 68, 73], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["operation", "TREATMENT", 44, 53], ["chest CT", "TEST", 55, 63], ["blood tests", "TEST", 68, 79], ["chest", "ANATOMY", 55, 60]]], ["The surgical team can also order an inhouse RT-PCR assay within 24h.", [["an inhouse RT-PCR assay", "TEST", 33, 56]]], ["If the subject's condition does not allow for a 24h wait, the patient is assumed to be COVID-19-positive.", [["patient", "ORGANISM", 62, 69], ["COVID-19", "GENE_OR_GENE_PRODUCT", 87, 95], ["patient", "SPECIES", 62, 69], ["the subject's condition", "PROBLEM", 3, 26], ["COVID", "TEST", 87, 92]]], ["For suspected or confirmed COVID-19 cases, non-operative management is preferred.", [["COVID", "TEST", 27, 32], ["non-operative management", "TREATMENT", 43, 67]]], ["If surgery is essential in these subjects, suitable personal protective equipment (PPE) should be used (Fig. 5) .", [["surgery", "TREATMENT", 3, 10], ["suitable personal protective equipment (PPE)", "TREATMENT", 43, 87]]], ["Furthermore they should remove their PPE and place the PPE in a labelled waste bag in an anteroom.", [["their PPE", "TREATMENT", 31, 40], ["the PPE", "TREATMENT", 51, 58], ["a labelled waste bag", "TREATMENT", 62, 82], ["waste bag", "OBSERVATION", 73, 82]]], ["There are various levels of emergency related to COVID-19 patient needs, and assessment is required to distinguish among them.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["COVID", "TEST", 49, 54], ["assessment", "TEST", 77, 87]]], ["Table 6 summarizes the key recommendations for the surgeon and surgical team in different stages [33] [34] [35] .Treatment of COVID-19Currently, there is no effective medicine for the treatment for COVID-19 patients, which can, in some patients, lead to lethal lung failure.", [["lung", "ANATOMY", 261, 265], ["COVID-19Currently", "CHEMICAL", 126, 143], ["COVID", "DISEASE", 198, 203], ["lung failure", "DISEASE", 261, 273], ["COVID-19Currently", "CELL", 126, 143], ["patients", "ORGANISM", 207, 215], ["patients", "ORGANISM", 236, 244], ["lung", "ORGAN", 261, 265], ["patients", "SPECIES", 207, 215], ["patients", "SPECIES", 236, 244], ["COVID", "TREATMENT", 126, 131], ["the treatment", "TREATMENT", 180, 193], ["COVID", "TEST", 198, 203], ["lethal lung failure", "PROBLEM", 254, 273], ["no", "UNCERTAINTY", 154, 156], ["lethal", "OBSERVATION_MODIFIER", 254, 260], ["lung", "ANATOMY", 261, 265], ["failure", "OBSERVATION", 266, 273]]], ["Furthermore, there is not any specific antiviral or vaccine for this virus [8] .", [["vaccine", "TREATMENT", 52, 59], ["this virus", "PROBLEM", 64, 74]]], ["Pathogenesis of coronavirus is an extremely complex process, and much of the required details in host-pathogen interaction remained unknown.", [["coronavirus", "DISEASE", 16, 27], ["coronavirus", "ORGANISM", 16, 27], ["coronavirus", "PROBLEM", 16, 27], ["coronavirus", "OBSERVATION", 16, 27], ["extremely", "OBSERVATION_MODIFIER", 34, 43], ["complex", "OBSERVATION_MODIFIER", 44, 51], ["process", "OBSERVATION", 52, 59]]], ["Discovering the useful medicine options for the treatment of the COVID-19 outbreak is vital [36, 37] (Table 7) .", [["the treatment", "TREATMENT", 44, 57], ["the COVID", "TEST", 61, 70]]], ["There are various possible treatment approaches [29] including (i) rises in ACE2 expression by injection of soluble recombinant ACE2 protein or using therapeutic vectors expressing high levels of ACE2 which may be applicable in the future [38] , (ii) using specific ACE inhibitors such as lisinopril, and (iii) inhibiting Ang II receptors.", [["lisinopril", "CHEMICAL", 289, 299], ["Ang II", "CHEMICAL", 322, 328], ["lisinopril", "CHEMICAL", 289, 299], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 128, 132], ["ACE2", "GENE_OR_GENE_PRODUCT", 196, 200], ["ACE", "GENE_OR_GENE_PRODUCT", 266, 269], ["lisinopril", "SIMPLE_CHEMICAL", 289, 299], ["Ang II receptors", "GENE_OR_GENE_PRODUCT", 322, 338], ["ACE2", "PROTEIN", 76, 80], ["ACE2 protein", "PROTEIN", 128, 140], ["ACE2", "PROTEIN", 196, 200], ["Ang II receptors", "PROTEIN", 322, 338], ["treatment approaches", "TREATMENT", 27, 47], ["ACE2 expression", "TREATMENT", 76, 91], ["soluble recombinant ACE2 protein", "TREATMENT", 108, 140], ["therapeutic vectors", "TREATMENT", 150, 169], ["ACE2", "TREATMENT", 196, 200], ["specific ACE inhibitors", "TREATMENT", 257, 280], ["lisinopril", "TREATMENT", 289, 299], ["Ang II receptors", "TREATMENT", 322, 338]]], ["In particular, the type I Ang II receptor has been reported to promote disease by motivating oedemas and disturbing lung function [38] .", [["lung", "ANATOMY", 116, 120], ["Ang II", "CHEMICAL", 26, 32], ["type I Ang II receptor", "GENE_OR_GENE_PRODUCT", 19, 41], ["lung", "ORGAN", 116, 120], ["type I Ang II receptor", "PROTEIN", 19, 41], ["motivating oedemas", "PROBLEM", 82, 100], ["disturbing lung function", "PROBLEM", 105, 129], ["lung", "ANATOMY", 116, 120]]], ["Hence, a type I Ang II receptor blocker (e.g., losartan) has been successively examined for improving COVID-19 pneumonia [29] .", [["Ang II", "CHEMICAL", 16, 22], ["losartan", "CHEMICAL", 47, 55], ["pneumonia", "DISEASE", 111, 120], ["losartan", "CHEMICAL", 47, 55], ["type I Ang II receptor", "GENE_OR_GENE_PRODUCT", 9, 31], ["losartan", "SIMPLE_CHEMICAL", 47, 55], ["a type I Ang II receptor blocker", "TREATMENT", 7, 39], ["losartan", "TREATMENT", 47, 55], ["COVID", "TEST", 102, 107], ["pneumonia", "PROBLEM", 111, 120], ["pneumonia", "OBSERVATION", 111, 120]]], ["Treatment with a soluble form of ACE2 probably acts as a competitive interceptor of coronavirus by inhibiting binding of the viral particle to the ACE2 receptor, consequently can slow coronavirus entry into the cells and protect the lung injury.", [["cells", "ANATOMY", 211, 216], ["lung", "ANATOMY", 233, 237], ["lung injury", "DISEASE", 233, 244], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["coronavirus", "ORGANISM", 84, 95], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 147, 160], ["coronavirus", "ORGANISM", 184, 195], ["cells", "CELL", 211, 216], ["lung", "ORGAN", 233, 237], ["ACE2", "PROTEIN", 33, 37], ["ACE2 receptor", "PROTEIN", 147, 160], ["coronavirus", "SPECIES", 184, 195], ["a soluble form of ACE2", "TREATMENT", 15, 37], ["coronavirus", "PROBLEM", 84, 95], ["the ACE2 receptor", "TREATMENT", 143, 160], ["the lung injury", "PROBLEM", 229, 244], ["lung", "ANATOMY", 233, 237], ["injury", "OBSERVATION", 238, 244]]], ["Remdesivir (adenosine analogue) that is used for the treatment of the Ebola disease is incorporated in the nascent chains of viral RNA, causing premature termination.", [["Remdesivir", "CHEMICAL", 0, 10], ["adenosine", "CHEMICAL", 12, 21], ["Ebola disease", "DISEASE", 70, 83], ["Remdesivir", "CHEMICAL", 0, 10], ["adenosine", "CHEMICAL", 12, 21], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["adenosine", "SIMPLE_CHEMICAL", 12, 21], ["Ebola", "ORGANISM", 70, 75], ["viral RNA", "RNA", 125, 134], ["Remdesivir (adenosine analogue", "TREATMENT", 0, 30], ["the Ebola disease", "PROBLEM", 66, 83], ["viral RNA", "PROBLEM", 125, 134], ["premature termination", "PROBLEM", 144, 165], ["Ebola disease", "OBSERVATION", 70, 83], ["nascent chains", "OBSERVATION", 107, 121], ["viral RNA", "OBSERVATION", 125, 134], ["premature", "OBSERVATION_MODIFIER", 144, 153]]], ["This drug is currently used for the treatment of COVID-19 infection. for treatment of COVID-19 infection in the in vitro [40] .", [["COVID-19", "CHEMICAL", 49, 57], ["infection", "DISEASE", 58, 67], ["COVID-19", "CHEMICAL", 86, 94], ["infection", "DISEASE", 95, 104], ["COVID-19", "ORGANISM", 49, 57], ["COVID-19", "CELL", 86, 94], ["COVID-19", "SPECIES", 49, 57], ["This drug", "TREATMENT", 0, 9], ["COVID-19 infection", "PROBLEM", 49, 67], ["treatment", "TREATMENT", 73, 82], ["COVID", "PROBLEM", 86, 91], ["19 infection", "PROBLEM", 92, 104], ["infection", "OBSERVATION", 58, 67], ["infection", "OBSERVATION", 95, 104]]], ["They found that chloroquine and remdesivir are potentially effective in the control of COVID-19 infection in vitro [40] .Treatment of COVID-19Chloroquine is a well-known drug that has currently been documented as a strong broadspectrum antiviral agent for the treatment of malarial and autoimmune disease.", [["chloroquine", "CHEMICAL", 16, 27], ["remdesivir", "CHEMICAL", 32, 42], ["COVID-19", "CHEMICAL", 87, 95], ["infection", "DISEASE", 96, 105], ["COVID-19Chloroquine", "CHEMICAL", 134, 153], ["malarial and autoimmune disease", "DISEASE", 273, 304], ["chloroquine", "CHEMICAL", 16, 27], ["remdesivir", "CHEMICAL", 32, 42], ["COVID-19Chloroquine", "CHEMICAL", 134, 153], ["chloroquine", "SIMPLE_CHEMICAL", 16, 27], ["remdesivir", "SIMPLE_CHEMICAL", 32, 42], ["COVID-19", "ORGANISM", 87, 95], ["COVID-19Chloroquine", "SIMPLE_CHEMICAL", 134, 153], ["COVID-19", "SPECIES", 87, 95], ["chloroquine", "TREATMENT", 16, 27], ["remdesivir", "TREATMENT", 32, 42], ["COVID", "TEST", 87, 92], ["COVID", "TREATMENT", 134, 139], ["19Chloroquine", "TREATMENT", 140, 153], ["a strong broadspectrum antiviral agent", "TREATMENT", 213, 251], ["malarial", "PROBLEM", 273, 281], ["autoimmune disease", "PROBLEM", 286, 304], ["infection", "OBSERVATION", 96, 105], ["malarial", "OBSERVATION", 273, 281], ["autoimmune disease", "OBSERVATION", 286, 304]]], ["This drug interferes with glycosylation of the cellular receptor, elevates endosomal pH needed for virus/cell fusion, and consequently reduces virus infection [41] .", [["cellular", "ANATOMY", 47, 55], ["endosomal", "ANATOMY", 75, 84], ["cell", "ANATOMY", 105, 109], ["infection", "DISEASE", 149, 158], ["cellular", "CELL", 47, 55], ["endosomal", "CELLULAR_COMPONENT", 75, 84], ["cell", "CELL", 105, 109], ["cellular receptor", "PROTEIN", 47, 64], ["glycosylation", "TREATMENT", 26, 39], ["the cellular receptor", "TREATMENT", 43, 64], ["elevates endosomal pH", "TREATMENT", 66, 87], ["virus/cell fusion", "TREATMENT", 99, 116], ["virus infection", "PROBLEM", 143, 158], ["cell fusion", "OBSERVATION", 105, 116]]], ["It has also recommended by some Chinese researchers to use traditional medicine to recover the physical signs of infection [43] [44] [45] [46] .", [["infection", "DISEASE", 113, 122], ["[43] [44] [45", "SIMPLE_CHEMICAL", 123, 136], ["traditional medicine", "TREATMENT", 59, 79], ["infection", "PROBLEM", 113, 122]]], ["Furthermore, zinc nanoparticle also due to potential antioxidant, antiinflammatory [47] , and antiviral effects can inhibit influenza viral load, and COVID-19 replication in the in vitro experiment [48] .Treatment of COVID-19Isolation of infected cases and supportive cares such as fluid management, oxygen therapy, and antimicrobials agents for the treatment of secondary bacterial infections and prevent endorgan dysfunction are suggested by WHO for patients needing hospital admission [8, 10] .Treatment of COVID-19Interferon-\u03b1 is a wide spectrum antivirus medicine that can be used to treatment of hepatitis B virus (HBV).", [["fluid", "ANATOMY", 282, 287], ["endorgan", "ANATOMY", 406, 414], ["zinc", "CHEMICAL", 13, 17], ["COVID-19Isolation", "CHEMICAL", 217, 234], ["oxygen", "CHEMICAL", 300, 306], ["bacterial infections", "DISEASE", 373, 393], ["endorgan dysfunction", "DISEASE", 406, 426], ["COVID-19Interferon-\u03b1", "CHEMICAL", 510, 530], ["hepatitis B", "DISEASE", 602, 613], ["zinc", "CHEMICAL", 13, 17], ["oxygen", "CHEMICAL", 300, 306], ["zinc nanoparticle", "SIMPLE_CHEMICAL", 13, 30], ["influenza viral", "ORGANISM", 124, 139], ["oxygen", "SIMPLE_CHEMICAL", 300, 306], ["patients", "ORGANISM", 452, 460], ["COVID-19Interferon-\u03b1", "SIMPLE_CHEMICAL", 510, 530], ["hepatitis B virus", "ORGANISM", 602, 619], ["HBV", "ORGANISM", 621, 624], ["patients", "SPECIES", 452, 460], ["hepatitis B virus", "SPECIES", 602, 619], ["hepatitis B virus", "SPECIES", 602, 619], ["HBV", "SPECIES", 621, 624], ["zinc nanoparticle", "TREATMENT", 13, 30], ["antiviral effects", "TREATMENT", 94, 111], ["influenza viral load", "PROBLEM", 124, 144], ["COVID", "TREATMENT", 150, 155], ["COVID", "TREATMENT", 217, 222], ["infected cases", "TREATMENT", 238, 252], ["supportive cares", "TREATMENT", 257, 273], ["fluid management", "TREATMENT", 282, 298], ["oxygen therapy", "TREATMENT", 300, 314], ["antimicrobials agents", "TREATMENT", 320, 341], ["secondary bacterial infections", "PROBLEM", 363, 393], ["endorgan dysfunction", "PROBLEM", 406, 426], ["COVID", "TREATMENT", 510, 515], ["19Interferon", "TREATMENT", 516, 528], ["a wide spectrum antivirus medicine", "TREATMENT", 534, 568], ["hepatitis B virus", "PROBLEM", 602, 619], ["infected", "OBSERVATION", 238, 246], ["secondary", "OBSERVATION_MODIFIER", 363, 372], ["bacterial infections", "OBSERVATION", 373, 393]]], ["Lopinavir is a protease inhibitor used for the treatment of human immunodeficiency viruses (HIV) with ritonavir as a booster that showed potential anti coronavirus activity.", [["Lopinavir", "CHEMICAL", 0, 9], ["human immunodeficiency viruses", "DISEASE", 60, 90], ["HIV", "DISEASE", 92, 95], ["ritonavir", "CHEMICAL", 102, 111], ["Lopinavir", "CHEMICAL", 0, 9], ["ritonavir", "CHEMICAL", 102, 111], ["Lopinavir", "SIMPLE_CHEMICAL", 0, 9], ["human immunodeficiency viruses", "ORGANISM", 60, 90], ["HIV", "ORGANISM", 92, 95], ["ritonavir", "SIMPLE_CHEMICAL", 102, 111], ["human", "SPECIES", 60, 65], ["immunodeficiency viruses", "SPECIES", 66, 90], ["human immunodeficiency viruses", "SPECIES", 60, 90], ["HIV", "SPECIES", 92, 95], ["anti coronavirus", "SPECIES", 147, 163], ["Lopinavir", "TREATMENT", 0, 9], ["a protease inhibitor", "TREATMENT", 13, 33], ["human immunodeficiency viruses", "PROBLEM", 60, 90], ["ritonavir", "TREATMENT", 102, 111], ["a booster", "TREATMENT", 115, 124], ["potential anti coronavirus activity", "PROBLEM", 137, 172], ["anti coronavirus activity", "OBSERVATION", 147, 172]]], ["In the patient with SARS cases treated with lopinavir/ritonavir and ribavirin had a lower risk of ARDS or death as compared with ribavirin alone [49] .", [["SARS", "DISEASE", 20, 24], ["lopinavir/ritonavir", "CHEMICAL", 44, 63], ["ribavirin", "CHEMICAL", 68, 77], ["ARDS", "DISEASE", 98, 102], ["death", "DISEASE", 106, 111], ["ribavirin", "CHEMICAL", 129, 138], ["lopinavir", "CHEMICAL", 44, 53], ["ritonavir", "CHEMICAL", 54, 63], ["ribavirin", "CHEMICAL", 68, 77], ["ribavirin", "CHEMICAL", 129, 138], ["patient", "ORGANISM", 7, 14], ["lopinavir", "SIMPLE_CHEMICAL", 44, 53], ["ritonavir", "SIMPLE_CHEMICAL", 54, 63], ["ribavirin", "SIMPLE_CHEMICAL", 68, 77], ["ribavirin", "SIMPLE_CHEMICAL", 129, 138], ["patient", "SPECIES", 7, 14], ["SARS cases", "PROBLEM", 20, 30], ["lopinavir", "TREATMENT", 44, 53], ["ritonavir", "TREATMENT", 54, 63], ["ribavirin", "TREATMENT", 68, 77], ["ARDS", "PROBLEM", 98, 102], ["death", "PROBLEM", 106, 111], ["ribavirin", "TREATMENT", 129, 138], ["ARDS", "OBSERVATION", 98, 102]]], ["The host immune system is one of the main factors in secondary infections.", [["immune system", "ANATOMY", 9, 22], ["infections", "DISEASE", 63, 73], ["secondary infections", "PROBLEM", 53, 73], ["host immune system", "OBSERVATION", 4, 22], ["main", "OBSERVATION_MODIFIER", 37, 41], ["secondary", "OBSERVATION_MODIFIER", 53, 62], ["infections", "OBSERVATION", 63, 73]]], ["Other involved factors that may increase mortality in COVID-19 patients are obesity, old age, diabetics, HIV infection, autoimmune disease, and pregnancy in women [50] .", [["obesity", "DISEASE", 76, 83], ["diabetics", "DISEASE", 94, 103], ["HIV infection", "DISEASE", 105, 118], ["autoimmune disease", "DISEASE", 120, 138], ["patients", "ORGANISM", 63, 71], ["women", "ORGANISM", 157, 162], ["patients", "SPECIES", 63, 71], ["HIV", "SPECIES", 105, 108], ["women", "SPECIES", 157, 162], ["HIV", "SPECIES", 105, 108], ["obesity", "PROBLEM", 76, 83], ["diabetics", "PROBLEM", 94, 103], ["HIV infection", "PROBLEM", 105, 118], ["autoimmune disease", "PROBLEM", 120, 138], ["obesity", "OBSERVATION", 76, 83], ["HIV infection", "OBSERVATION", 105, 118], ["autoimmune disease", "OBSERVATION", 120, 138]]], ["Therefore, early diagnosis and timely treatment of these critical patients to prevent secondary infection are necessary.", [["infection", "DISEASE", 96, 105], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["these critical patients", "TREATMENT", 51, 74], ["secondary infection", "PROBLEM", 86, 105], ["secondary", "OBSERVATION_MODIFIER", 86, 95], ["infection", "OBSERVATION", 96, 105]]], ["Immunoglobulin injection is recommended to increase the antiinfection drug ability for severe cases [50] .", [["Immunoglobulin", "GENE_OR_GENE_PRODUCT", 0, 14], ["Immunoglobulin injection", "TREATMENT", 0, 24], ["the antiinfection drug", "TREATMENT", 52, 74], ["severe cases", "PROBLEM", 87, 99]]], ["Furthermore, paracetamol (400mg per time, every 8 h when required) is recommended in the patient with high temperature [9, 37] .Treatment of COVID-19In summary, at present, there are no vaccines and specific antiviral medicine for the treatment of COVID-19 .", [["paracetamol", "CHEMICAL", 13, 24], ["COVID-19In", "CHEMICAL", 141, 151], ["paracetamol", "CHEMICAL", 13, 24], ["paracetamol", "SIMPLE_CHEMICAL", 13, 24], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["paracetamol", "TREATMENT", 13, 24], ["vaccines", "TREATMENT", 186, 194], ["specific antiviral medicine", "TREATMENT", 199, 226], ["COVID", "TEST", 248, 253]]], ["All of the recommended drugs come from knowledge treating MERS, SARS, or another family of coronavirus.", [["SARS", "DISEASE", 64, 68], ["coronavirus", "DISEASE", 91, 102], ["coronavirus", "ORGANISM", 91, 102], ["drugs", "TREATMENT", 23, 28], ["coronavirus", "PROBLEM", 91, 102]]], ["Further researches are required to provide evidences on the effectiveness of these drugs.", [["these drugs", "TREATMENT", 77, 88]]], ["COVID-19 detection in various clinical samples (positive rate).Clinical specimenWang et al. study [24] W\u00f6lfel et al. study [52]A. Preoperative recommendation\uf0b7 Surgeons should check all scheduled elective program and cancel, minimize, or postpone all non-urgent surgery \uf0b7 Surgeons must plan surgery according to the severity of the threat to the subject's life and health \uf0b7 In an emergency condition, cases should be located in the separated holding part and transferred to the operating room dedicated to COVID-19 patients \uf0b7 Transport operators should sanitize hands and wear personal protective equipment (PPE) before transfer and should minimize exposure with cases \uf0b7 Transfer routes of COVID-19 patients must be correctly managed and be as short as possible \uf0b7 The cases, wearing a surgical face mask, should be transported from the pre-defined short, direct path with minimum contact \uf0b7 Operators (i.e., surgeon, nurses, technicians, and anesthetist) need to be trained in the use of PPE \uf0b7 Operators should wash hand in a different moment, including before and after touching a patient or patient surroundings, after body fluid exposure and before engaging in clean/aseptic processes (with water and soap or 2 to 3% hydrogen peroxide solution or gel) \uf0b7 If oxygen is required, it can be administered by face mask over the surgical mask \uf0b7 Any non-intubated cases should wear a surgical mask, disposable cap, gloves, and shoe covers during transport \uf0b7 Operators should treat COVID-19 cases with respect, dignity, and kindness \uf0b7 The on-call shift can decrease the number of times surgeons move between the hospital and home \uf0b7 On-call surgeons should manage the initial triage arrangements and postoperative care with remote supportB.", [["samples", "ANATOMY", 39, 46], ["hand", "ANATOMY", 1014, 1018], ["body", "ANATOMY", 1119, 1123], ["face", "ANATOMY", 1304, 1308], ["COVID-19", "CHEMICAL", 0, 8], ["hydrogen peroxide", "CHEMICAL", 1218, 1235], ["oxygen", "CHEMICAL", 1258, 1264], ["COVID", "DISEASE", 1474, 1479], ["hydrogen peroxide", "CHEMICAL", 1218, 1235], ["oxygen", "CHEMICAL", 1258, 1264], ["samples", "CANCER", 39, 46], ["patients", "ORGANISM", 514, 522], ["patients", "ORGANISM", 698, 706], ["hand", "ORGANISM_SUBDIVISION", 1014, 1018], ["patient", "ORGANISM", 1080, 1087], ["patient", "ORGANISM", 1091, 1098], ["body", "ORGANISM_SUBDIVISION", 1119, 1123], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 1218, 1235], ["oxygen", "SIMPLE_CHEMICAL", 1258, 1264], ["patients", "SPECIES", 514, 522], ["patients", "SPECIES", 698, 706], ["patient", "SPECIES", 1080, 1087], ["patient", "SPECIES", 1091, 1098], ["COVID", "TEST", 0, 5], ["various clinical samples", "TEST", 22, 46], ["study", "TEST", 92, 97], ["all scheduled elective program", "TREATMENT", 181, 211], ["all non-urgent surgery", "TREATMENT", 246, 268], ["surgery", "TREATMENT", 290, 297], ["personal protective equipment", "TREATMENT", 576, 605], ["a surgical face mask", "TREATMENT", 782, 802], ["body fluid exposure", "TREATMENT", 1119, 1138], ["clean/aseptic processes", "TREATMENT", 1162, 1185], ["soap", "TREATMENT", 1202, 1206], ["3% hydrogen peroxide solution", "TREATMENT", 1215, 1244], ["oxygen", "TREATMENT", 1258, 1264], ["the surgical mask", "TREATMENT", 1319, 1336], ["a surgical mask", "TREATMENT", 1375, 1390], ["disposable cap", "TREATMENT", 1392, 1406], ["gloves", "TREATMENT", 1408, 1414], ["COVID", "TEST", 1474, 1479], ["postoperative care", "TREATMENT", 1691, 1709], ["remote supportB", "TREATMENT", 1715, 1730], ["aseptic", "OBSERVATION", 1168, 1175]]], ["Operative recommendationOperating room \uf0b7 The operating room and entrance should be equipped with a negative pressure system \uf0b7 In the hospitals without negative pressure, the positive pressure and air conditioning must be turned off \uf0b7 A high frequency of air changes (25/hour) are proposed for the operating room \uf0b7 The COVID-dedicated operating room must be labeled \"COVID-19 infectious surgery\" on the door \uf0b7 The appropriate function of the laminar flow and the high-efficiency filter of the operating room must be ensured \uf0b7 Once the infected cases have entered, the operating room doors must be closed \uf0b7 All doors must be kept closed \uf0b7 Unnecessary equipment must be moved away from an infected patient \uf0b7 Minimal materials should be prepared for each operation \uf0b7 Single-use material should be preferred where possible \uf0b7 Use autonomous service (robots and transport system) for transfer of samples and test kits \uf0b7 Clinical documentation should put outside the operating room \uf0b7 Any activity that involves the pulmonary secretions, pharyngeal, nasal mucosal, and oral surfaces is recognized as a high risk to the operating room operators \uf0b7 The powered devices (e.g., microdebriders, saws, drills, and ultrasonic shears) must be considered higher risk \uf0b7 All electronic devices (hospital case sheets, mobile, laptop, and pagers) should be left outside the room \uf0b7 Anesthetic, ultrasound machine, and computers monitor surfaces should be covered with plastic wrap to simplify cleaning \uf0b7 All linen including pillowcases, crossbars, and sheets must be touched wearing PPE \uf0b7 Linen can be contaminated and should hence be handled and transported carefully \uf0b7 All essential material (e.g., scalpel blades, stitches, etc.) must be collected in a sterilizable steel basket \uf0b7 Operating room and adjacent areas must be cleaned, sterilized, and disinfected after each operationStaffs and patients\uf0b7 All surgery should be done in a rapid and effective manner \uf0b7 Reduce the total number of staff working in the operating room \uf0b7 Decrease medical students and apprentice in the operating room \uf0b7 Only operators that participate in direct care are permitted to enter the operating room \uf0b7 All staffs should enter the operating room timely \uf0b7 Staffs should not leave until the operation is finished, and once out they should not re-enter \uf0b7 Prepare everything needed for operation and reduce staffs transiting in and out the operating room \uf0b7 All staff in contact with the COVID-19 cases must wear PPE \uf0b7 Alcoholic hand hygiene solution must continuously be available \uf0b7 Double gloves are proposed to change the outer pairC.", [["laminar", "ANATOMY", 441, 448], ["pulmonary secretions", "ANATOMY", 1007, 1027], ["pharyngeal", "ANATOMY", 1029, 1039], ["nasal mucosal", "ANATOMY", 1041, 1054], ["oral surfaces", "ANATOMY", 1060, 1073], ["crossbars", "ANATOMY", 1513, 1522], ["hand", "ANATOMY", 2483, 2487], ["patient", "ORGANISM", 695, 702], ["pulmonary secretions", "MULTI-TISSUE_STRUCTURE", 1007, 1027], ["pharyngeal", "MULTI-TISSUE_STRUCTURE", 1029, 1039], ["nasal mucosal", "MULTI-TISSUE_STRUCTURE", 1041, 1054], ["oral", "ORGANISM_SUBDIVISION", 1060, 1064], ["patients", "ORGANISM", 1870, 1878], ["outer pairC", "PROTEIN", 2579, 2590], ["patient", "SPECIES", 695, 702], ["patients", "SPECIES", 1870, 1878], ["the positive pressure", "TREATMENT", 170, 191], ["air conditioning", "TREATMENT", 196, 212], ["infectious surgery", "TREATMENT", 375, 393], ["the laminar flow", "TEST", 437, 453], ["the high-efficiency filter", "TREATMENT", 458, 484], ["each operation", "TREATMENT", 746, 760], ["Single-use material", "TREATMENT", 763, 782], ["samples and test kits", "TEST", 889, 910], ["the pulmonary secretions", "PROBLEM", 1003, 1027], ["pharyngeal, nasal mucosal, and oral surfaces", "PROBLEM", 1029, 1073], ["The powered devices (e.g., microdebriders, saws, drills, and ultrasonic shears", "TREATMENT", 1137, 1215], ["All electronic devices", "TREATMENT", 1250, 1272], ["ultrasound machine", "TREATMENT", 1370, 1388], ["computers monitor surfaces", "TREATMENT", 1394, 1420], ["plastic wrap", "TREATMENT", 1444, 1456], ["All linen", "TREATMENT", 1480, 1489], ["crossbars", "TREATMENT", 1513, 1522], ["PPE \uf0b7 Linen", "TREATMENT", 1559, 1570], ["scalpel blades", "TREATMENT", 1677, 1691], ["stitches", "TREATMENT", 1693, 1701], ["a sterilizable steel basket", "TREATMENT", 1730, 1757], ["All surgery", "TREATMENT", 1880, 1891], ["operation", "TREATMENT", 2341, 2350], ["PPE", "TREATMENT", 2467, 2470], ["Alcoholic hand hygiene solution", "TREATMENT", 2473, 2504], ["Double gloves", "TREATMENT", 2538, 2551], ["pressure", "OBSERVATION_MODIFIER", 160, 168], ["pressure", "OBSERVATION_MODIFIER", 183, 191], ["air conditioning", "OBSERVATION", 196, 212], ["air", "OBSERVATION", 254, 257], ["function", "OBSERVATION_MODIFIER", 425, 433], ["laminar flow", "OBSERVATION", 441, 453], ["high", "OBSERVATION_MODIFIER", 462, 466], ["efficiency filter", "OBSERVATION", 467, 484], ["activity", "OBSERVATION", 980, 988], ["pulmonary", "ANATOMY", 1007, 1016], ["secretions", "OBSERVATION", 1017, 1027], ["pharyngeal", "ANATOMY", 1029, 1039], ["nasal mucosal", "ANATOMY", 1041, 1054], ["essential", "OBSERVATION_MODIFIER", 1651, 1660], ["material", "OBSERVATION", 1661, 1669]]], ["Postoperative recommendation\uf0b7 The operation room is recognized as an area with high risk of cross-infection and contamination \uf0b7 Clean surface and equipment, rinse and dry, and disinfect with 2 to 3% hydrogen peroxide or 2000-5000 mg/L sodium hypochlorite solution, or 70% alcohol \uf0b7 Grossly contaminated equipment should be cleaned and disinfected by 5000 g/L chlorine solution \uf0b7 The hospital stay must reduce to the shortest during coronavirus pandemic to increase the hospital capacity and reduction contamination and transmission risk \uf0b7 PPE must be carefully removed and disposed of in dedicated doffing areas \uf0b7 Patient transfer to and from the operating room must be as rapid as possible \uf0b7 Cases would be transferred while wearing a surgical mask \uf0b7 All areas where COVID-19 patients have transferred must be carefully cleaned and disinfected \uf0b7 Recovery phase should be occurred in the operating room, and then transfer to the ICU/general ward \uf0b7 Disposable materials should be discarded through IRHW (infectious-risk health waste) containers, even if not used and should be decontaminated \uf0b7 All anesthesia materials should be disinfected promptly \uf0b7 For high-risk cases that have a cough with a fever after the operation, a chest imaging and PCR test should be done \uf0b7 For confirmed or suspected cases, appropriate oxygen therapy should be given after operation \uf0b7 The surgical team should pay attention to organ support treatment and nutritional therapy after surgery \uf0b7 There is a high risk of deep vein thrombosis (DVT) and secondary lung infections in confirmed or suspected cases \uf0b7 All waste in the operating room must be double-bagged and labeled \"CORONAVIRUS\" or \"COVID-19\" \uf0b7 Visitors should be limited to visit COVID-19 patients, but if strictly essential, limit the number of visitors and the amount of time \uf0b7 Prepare perfect protocols about how to put on and remove PPE, and do hand hygiene", [["surface", "ANATOMY", 134, 141], ["chest", "ANATOMY", 1225, 1230], ["organ", "ANATOMY", 1406, 1411], ["deep vein", "ANATOMY", 1494, 1503], ["DVT", "ANATOMY", 1516, 1519], ["lung", "ANATOMY", 1535, 1539], ["hand", "ANATOMY", 1886, 1890], ["hydrogen peroxide", "CHEMICAL", 199, 216], ["sodium hypochlorite", "CHEMICAL", 235, 254], ["alcohol", "CHEMICAL", 272, 279], ["chlorine", "CHEMICAL", 359, 367], ["coronavirus", "DISEASE", 432, 443], ["cough", "DISEASE", 1183, 1188], ["fever", "DISEASE", 1196, 1201], ["oxygen", "CHEMICAL", 1315, 1321], ["deep vein thrombosis", "DISEASE", 1494, 1514], ["DVT", "DISEASE", 1516, 1519], ["lung infections", "DISEASE", 1535, 1550], ["hydrogen peroxide", "CHEMICAL", 199, 216], ["sodium hypochlorite", "CHEMICAL", 235, 254], ["alcohol", "CHEMICAL", 272, 279], ["chlorine", "CHEMICAL", 359, 367], ["oxygen", "CHEMICAL", 1315, 1321], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 199, 216], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 235, 254], ["alcohol", "SIMPLE_CHEMICAL", 272, 279], ["chlorine", "SIMPLE_CHEMICAL", 359, 367], ["patients", "ORGANISM", 777, 785], ["oxygen", "SIMPLE_CHEMICAL", 1315, 1321], ["organ", "ORGAN", 1406, 1411], ["deep vein", "MULTI-TISSUE_STRUCTURE", 1494, 1503], ["lung", "ORGAN", 1535, 1539], ["patients", "ORGANISM", 1726, 1734], ["hand", "ORGANISM_SUBDIVISION", 1886, 1890], ["patients", "SPECIES", 777, 785], ["patients", "SPECIES", 1726, 1734], ["The operation room", "TREATMENT", 30, 48], ["cross-infection", "PROBLEM", 92, 107], ["contamination", "PROBLEM", 112, 125], ["Clean surface and equipment", "TREATMENT", 128, 155], ["rinse", "TREATMENT", 157, 162], ["disinfect", "TREATMENT", 176, 185], ["3% hydrogen peroxide", "TREATMENT", 196, 216], ["sodium hypochlorite solution", "TREATMENT", 235, 263], ["the hospital capacity", "TREATMENT", 465, 486], ["reduction contamination", "TREATMENT", 491, 514], ["transmission risk", "TREATMENT", 519, 536], ["PPE", "TREATMENT", 539, 542], ["a surgical mask", "TREATMENT", 734, 749], ["COVID", "TREATMENT", 768, 773], ["Disposable materials", "TREATMENT", 948, 968], ["All anesthesia materials", "TREATMENT", 1093, 1117], ["a cough", "PROBLEM", 1181, 1188], ["a fever", "PROBLEM", 1194, 1201], ["the operation", "TREATMENT", 1208, 1221], ["a chest imaging", "TEST", 1223, 1238], ["PCR test", "TEST", 1243, 1251], ["appropriate oxygen therapy", "TREATMENT", 1303, 1329], ["organ support treatment", "TREATMENT", 1406, 1429], ["nutritional therapy", "TREATMENT", 1434, 1453], ["surgery", "TREATMENT", 1460, 1467], ["deep vein thrombosis", "PROBLEM", 1494, 1514], ["DVT)", "PROBLEM", 1516, 1520], ["secondary lung infections", "PROBLEM", 1525, 1550], ["PPE", "TREATMENT", 1874, 1877], ["cross-infection", "OBSERVATION", 92, 107], ["cough", "OBSERVATION", 1183, 1188], ["chest", "ANATOMY", 1225, 1230], ["high", "OBSERVATION_MODIFIER", 1481, 1485], ["deep", "ANATOMY_MODIFIER", 1494, 1498], ["vein", "ANATOMY", 1499, 1503], ["thrombosis", "OBSERVATION", 1504, 1514], ["DVT", "OBSERVATION", 1516, 1519], ["secondary", "OBSERVATION_MODIFIER", 1525, 1534], ["lung", "ANATOMY", 1535, 1539], ["infections", "OBSERVATION", 1540, 1550], ["waste", "OBSERVATION", 1589, 1594]]]], "PMC7224644": [], "PMC7392145": [["A pandemic, by definition, represents worldwide, simultaneous epidemics caused by a novel pathogen.", [["A pandemic", "PROBLEM", 0, 10], ["simultaneous epidemics", "PROBLEM", 49, 71], ["a novel pathogen", "PROBLEM", 82, 98], ["pandemic", "OBSERVATION", 2, 10]]], ["The multinational nature of such an event inevitably leads to cross-national comparisons of epidemic growth, impact, and public health response.", [["epidemic growth", "PROBLEM", 92, 107]]], ["Such comparisons lend themselves to ecological research: For example, the apparent slower epidemic growth rates in countries that use bacilli Calmette\u2013Gu\u00e9rin (BCG) vaccine has caused some researchers to assert that BCG vaccination may affect susceptibility to severe acute respiratory syndrome coronavirus 2 (1).", [["bacilli Calmette\u2013Gu\u00e9rin", "CHEMICAL", 134, 157], ["BCG", "CHEMICAL", 159, 162], ["acute respiratory syndrome coronavirus", "DISEASE", 267, 305], ["bacilli Calmette\u2013Gu\u00e9rin", "SIMPLE_CHEMICAL", 134, 157], ["BCG", "ORGANISM", 159, 162], ["severe acute respiratory syndrome coronavirus", "SPECIES", 260, 305], ["the apparent slower epidemic growth rates", "PROBLEM", 70, 111], ["bacilli Calmette", "TREATMENT", 134, 150], ["Gu\u00e9rin (BCG) vaccine", "TREATMENT", 151, 171], ["BCG vaccination", "TREATMENT", 215, 230], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 260, 305], ["severe", "OBSERVATION_MODIFIER", 260, 266], ["acute", "OBSERVATION_MODIFIER", 267, 272], ["respiratory syndrome", "OBSERVATION", 273, 293]]], ["Others have made similar observations about higher mean temperature and slower growth of the coronavirus 2019 (COVID-19) epidemic (2).", [["coronavirus", "DISEASE", 93, 104], ["higher mean temperature", "PROBLEM", 44, 67], ["the coronavirus", "TEST", 89, 104], ["COVID", "TEST", 111, 116]]], ["However, they also represent\u201cunfair comparisons\u201d (3), because the countries in question differ fundamentally on a confounder known to be associated with COVID-19 severity: age.", [["COVID", "TEST", 153, 158]]]], "PMC7323126": []}